WO2022053541A1 - Compounds for use as appetite suppressant - Google Patents
Compounds for use as appetite suppressant Download PDFInfo
- Publication number
- WO2022053541A1 WO2022053541A1 PCT/EP2021/074763 EP2021074763W WO2022053541A1 WO 2022053541 A1 WO2022053541 A1 WO 2022053541A1 EP 2021074763 W EP2021074763 W EP 2021074763W WO 2022053541 A1 WO2022053541 A1 WO 2022053541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- halogen
- alkyl
- group
- pyrrolidinyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 233
- 239000002830 appetite depressant Substances 0.000 title claims description 10
- 239000003814 drug Substances 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 640
- 150000002367 halogens Chemical class 0.000 claims description 640
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 422
- -1 guanidinyl Chemical group 0.000 claims description 312
- 125000003545 alkoxy group Chemical group 0.000 claims description 256
- 239000011737 fluorine Substances 0.000 claims description 205
- 229910052731 fluorine Inorganic materials 0.000 claims description 205
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 197
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 190
- 125000001072 heteroaryl group Chemical group 0.000 claims description 180
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 180
- 125000000217 alkyl group Chemical group 0.000 claims description 161
- 125000003118 aryl group Chemical group 0.000 claims description 159
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 155
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 143
- 239000000460 chlorine Substances 0.000 claims description 137
- 229910052801 chlorine Inorganic materials 0.000 claims description 133
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 132
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 132
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 120
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 120
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 116
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 88
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 78
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 64
- 125000003368 amide group Chemical group 0.000 claims description 52
- 125000002757 morpholinyl group Chemical group 0.000 claims description 49
- 125000003277 amino group Chemical group 0.000 claims description 48
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 44
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 43
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 125000001544 thienyl group Chemical group 0.000 claims description 39
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 35
- 125000004076 pyridyl group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 31
- 125000003386 piperidinyl group Chemical group 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 28
- 125000004193 piperazinyl group Chemical group 0.000 claims description 25
- 208000008589 Obesity Diseases 0.000 claims description 22
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 125000001041 indolyl group Chemical group 0.000 claims description 20
- 235000020824 obesity Nutrition 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 19
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 18
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 17
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000005545 phthalimidyl group Chemical group 0.000 claims description 13
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims description 12
- 230000004584 weight gain Effects 0.000 claims description 12
- 235000019786 weight gain Nutrition 0.000 claims description 12
- 125000005466 alkylenyl group Chemical group 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 208000030814 Eating disease Diseases 0.000 claims description 9
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 235000014632 disordered eating Nutrition 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 6
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 5
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000008020 Cohen syndrome Diseases 0.000 claims description 5
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims description 5
- 208000012708 MOMO syndrome Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 11
- 208000011580 syndromic disease Diseases 0.000 abstract description 8
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 161
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 110
- 239000000243 solution Substances 0.000 description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
- 229910001868 water Inorganic materials 0.000 description 82
- 239000000203 mixture Substances 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- 239000000725 suspension Substances 0.000 description 73
- 239000007787 solid Substances 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 238000005160 1H NMR spectroscopy Methods 0.000 description 62
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 58
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 31
- 229910052786 argon Inorganic materials 0.000 description 29
- 239000003480 eluent Substances 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- 239000002244 precipitate Substances 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000007832 Na2SO4 Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 14
- 239000002480 mineral oil Substances 0.000 description 14
- 235000010446 mineral oil Nutrition 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 208000021017 Weight Gain Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000036528 appetite Effects 0.000 description 9
- 235000019789 appetite Nutrition 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 235000012631 food intake Nutrition 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- QKHVYVWUZZAQBC-UHFFFAOYSA-N 2-chloro-5-pyridin-2-ylpyrimidine Chemical compound C1=NC(Cl)=NC=C1C1=CC=CC=N1 QKHVYVWUZZAQBC-UHFFFAOYSA-N 0.000 description 5
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000016097 disease of metabolism Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- GBARCMIFTACERW-UHFFFAOYSA-N n-(2-aminoethyl)-p-chlorobenzamide Chemical compound OCCNC(=O)C1=CC=C(Cl)C=C1 GBARCMIFTACERW-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PVURAUIMVICLOH-UHFFFAOYSA-M zinc;cyclohexane;bromide Chemical compound Br[Zn+].C1CC[CH-]CC1 PVURAUIMVICLOH-UHFFFAOYSA-M 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 3
- CHIFTAQVXHNVRW-UHFFFAOYSA-N 1h-indole-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNC2=C1 CHIFTAQVXHNVRW-UHFFFAOYSA-N 0.000 description 3
- MTQSUJQCUCSASJ-UHFFFAOYSA-N 2-bromo-9-methylcarbazole Chemical compound C1=C(Br)C=C2N(C)C3=CC=CC=C3C2=C1 MTQSUJQCUCSASJ-UHFFFAOYSA-N 0.000 description 3
- FZIFJKSBGDPGRP-UHFFFAOYSA-N 2-quinolin-7-yloxyethanamine Chemical compound C1=CC=NC2=CC(OCCN)=CC=C21 FZIFJKSBGDPGRP-UHFFFAOYSA-N 0.000 description 3
- FECDOLVWBGYZFS-UHFFFAOYSA-N 9-methylcarbazole-2-thiol Chemical compound CN1C(C=C(C=C2)S)=C2C2=CC=CC=C12 FECDOLVWBGYZFS-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- GIHVVBONZHSNJL-UHFFFAOYSA-N N-[bis(methylsulfanyl)methylidene]-4-chlorobenzamide Chemical compound CSC(SC)=NC(=O)C1=CC=C(Cl)C=C1 GIHVVBONZHSNJL-UHFFFAOYSA-N 0.000 description 3
- 241001181114 Neta Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 208000014679 binge eating disease Diseases 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 3
- 229960003015 rimonabant Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 2
- ISJBQSJDQZLCSF-UHFFFAOYSA-N (4-chlorophenyl)azanium;chloride Chemical compound [Cl-].[NH3+]C1=CC=C(Cl)C=C1 ISJBQSJDQZLCSF-UHFFFAOYSA-N 0.000 description 2
- RECCURWJDVZHIH-UHFFFAOYSA-N (4-chlorophenyl)urea Chemical compound NC(=O)NC1=CC=C(Cl)C=C1 RECCURWJDVZHIH-UHFFFAOYSA-N 0.000 description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QPILYVQSKNWRDD-UHFFFAOYSA-N 1-methyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2C(C)NCCC2=C1 QPILYVQSKNWRDD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 2
- WSZRCNZXKKTLQE-UHFFFAOYSA-N 2-chloro-5-iodopyrimidine Chemical compound ClC1=NC=C(I)C=N1 WSZRCNZXKKTLQE-UHFFFAOYSA-N 0.000 description 2
- JJNIWMPNOFGQEA-UHFFFAOYSA-N 2-chloro-5-phenylpyrimidine Chemical compound C1=NC(Cl)=NC=C1C1=CC=CC=C1 JJNIWMPNOFGQEA-UHFFFAOYSA-N 0.000 description 2
- XHJZVXSJNSGBDF-UHFFFAOYSA-N 2-chloro-5-pyrimidin-2-ylpyrimidine Chemical compound ClC1=NC=C(C=N1)C1=NC=CC=N1 XHJZVXSJNSGBDF-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- QUPKVFWBIXCHJH-UHFFFAOYSA-N 2-quinolin-7-yloxyacetonitrile Chemical compound C1=CC=NC2=CC(OCC#N)=CC=C21 QUPKVFWBIXCHJH-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- SCTIEZPQUAFPMR-UHFFFAOYSA-N 4-chloro-N-[2-(5-iodopyrimidin-2-yl)oxyethyl]benzamide Chemical compound O=C(C(C=C1)=CC=C1Cl)NCCOC(N=C1)=NC=C1I SCTIEZPQUAFPMR-UHFFFAOYSA-N 0.000 description 2
- LWFVLQNVCIBMRB-UHFFFAOYSA-N 6-chloro-2-(chloromethyl)-1,3-benzoxazole Chemical compound C1=C(Cl)C=C2OC(CCl)=NC2=C1 LWFVLQNVCIBMRB-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- STBGNWWJNROGKL-UONOGXRCSA-N CC(C)(C)OC(N(C1)[C@H](CNC(C(C=C2)=CC=C2Cl)=O)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](CNC(C(C=C2)=CC=C2Cl)=O)C[C@H]1O)=O STBGNWWJNROGKL-UONOGXRCSA-N 0.000 description 2
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- UNJDJDZSEXGRJI-UHFFFAOYSA-N NCCOC1=CN=C(Br)C=C1 Chemical compound NCCOC1=CN=C(Br)C=C1 UNJDJDZSEXGRJI-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FRYRCAJKHIYSAA-UHFFFAOYSA-N OC(CN1)CNC1=NC(C(C=C1)=CC=C1Cl)=O Chemical compound OC(CN1)CNC1=NC(C(C=C1)=CC=C1Cl)=O FRYRCAJKHIYSAA-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 208000001022 morbid obesity Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FLEWMVXZGYVQPX-UHFFFAOYSA-N tert-butyl N-[2-(5-morpholin-4-ylpyrimidin-2-yl)oxyethyl]carbamate Chemical compound CC(C)(C)OC(NCCOC(N=C1)=NC=C1N1CCOCC1)=O FLEWMVXZGYVQPX-UHFFFAOYSA-N 0.000 description 2
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 2
- ADMJUNZHSHOPEF-UHFFFAOYSA-N tert-butyl n-[2-(6-bromopyridin-3-yl)oxyethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOC1=CC=C(Br)N=C1 ADMJUNZHSHOPEF-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- VCYBVWFTGAZHGH-UHFFFAOYSA-N 1-methylindole-2,3-dione Chemical compound C1=CC=C2N(C)C(=O)C(=O)C2=C1 VCYBVWFTGAZHGH-UHFFFAOYSA-N 0.000 description 1
- FKASAVXZZLJTNX-UHFFFAOYSA-N 2-(dimethylamino)acetic acid;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(O)=O FKASAVXZZLJTNX-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PJRGCJBBXGNEGD-UHFFFAOYSA-N 2-bromo-9h-carbazole Chemical compound C1=CC=C2C3=CC=C(Br)C=C3NC2=C1 PJRGCJBBXGNEGD-UHFFFAOYSA-N 0.000 description 1
- QWLGCWXSNYKKDO-UHFFFAOYSA-N 2-chloro-5-iodopyridine Chemical compound ClC1=CC=C(I)C=N1 QWLGCWXSNYKKDO-UHFFFAOYSA-N 0.000 description 1
- QCEPIUWMXRQPIF-UHFFFAOYSA-N 2-chloro-6-hydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=CC=C1Cl QCEPIUWMXRQPIF-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- GFUFUJMSZWBPNH-UHFFFAOYSA-N 4-(2-acetamidoethyl)benzoic acid Chemical compound CC(=O)NCCC1=CC=C(C(O)=O)C=C1 GFUFUJMSZWBPNH-UHFFFAOYSA-N 0.000 description 1
- ZYLSPYRFWDYNNN-UHFFFAOYSA-N 4-chloro-N-[2-(5-cyanopyrimidin-2-yl)oxyethyl]benzamide Chemical compound N#CC(C=N1)=CN=C1OCCNC(C(C=C1)=CC=C1Cl)=O ZYLSPYRFWDYNNN-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- BLNVISNJTIRAHF-UHFFFAOYSA-N 4-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1 BLNVISNJTIRAHF-UHFFFAOYSA-N 0.000 description 1
- OKPUICCJRDBRJT-UHFFFAOYSA-N 4-chlorobenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(Cl)C=C1 OKPUICCJRDBRJT-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- XIGNIMRSWWYMRJ-UHFFFAOYSA-N 5-pyridin-2-yl-1H-pyrimidine-2-thione Chemical compound SC(N=C1)=NC=C1C1=NC=CC=C1 XIGNIMRSWWYMRJ-UHFFFAOYSA-N 0.000 description 1
- PTEFNEALEPSHLC-UHFFFAOYSA-N 6-bromopyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1 PTEFNEALEPSHLC-UHFFFAOYSA-N 0.000 description 1
- MXLDJTXXAYVWDF-UHFFFAOYSA-N 7-(trifluoromethyl)-1h-indole-2,3-dione Chemical compound FC(F)(F)C1=CC=CC2=C1NC(=O)C2=O MXLDJTXXAYVWDF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010199 LiAl Inorganic materials 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- IQBGUEXJSNXKKS-RFZPGFLSSA-N NC[C@@H](C[C@H](C1)O)N1C(O)=O Chemical compound NC[C@@H](C[C@H](C1)O)N1C(O)=O IQBGUEXJSNXKKS-RFZPGFLSSA-N 0.000 description 1
- 208000007301 Night Eating Syndrome Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- XCJLXFIGEMUOEE-UHFFFAOYSA-N acetamide;2,2,2-trifluoroacetic acid Chemical compound CC(N)=O.OC(=O)C(F)(F)F XCJLXFIGEMUOEE-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- OTKPPUXRIADSGD-PPRNARJGSA-N avoparcina Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2C([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C(C=C2)[C@@H](O)[C@H](C(N[C@H](C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@H]1C[C@@H](N)[C@@H](O)[C@H](C)O1 OTKPPUXRIADSGD-PPRNARJGSA-N 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 229940120049 belviq Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 229940012193 contrave Drugs 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MPSVVZLIWUIPOL-UHFFFAOYSA-N ethyl (2e)-2-amino-2-hydrazinylideneacetate Chemical compound CCOC(=O)C(\N)=N\N MPSVVZLIWUIPOL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- CPUYYKBUTFSBJH-UHFFFAOYSA-N indole-3-thione Chemical class C1=CC=C2C(=S)C=NC2=C1 CPUYYKBUTFSBJH-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- FODOUIXGKGNSMR-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O FODOUIXGKGNSMR-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 125000002265 phtalazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- XCRPPAPDRUBKRJ-UHFFFAOYSA-N quinolin-7-ol Chemical compound C1=CC=NC2=CC(O)=CC=C21 XCRPPAPDRUBKRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QWQOVHQSXJGTPM-JGVFFNPUSA-N tert-butyl (2S,4R)-2-(aminomethyl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1CN QWQOVHQSXJGTPM-JGVFFNPUSA-N 0.000 description 1
- YQBJPXLVAATVHK-UHFFFAOYSA-N tert-butyl N-[2-(5-bromopyrimidin-2-yl)oxyethyl]carbamate Chemical compound BrC=1C=NC(=NC=1)OCCNC(OC(C)(C)C)=O YQBJPXLVAATVHK-UHFFFAOYSA-N 0.000 description 1
- GOQZIPJCBUYLIR-UHFFFAOYSA-N tert-butyl n-[n-[(2-methylpropan-2-yl)oxycarbonyl]-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OC(C)(C)C GOQZIPJCBUYLIR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WTFFOOAJSDVASL-UHFFFAOYSA-N tributyl(pyrimidin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CC=N1 WTFFOOAJSDVASL-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- IKVDXUFZJARKPF-UHFFFAOYSA-M zinc;cyclopropane;bromide Chemical compound Br[Zn+].C1C[CH-]1 IKVDXUFZJARKPF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to new compounds, in particular compounds capable of ameliorating the metabolic syndrome, and their uses, especially for the treatment of diseases and disorders.
- Anti-obesity or weight loss drugs are pharmacological agents that reduce or control weight. These drugs may alter either appetite, absorption of calories and/or energy expenditure.
- Sibutramine (Meridia), which acts in the brain to inhibit deactivation of the neurotransmitters, thereby decreasing appetite, was withdrawn from the United States and Canadian markets in October 2010 due to cardiovascular concerns.
- Lorcaserin marketed under the brand name Belviq, is a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite. However, it was removed from the market in the United States in 2020 due to its increased risk of cancer.
- Qsymia phentermine-topiramate was approved by the FDA in 2012 for the chronic treatment of obesity.
- anti-obesity drugs are only prescribed for obesity where it is hoped that the benefits of the treatment outweigh its risks.
- the present invention relates to compounds capable of reducing food intake and their uses for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain.
- a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain.
- the present invention relates to new compounds, a pharmaceutical or veterinary composition comprising a new compound according to the disclosure and their uses as a drug.
- the present invention relates to a compound of formula (A) for use as appetite suppressant, in particular for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain, wherein the compound has the formula (A) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
- Cy is a ring selected from the group consisting of a) with
- - Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen; - Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen; with X4, X 5 and
- Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl
- R 7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy
- Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N
- Rb being H or
- - L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NR e -, -C(O)-NR e -, -NR e -C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NR e -, -S(O2)-NR e -, -NR e -S(O)- and -NRe-SfCh)-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- the present invention relates to a compound for use as mentioned above, wherein the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof wherein
- - Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- - Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen;
- - Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- - L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NR e -, -NR e -C(O)-, -C(O)-, -S(O)-, - S(O 2 )-, -C(O)-NR e -, -S(O)-NR e -, -S(O 2 )-NR e -, -NR e -S(O)-and -NR e -S(O 2 )-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- - A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, ring, Ci-Cg alkyl, Ci-Cg alkyloxy,
- the present application also relates to a new compound having the formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof wherein - Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- - Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen, with at least two among Xi, X2 and X3 being N; preferably Xi is CH and X2 and X3 are N;
- - Y is present or absent and is selected from the group consisting of S, NH, O, sulfinyl, and sulfonyl,
- - L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NR e -, -NR e -C(O)-, -C(O)-, -S(O)-, - S(O 2 )-, -C(O)-NR e -, -S(O)-NR e -, -S(O 2 )-NR e -, -NR e -S(O)-and -NR e -S(O 2 )-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- - A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, ring, Ci-Cg alkyl, Ci-Cg alkyl
- the compound of formula (B) has -Y-L-B- selected in the group consisting of -NH- C(O)-NH-, -NH-S(O)-NH-, -NH-S(O 2 )-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O 2 )-NH-, -S-CH 2 - C(O)-NH-, -S-CH 2 -S(O)-NH-, -S-CH 2 -S(O 2 )-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH
- 1,4,5,6-Tetrahydropyrimidinyl- 1,4,5,6-Tetrahydropyrimidinyl-
- -NH-tetrahydropyrimidyl- e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-
- -O-1,4,5,6-Tetrahydropyrimidinyl- e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-
- Ri selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy
- XI, X2 and X3 selected in one of the following combinations: Xi, X2 and X3 are CH; Xi is CH and X2 and X3 are N; Xi is N and X2 and X3 are CH, and Xi and X2 are CH and X3 is N; preferably Xi is CH and X2 and X3 are N;
- Tetrahydropyrimidinyl- Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-; more preferably selected from the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH2-CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
- A being a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci- Cg alkyl, preferably said Ci-Cg alkyl being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an
- the compound of formula (B) has
- Ri selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C 3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C 3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C 3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C 3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by
- Tetrahydropyrimidinyl- Tetrahydropyrimidinyl-), -O-CH 2 -CH 2 -NH-, -S-CH 2 -; more preferably selected from the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
- A being a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci- Cg alkyl, preferably said Ci-Cg alkyl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH),
- the compound of formula (B) has
- Ri being selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a Ci-C 3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C 3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in
- - Y-L-B- selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH- C(O)-, -NH-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH 2 -CH(CH 2 - OCH 3 )-NH-C(O)-, - -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -O-cyclohexyl-NH- C(O)-, -O-cyclopentyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O
- A being a ring selected from the group consisting of phenyl, benzoxazolyl, 2-pyridinyl, 3- pyridinyl, isoindolinonyl, and thiophenyl, said ring being optionally substituted by a halogen, preferably a chlorine and/or a fluorine, by a hydroxy, by a nitro, by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably a methoxy, by a pyridinyl, preferably a 2- pyridinyl, by a morpholinyl, by a pyrrolidonyl, by a Co-C3alkyl-C(0)-OR, by a C1-C3 alkyl optionally substituted by at least one halogen, a guanidinyl, a Co-Csalkyl-NRR, a Co-Csalkyl-NH- C(O)-OR, a
- the compound of formula (B) may have one of the following formulae:
- Ri, Y and A as defined above, Z being O, N or S, and n being an integer from 0 to 4, preferably being 1.
- the compound is selected in any of the Tables 1, 2 and 3.
- the present invention relates to a compound for use as mentioned above, wherein the compound has a formula (C) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
- - Cy is a ring selected from the group consisting of with X4, X 5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3 being H or a C1-C3 alkyl optionally substituted by at least one halogen; and R4 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; with X 7 , Xg, and Xg being independently N or CR and at
- - Y-L-B- is absent or selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH 2 -, C(O)-NH-, -S-(CH 2 ) 3 - C(O)-NH-, -S-(CH 2 )4-C(O)-NH-, -S-(CH 2 ) 2 -NH- C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-CO-, -NH- CH 2 -C(O)-NH-, -O-CH2-, -O-(
- - A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, a 5-10- membered heteroaryl, preferably a 9-membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of halogen, a cyano, hydroxy, an ethynyl (-CECH), nitro, amino, amido, a Ci-Cg alkyl optionally substituted by at least one halogen, an amino group, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted
- the compound of formula (C) for use as mentioned above may have a formula (C-l) with X4, X 5 and Xg being N or CH;
- R 2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy;
- R 3 being H or a methyl optionally substituted by a halogen, preferably a fluorine;
- R4 being H or a fluorine, R 5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of -S-CH 2 -C(O)-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )-CH 2
- A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co- C3alkyl-NH-C(O)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A being benzoxazolyl, benzothiazolyl, thienopyri
- the present application also relates to a new compound having the formula (C-l) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof with X 4 , X 5 and Xg being N or CH; R2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 being H or a methyl optionally substituted by a halogen, preferably a fluorine; R 4 being H or a fluorine, R 5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of - C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidiny
- A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co- C 3 alkyl-NH-C(O)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH 2 -, -S-CH 2 -, and -S-(CH 2 ) 3 - and A being a benzoxazolyl or a benzo
- the compound of formula (C) for use as mentioned above may have a formula (C-2) with one of X 7 and X 8 being N and the other is CH, , Xg being CH or N and X10 being CRb, with Rb being H or a Ci-C 3 alkyl optionally substituted by a halogen, a hydroxy, a Ci-C 3 alkyloxy, or a NR'R' with R' being independently H or a Ci-C 3 alkyl; R 7 being H; with -Y-L-B- being selected from the group consisting of -O-CH 2 -, -O-(CH 2 ) 2 -NH-C(O)-, -S-(CH 2 ) 2 -NH-CO- , -O-(CH 2 ) 2 -N(CH 3 )-C(O)-, -O-CH 2 -C(O)-NH-, and -S-CH 2 -C(O)-NH-
- the compound of formula (C) for use as mentioned above may have a formula (C-3) with Xu being S, O or NH, X12 and X13 being N or CH; Rs being H, a phenyl or a pyridinyl, in particular a 2-pyridinyl; with -Y-L-B- being absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-; and with A being selected in the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
- Xu being S, O or NH
- the compound of formula (C) for use as mentioned above is selected in any of the Tables 4, 5 and 6.
- the present invention further relates to a new compound selected in Table 7, 8 or 9.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a new compound according to the present invention and to a new compound according to the present invention for use as a medicament.
- the present invention relates to compounds capable of reducing food intake and their uses as appetite suppressant, in particular for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain.
- a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain.
- the present invention relates to new compounds, a pharmaceutical or veterinary composition comprising a new compound according to the disclosure and their uses as a drug.
- Ci-Cg can also be used with lower numbers of carbon atoms such as C1-C2.
- Ci-Cg it means that the corresponding hydrocarbon chain may comprise from 1 to 6 carbon atoms, especially 1, 2, 3, 4, 5, or 6 carbon atoms.
- C1-C4 it means that the corresponding hydrocarbon chain may comprise from 1 to 4 carbon atoms, especially 1, 2, 3 or 4 carbon atoms.
- C1-C3 it means that the corresponding hydrocarbon chain may comprise from 1 to 3 carbon atoms, especially 1, 2, or 3 carbon atoms.
- C0-C3 means that the corresponding hydrocarbon chain may comprise from 0 to 3 carbon atoms, especially 0, 1, 2 or 3 carbon atoms. In particular, when in the context of Co, the hydrocarbon chain is absent.
- alkyl refers to a saturated, linear or branched aliphatic group.
- (Ci-Cg)alkyl more specifically means methyl, ethyl, propyl, isopropyl, butyl, pentyl, or hexyl.
- (Ci-C4)alkyl more specifically means methyl, ethyl, propyl, or isopropyl.
- (Ci-Csjalkyl” more specifically means methyl, ethyl or propyl.
- the "alkyl” is a methyl.
- Me it refers to a methyl.
- alkoxy or "alkyloxy” corresponds to the alkyl group as above defined bonded to the molecule by an -O- (ether) bond.
- (Ci-Cg)alkoxy includes methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, pentyloxy, or hexyloxy.
- (Ci-C4)alkoxy includes methoxy, ethoxy, propyloxy, isopropyloxy or butyloxy.
- Ci-Csjalkoxy includes methoxy, ethoxy, propyloxy or isopropyloxy.
- the "alkoxy" or "alkyloxy” is a methoxy.
- cycloalkyl corresponds to a saturated or unsaturated mono-, bi- or tri-cyclic alkyl group comprising between 3 and 20 atoms of carbons. It also includes fused, bridged, or spiro-connected cycloalkyl groups.
- cycloalkyl includes for instance cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, preferably cyclopropyl.
- spirocycloalkyl includes for instance a spirocyclopentyl.
- the term “cycloalkyl” corresponds to a saturated monocycloalkyl group comprising between 3 and 7 atoms of carbons.
- the cycloalkyl group is cyclohexyl.
- heterocycloalkyl corresponds to a saturated or unsaturated cycloalkyl group as above defined further comprising at least one heteroatom such as nitrogen, oxygen, or sulphur atom, preferably at least one nitrogen atom or oxygen atom. It also includes fused, bridged, or spiro- connected heterocycloalkyl groups.
- heterocycloalkyl groups include, but are not limited to dioxolanyl, benzo [1,3] dioxolyl, azetidinyl, oxetanyl, pyrazolinyl, pyranyl, thiomorpholinyl, pyrazolidinyl, piperidyl, piperazinyl, 1,4-dioxanyl, imidazolinyl, phthalimidyl, pyrrolinyl, pyrrolidinyl, piperidinyl, imidazolidinyl, morpholinyl, 1,4-dithianyl, pyrrolidonyl, oxozolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothiazolidinyl, dihydropyranyl, tetrahydropyrany
- the heterocycloalkyl group is for instance azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or pyrrolidonyl.
- the heterocycloalkyl group is morpholinyl.
- aryl corresponds to a mono- or bi-cyclic aromatic hydrocarbons having from 6 to 12 carbon atoms.
- aryl includes phenyl, naphthyl, or anthracenyl.
- the aryl is a phenyl.
- heteroaryl corresponds to an aromatic, mono- or poly-cyclic group comprising between 5 and 14 atoms and comprising at least one heteroatom such as nitrogen, oxygen or sulphur atom.
- heteroaryl further includes the "fused arylheteroaryl”, “fused arylheterocycloalkyl” and “fused heteroarylcycloalkyl”.
- fused arylheteroaryl may for instance include non-exhaustively quinolinyl, indole, or benzoxazole.
- fused arylheterocycloalkyl and “fused heteroarylcycloalkyl” correspond to a bicyclic group in which an aryl as above defined or a heteroaryl is respectively bounded to the heterocycloalkyl or the cycloalkyl as above defined by at least two carbons. In other terms, the aryl or the heteroaryl shares a carbon bond with the heterocycloalkyl or the cycloalkyl.
- Examples of such mono- and poly-cyclic heteroaryl group, fused arylheterocycloalkyl and fused arylcycloalkyl may be: pyridinyl, thiazolyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienopyridinyl, benzofuranyl, thianaphthalenyl, indolyl, indolinyl, quinolinyl, isoquinolinyl, benzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, triazinyl, thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthinyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, in
- the heteroaryl is for instance pyridinyl, pyrimidyl, 1,2,4-triazinyl or benzoxazolyl.
- the heteroaryl is for instance tetrazolyl or 1,2,3-trizolyl.
- the heteroaryl is for instance thiophenyl.
- fused when applied to the description of two rings corresponds to a bicyclic group in which the first ring is respectively bounded to the second ring by at least two carbons.
- halogen corresponds to a fluorine, chlorine, bromine, or iodine atom, preferably a fluorine, a chlorine or an iodine.
- substituted by at least or “substituted by” means that the group is substituted by one or several substituents of the list.
- a (Ci-Cg)alkyl substituted by at least one halogen” or "a (Ci-Cg)alkyl substituted by a halogen” may include a fluoromethyl (-CH2F), a difluoromethyl (-CHF2), or a trifluoromethyl (-CF3).
- stereoisomers are isomeric compounds that have the same molecular formula and sequence of bonded atoms, but differ in the 3D-dimensional orientations of their atoms in space.
- the stereoisomers include enantiomers, diastereoisomers, Cis-trans and E-Z isomers, conformers, and anomers.
- the stereoisomers include diastereoisomers and enantiomers.
- the “tautomers” are isomeric compounds that differ only in the position of the protons and the electrons.
- the "pharmaceutically salts” include inorganic as well as organic acids salts.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, maleic, methanesulfonic and the like.
- Further examples of pharmaceutically inorganic or organic acid addition salts include the pharmaceutically salts listed in J. Pharm. Sci. 1977, 66, 2, and in Handbook of Pharmaceutical Salts: Properties, Selection, and Use edited by P. Heinrich Stahl and Camille G. Wermuth 2002.
- the salt is selected from the group consisting of maleate, chlorhydrate, bromhydrate, and methanesulfonate.
- the "pharmaceutically salts” also include inorganic as well as organic base salts.
- suitable inorganic bases include sodium or potassium salt, an alkaline earth metal salt, such as a calcium or magnesium salt, or an ammonium salt.
- suitable salts with an organic base includes for instance a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- the salt is selected from the group consisting of sodium and potassium salt.
- treatment refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of a disease.
- amelioration or eradication of the disease, or symptoms associated with it refers to the amelioration or eradication of the disease, or symptoms associated with it.
- this term refers to minimizing the spread or worsening of the disease, resulting from the administration of one or more therapeutic agents to a subject with such a disease.
- the terms “subject”, “individual” or “patient” are interchangeable and refer to an animal, preferably to a mammal, even more preferably to a human, including adult and child.
- the term “subject” can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep and non-human primates, among others.
- Quantity means a fraction of a molecule.
- dose means a fraction of a molecule.
- the terms “active principle”, “active ingredient” and “active pharmaceutical ingredient” are equivalent and refers to a component of a pharmaceutical composition having a therapeutic effect.
- therapeutic effect refers to an effect induced by an active ingredient, or a pharmaceutical composition according to the invention, capable to prevent or to delay the appearance or development of a disease or disorder, or to cure or to attenuate the effects of a disease or disorder.
- effective amount refers to a quantity of an active ingredient or of a pharmaceutical composition which prevents, removes or reduces the deleterious effects of the disease. It is obvious that the quantity to be administered can be adapted by the man skilled in the art according to the subject to be treated, to the nature of the disease, etc.
- doses and regimen of administration may be function of the nature, of the stage and of the severity of the disease to be treated, as well as of the weight, the age and the global health of the subject to be treated, as well as of the judgment of the doctor.
- an amount is effective, for example, when its administration results in one or more of weight loss, management of weight, suppression of appetite for food, control of food intake, loss of body fat, prevention or modulation of hypoglycaemia, prevention or modulation of hyperglycaemia, promotion of insulin synthesis, or reduction in food intake.
- pharmaceutically acceptable excipient refers to any ingredient except active ingredients which are present in a pharmaceutical composition. Its addition may be aimed to confer a particular consistency or other physical or gustative properties to the final product. A pharmaceutically acceptable excipient must be devoid of any interaction, in particular chemical, with the active ingredients.
- the compound has the formula (A)
- Cy is a ring selected from the group consisting of with
- - Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- - Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen; b) with X4, X 5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH),
- Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl
- R 7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy
- Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N
- Rg being H
- - Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, -
- - L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NR e -, -C(O)-NR e -, -NR e -C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NR e -, -S(O2)-NR e -, -NR e -S(O)- and -NRe-SfCh)-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- - A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg al
- the compound has the formula (B) and any pharmaceutical salt, stereoisomer, tautomer or solvate thereof wherein
- - Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- - Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen;
- - Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, - C(O)-NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- - L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(C>2)-NRe-, -NRe-S(O)- and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- - A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg al
- the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- - Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- - L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl, - B is present or absent and is selected from the group consisting of -NR e -, -NR e -C(O)-, -C(O)-, -S(O)-, - S(O 2 )-, -C(O)-NR e -, -S(O)-NR e -, -S(
- - A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido (- C(O)-NH 2 ), guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl
- the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- - Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci-C 3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a Ci-C 3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen.
- the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- - Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci-C 3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a Ci-C 3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- - Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- - L is present or absent and is selected from the group consisting of a linear Ci-C 2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a Ci-C 3 alkyl, the Ci-C 3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- - B is present or absent and is selected from the group consisting of -NR e -, -NR e -C(O)-, -C(O)-, -S(O)-, - S(O 2 )-, -C(O)-NR e -, -S(O)-NR e -, -S(O 2 )-NR e -, -NR e -S(O)-and -NR e -S(O 2 )-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen, and
- - A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, ring, Ci-Cg alkyl, Ci-Cg alkyloxy,
- -Y-L-B- is selected in the group consisting of - NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O 2 )-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O 2 )-NH-, -S- CH 2 -C(O)-NH-, -S-CH 2 -S(O)-NH-, -S-CH 2 -S(O 2 )-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )-CH 2 -C(O)-NH-, -O-CH 2 - C(O)-NH-, -O-CH 2 -S(O)-NH-, -O-CH 2 -S(O 2 )-NH-, -O-CH 2 -C
- 1,4,5,6-Tetrahydropyrimidinyl- 1,4,5,6-Tetrahydropyrimidinyl-
- -NH-tetrahydropyrimidyl- e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-
- -O-1,4,5,6-Tetrahydropyrimidinyl- e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-
- -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-
- -Y-L-B- is selected from the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH2-CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-, more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O- CH2-CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-.
- the two connecting bonds can be in positions 1 and 2, 1 and 3 or 1 and 4.
- the two connecting bonds are in positions 1 and 4, the two connecting bonds are in trans or cis configuration, preferably trans configuration.
- the two connecting bonds are in trans configuration.
- the two connecting bonds can be in positions 1 and 2 or 1 and 3, preferably 1 and 3.
- the two connecting bonds are in trans configuration.
- -Y-L-B- includes a moiety -piperidinyl-C(O)-
- -piperidinyl-C(O)- may have the following structure
- -Y-L-B- includes a moiety -piperidinyl-NH-
- -piperidinyl-NH- has the following structure
- -Y-L-B- is -piperidinyl-NH-C(O)-, it may have the following structure
- -Y-L-B- includes a moiety -tetrahydropyrimidyl-
- -tetrahydropyrimidyl- may have the following structure
- -Y-L-B- is -tetrahydropyrimidyl-C(O)-, it may have the following structure
- -Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O 2 )-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)- NH-, -O-S(O 2 )-NH-, -S-CH 2 -C(O)-NH-, -S-CH 2 -S(O)-NH-, -S-CH 2 -S(O 2 )-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )- CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -S(O)-NH-,
- 1,4,5,6-Tetrahydropyrimidinyl- 1,4,5,6-Tetrahydropyrimidinyl-
- -NH-tetrahydropyrimidyl- e.g., -0-1, 4,5,6-
- -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O- CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH2-CH(CH 2 -OCH 3 )-NH-C(O)-, -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )- CH 2 -NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH 2 -NH-S-S-CH 2 -C(O)-NH-, -O-CH 2 -C(O
- -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -O-CH2-CH2-NH-S(O 2 )- , -O-CH2-CH2-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH 2 -CH(CH 2 -OCH 3 )-NH-C(O)-, -O-CH 2 -CH(CH 3 )-NH- C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -NH-C(O)-NH-, -NH-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -NH-CH 2 -CH 2 -NH
- -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-.
- -Y-L-B- is selected from the group consisting of -O-CH 2 -CH 2 -NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH 2 -, preferably is -O-CH2- or -S-
- Ri can be selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen.
- Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci- C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen.
- Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or
- Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a C1-C3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen.
- Xi, X2 and X3 are N.
- Xi, X2 and X3 are CR a and R a is H.
- Xi and X2 are CR a with Ra being H and X3 is N.
- Xi is CR a with R a being H and X2 and X3 are N.
- X2 is CR a with R a being H and Xi and X3 are N.
- Xi is CR a with R a being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N.
- Xi, X2 and X3 are as following:
- Xi, X2 and X3 are CH; or
- Xi is CH and X2 and X3 are N;
- Xi and X2 are CH and X3 is N.
- Xi, X2 and X3 are as following:
- Xi, X2 and X3 are CH; or
- Xi is CH and X2 and X3 are N.
- Xi is CH and X2 and X3 are N.
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10-membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyl, Ci-C
- A is a ring selected from the group consisting of a phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl, a 9-membered heteroaryl and a 10-membered heteroaryl
- the 5- membered heteroaryl can be preferably selected from the group consisting of thiophenyl, furanyl, and pyrrolyl
- the 6-membered heteroaryl can be pyridinyl or pyrimidinyl, preferably pyridinyl
- the 9- membered heteroaryl can be preferably selected from the group consisting of benzoxazolyl, benzimidazolyl, benzothiophenyl, indolyl, isoindolinonyl, and benzothiazolyl
- the 10-membered heteroaryl can be preferably selected from the group consisting of quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, and quin
- A is substituted ring.
- A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2- pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl a phthalimidyl and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl.
- A is an optionally substituted phenyl, thiophenyl, an isoindolinonyl, 2- pyridinyl or 3- pyridinyl, preferably a substituted phenyl, thiophenyl, 2- pyridinyl or 3- pyridinyl.
- the substitution of the ring A can be selected from a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano,
- this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound. More preferably, this substitution is in para position of the ring with respect to the connecting bound of A to the rest of the compound.
- the substitution of the ring A can be selected from the group consisting of a halogen, optionally a chlorine, a iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl; a guanidinyl; -NRR, -NH-C(O)-R, -NH-C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl; a Ci-Cg alkyloxy optionally substituted by at least one halogen; and a heterocycloalkyl such as morpholinyl, or pyrrolidinyl, or pyrrolidonyl.
- a halogen optionally a
- A is a phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl, or a 9-membered heteroaryl substituted by a chlorine.
- A can be a phenyl, a thiophenyl, a 2- pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, a phthalimidyl and a benzothiophenyl substituted by a chlorine, preferably in position para.
- A could be a phenyl, optionally substituted by one or several substituents selected from the group consisting of a halogen, especially a chlorine, a fluorine or an iodine, preferably a chlorine, in particular in position para; optionally with an addition substitution by a halogen, preferably in meta, more preferably a fluorine in meta, or by a hydroxy, preferably in ortho; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl or pyrrolidonyl,; a guanidinyl; -NRR, -NH-C(O)-R, -NH- C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl; a Ci-Cg alkyloxy optionally substituted by a halogen, preferably a methoxy,
- A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C3alkyl-C(0)-OR, Co-C3alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl optionally substituted by NR'R' or OR' with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen.
- A could be selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH2-NH2, -(CH2)2-NH2, -CH2-N(CH3)2, -CH2-pyrrolidinyl, -CH2-morpholinyl, -CH2-guanidinyl, by -CH2-C(O)-NH2, -C(O)-NH2, a methoxy, -CH2-NH-C(O)-CH3, -CH2- NH-C(O)-CH2-NH 2 , -CH2-NH-C(O)-CH(iPr)-NH2, -CH2-NH-C(O)-CH2-N(CH 3 )2, nitro, -(CH 2 )2-NH-C(O)-CH3; a phenyl substituted in para by a chlorine and in meta by a fluorine or a methoxy
- A could be selected from the group consisting of a phenyl, a phenyl substituted in para by a chlorine; a phenyl substituted in para by a chlorine and in meta by a fluorine, a methoxy, or a hydroxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a methoxy, a fluorine, or a methyl; a phenyl substituted in para by a fluorine, a methyl, a methoxy, -CH 2 - NH-C(O)-CH 3 , -CH 2 -CH2-NH-C(O)-CH3,-CH2-NH 2 , -CH 2 -morpholinyl, -CH 2 -guanidinyl, -C(O)-NH 2 , -CH 2 -NH- C(O)-CH(iPr)-NH 2 , a morpholinyl, or a
- A could be selected from the group consisting of a phenyl substituted in para by a chlorine, a phenyl substituted in para by a chlorine and in meta by a fluorine, a phenyl substituted in para by a chlorine and by a hydroxy in ortho, a phenyl substituted in para by -CH 2 -NH-C(O)-CH3, a phenyl substituted in para by a nitro, a 2- pyridinyl substituted in para by a chlorine, and a thiophenyl substituted by a halogen, preferably a chlorine.
- the compound of formula (B) has
- Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy
- XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are N; Xi, X2 and X3 are CH; Xi and X2 are CH and X3 is N; Xi is CH and X2 and X3 are N; X2 is CH and Xi and X3 are N; and Xi is CR a with R a being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N;
- -Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O 2 )-NH-, -S-C(O)-NH-, -O-C(O)-NH-, - O-S(O)-NH-, -O-S(O 2 )-NH-, -S-CH 2 -C(O)-NH-, -S-CH 2 -S(O)-NH-, -S-CH 2 -S(O)-NH-, -S-CH 2 -S(O 2 )-NH-, -S(O)- CH 2 -C(O)-NH-, -S(O 2 )-CH 2 -C(O)-NH-, -O-CH 2 -S(O
- the compound of formula (B) has
- Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a Ci-C 3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C 3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in
- XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are CH; Xi and X2 are CH and X3 is N; Xi is CH and X2 and X3 are N; X2 is CH and Xi and X3 are N; and Xi is CR a with R a being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N;
- -Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -O-CH2-CH2- NH-S(O 2 )-, -O-CH2-CH2-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH2-CH(CH 2 -OCH 3 )-NH- C(O)-, -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -NH-C(O)-, -NH-C(O)-, -NH-C(
- A is a ring selected from the group consisting of a phenyl, a 5-membered heteroaryl, a 6- membered heteroaryl, and a 9-membered heteroaryl; the ring being substituted by one or several substitution(s) selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyl
- the compound of formula (B) has
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a Ci-C 3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl;
- Xi, X2 and X 3 are as following: Xi, X2 and X 3 are CH; or Xi is CH and X2 and X 3 are N; or Xi and X2 are CH and X 3 is N; preferably Xi, X2 and X 3 are CH; or Xi is CH and X2 and X 3 are N; more preferably Xi is CH and X2 and X 3 are N;
- -Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -O-CH2-CH2- NH-S(O 2 )-, -O-CH2-CH2-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH 2 -CH(CH 2 -OCH 3 )-NH- C(O)-, -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -NH-C(O)-, -NH-C(O)-, -NH-
- A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3- pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl, and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl; the ring being substituted by being substituted by one or several substitution(s) selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen,
- the compound of formula (B) has
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a Ci-C 3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl;
- Xi, X 2 and X 3 are as following: Xi, X 2 and X 3 are CH; or Xi is CH and X 2 and X 3 are N; or Xi and X 2 are CH and X 3 is N; preferably Xi, X 2 and X 3 are CH; or Xi is CH and X 2 and X 3 are N; more preferably Xi is CH and X 2 and X 3 are N;
- -Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -O-CH 2 -CH 2 - NH-S(O 2 )-, -O-CH 2 -CH 2 -NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH 2 -CH(CH 2 -OCH 3 )-NH- C(O)-, -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -NH-C(O)-, -NH-C(
- A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3- pyridinyl, an isoindolinonyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl; the ring being substituted by one or several substituents selected from the group consisting of a halogen, optionally a chlorine, an iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido;
- A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C 3 alkyl-C(0)-OR, Co-C 3 alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl optionally substituted by a group -NR'R' or OR', with R' being independently H or a Ci-C 3 alkyl optionally substituted by at least one halogen.
- the compound of formula (B) has
- Ri is selected from the group consisting of a phenyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a Ci-C 3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a pyridinyl, preferably 2-pyridinyl or 3-pyridinyl, optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a C1-C3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; an iodine, a
- XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are CH; Xi is CH and X2 and X3 are N; and Xi and X2 are CH and X3 is N;
- -Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH 2 -C(O)-NH-, -O-CH 2 -C(O)-NH-, -O-CH 2 -CH 2 -NH-C(O)-, -O-CH2-CH2- NH-S(O 2 )-, -O-CH2-CH2-NH-, -O-CH 2 -CH(CH 2 -OH)-NH-C(O)-, -O-CH2-CH(CH 2 -OCH 3 )-NH- C(O)-, -O-CH 2 -CH(CH 3 )-NH-C(O)-, -O-CH(CH 3 )-CH 2 -NH-C(O)-, -NH-C(O)-, -NH-C(O)-, -NH-C(
- A is selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH 2 -NH 2 , -(CH 2 ) 2 -NH 2 , -CH 2 -N(CH3) 2 , -CH 2 -pyrrolidinyl, - CH 2 -morpholinyl, -CH 2 -guanidinyl, by -CH 2 -C(O)-NH 2 , -C(O)-NH 2 , a methoxy, -CH 2 -NH-C(O)-CH3, -CH 2 -NH-C(O)-CH 2 -NH 2 , -CH 2 -NH-C(O)-CH(iPr)-NH 2 , -CH 2 -NH-C(O)-CH 2 -N(CH 3 ) 2 , nitro, -(CH 2 ) 2
- the compound of formula (B) has one of the following formulae:
- Ri, Y and A as defined above in any one of the particular aspects, Z being O, NH or S, and n being an integer from 0 to 4, preferably being 1, and any pharmaceutical salt, stereoisomer, tautomer or solvate thereof.
- the compound of formula (B) has one of the following formulae: with Ri, Y and A as defined above in any one of the particular aspects and any pharmaceutical salt, stereoisomer, tautomer thereof.
- Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
- Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
- A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl, a phthalimidyl and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl, the substitution of the ring A being selected from the group consisting of a halogen, optionally a chlorine, an iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro;
- A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C3alkyl-C(0)-OR, Co-C3alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl optionally substituted by a group -NR'R' or OR', with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen.
- A is selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH2-NH2, -(Cbhh-NI-h, -CH 2 -N(CH 3 )2, -CH2-pyrrolidinyl, -CH2-morpholinyl, -CH2-guanidinyl, by -CH2-C(O)-NH2, -C(O)-NH2, a methoxy, -CH 2 -NH-C(O)-CH 3 , -CH2-NH-C(O)-CH 2 -NH2, -CH2-NH-C(O)-CH(iPr)-NH2, -CH2-NH-C(O)-CH 2 - N(CH 3 )2, nitro, -(CH2)2-NH-C(O)-CH 2 - N(CH 3 )2, nitro, -(CH2)2-NH-C(
- A is selected from the group consisting of a phenyl, a phenyl substituted in para by a chlorine; a phenyl substituted in para by a chlorine and in meta by a fluorine, a methoxy, or a hydroxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a methoxy, a fluorine, or a methyl; a phenyl substituted in para by a fluorine, a methyl, a methoxy, -CH 2 -NH-C(O)-CH 3 , -CH2-CH2-NH-C(O)-CH 3 ,-CH 2 -NH2, -CH 2 -morpholinyl, -CH 2 -guanidinyl, - C(O)-NH2, -CH2-NH-C(O)-CH(iPr)-NH2,
- A is selected from selected from the group consisting of a phenyl substituted in para by a chlorine, a phenyl substituted in para by a chlorine and in meta by a fluorine, a phenyl substituted in para by a chlorine and by a hydroxy in ortho, a phenyl substituted in para by -CH2-NH-C(O)-CH 3 , a phenyl substituted in para by a nitro, a 2- pyridinyl substituted in para by a chlorine, and a thiophenyl substituted by a halogen, preferably a chlorine.
- the compounds of (B-2) has a 9-membered ring which is substituted by a halogen, preferably a chlorine.
- the compound of formula (B) is selected from the compounds as shown in Tables 1, 2 and 3 and any pharmaceutical salt, stereoisomer, tautomer thereof.
- the compound of the invention is as disclosed above and has an appetite suppressor effect as measured in the assay disclosed in the example section.
- the food intake reduction in % compared to vehicle is of at least 10, 15, 20, 25, 30, 35, 40, 45 or 50%.
- - Cy is a ring selected from the group consisting of with X4, X 5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, and a C1-C3 alkoxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy; with X 7 , Xg, and
- - Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, - C(O)-NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- - L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membere
- - B is present or absent and is selected from the group consisting of -NR e -, -C(O)-NR e -, -NR e -C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NR e -, -S(O2)-NR e -, -NR e -S(O)- and -NRe-SfCh)-, with R e being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- - A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted by a halogen,
- the compound has the formula (C) Cy-Y-L-B-A (C) and any pharmaceutical salt, stereoisomer, tautomer or a solvate thereof wherein
- - Cy is a ring selected from the group consisting of with X4, X 5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3 being H or a C1-C3 alkyl optionally substituted by at least one halogen; and R4 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; with X 7 , Xg, and Xg being independently N or CR and at
- - Y-L-B- is absent or selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH 2 -, C(O)-NH-, -S-(CH 2 ) 3 - C(O)-NH-, -S-(CH 2 )4-C(O)-NH-, -S-(CH 2 ) 2 -NH- C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-CO-, -NH- CH 2 -C(O)-NH-, -O-CH2-, -O-(
- - A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, a 5-10- membered heteroaryl, preferably a 9-membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of halogen, a cyano, hydroxy, an ethynyl (-CECH), nitro, amino, amido, a Ci-Cg alkyl optionally substituted by at least one halogen, an amino group, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted
- the compound of the formula (C) may have one of the formulae (C-l), (C-2) and (C-3) and any pharmaceutical salt, stereoisomer, tautomer or a solvate thereof with Xs, Rs, Y, L, B and A being as defined above.
- the compound of formula (C) has a formula (C-l) and X4, X 5 and Xg are independently N or CH;
- R2 is selected from the group consisting of a methyl, an ethyl, a n-propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy;
- R3 is H or a methyl optionally substituted by a halogen, preferably a fluorine;
- R4 being H or a fluorine, R 5 and Rg are H; and
- -Y-L-B- is absent or selected from the group consisting of selected from the group consisting of -S-CH 2 -C(O)-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )-CH 2 -, C(O)-NH-, -S-(CH 2 ) 3 - C(O)-NH-, -S-(CH 2 ) 4 - C(O)-NH-, -S-(CH 2 ) 2 -NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, - S-CH 2 -, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-CO-, -NH-CH 2 -C(O)-NH
- A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co-C 3 alkyl-NH-C(0)-R, with R being H or a Ci-C 4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or
- -Y-L-B- is absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2) 3 - and A is benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, in particular a chlorine, preferably in position 6.
- the compound of formula (C) has a formula (C-l) and X 4 , X 5 and Xg are independently N or CH;
- R2 is selected from the group consisting of a methyl, an ethyl, a n-propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy;
- R 3 is H or a methyl optionally substituted by a halogen, preferably a fluorine;
- R 4 being H or a fluorine, R 5 and Rg are H; and
- -Y-L-B- is absent or selected from the group consisting of selected from the group consisting of - C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )- CO-, -NH-CH 2 -C(O)-NH-, -O-(CH 2 )-C(O)-NH-, -O-(CH 2 ) 3 -C(O)-NH-, - piperazinyl-C(O)-, -0-2-oxo- pyrrolidinyl-, -N(CH 3 )-CH 2 -C(O)-NH-, -C(O)-NH-, -CH 2 -NH-C(O)-, -(CH 2 ) 2 -C(O)-NH
- A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co-C 3 alkyl-NH-C(0)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or
- -Y-L-B- is absent or selected from the group consisting of -O-CH 2 -, -S-CH 2 -, and -S-(CH 2 )3- and A is a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6.
- R 2 is a methyl, ethyl or propyl, optionally substituted by a methoxy or at least one halogen;
- R3 and R 5 are H
- R4 is H or a halogen, preferably a fluorine
- Re is H, CH3, or CF3.
- X4, X 5 and Xg are N, or X4, X 5 and Xg are CH,
- R 2 is a methyl, ethyl or propyl optionally substituted by a methoxy
- R3 and R4 are H.
- -Y-L-B- is absent or selected from the group consisting of selected from the group consisting of -S-CH 2 -C(O)-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )-CH 2 -, C(O)-NH-, - S-(CH 2 ) 3 - C(O)-NH-, -S-(CH 2 ) 4 -C(O)-NH-, -S-(CH 2 ) 2 -NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, - S-piperidinyl-C(O)-, -S-CH 2 -, -O-(CH 2
- -Y-L-B- is selected from the group consisting of -S-CH 2 -C(O)-NH-, -S(O)-CH 2 -C(O)-NH-, -S(O 2 )- CH 2 -C(O)-NH-, -S-(CH 2 ) 3 -C(O)-NH-, -S-(CH 2 ) 4 -C(O)-NH-, -S-(CH 2 ) 2 -NH-C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-C(O)-, -NH-CH 2 -C(O)- NH-, -O-(CH 2 )
- -Y-L-B- is selected from the group consisting of -S-CH 2 -C(O)-NH-, -S(O)-CH 2 -C(O)-NH- , -S(O 2 )-CH 2 -C(O)-NH-, -S-(CH 2 ) 3 -C(O)-NH-, -S-(CH 2 ) 4 -C(O)-NH-, -S-(CH 2 ) 2 -NH-CO-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-C(O)-, -NH-CH 2 -C(O)- NH-, and -O-piperidinyl-
- -Y-L-B- is selected in one of the following groups:
- -Y-L-B- is absent or selected from the group consisting of selected from the group consisting of C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )- CO-, -NH-CH 2 -C(O)-NH-, -O-(CH 2 )-C(O)-NH-, -O-(CH 2 ) 3 -C(O)-NH-, - piperazinyl-C(O)-, -O-2-oxo- pyrrolidinyl-, -N(CH 3 )-CH 2 -C(O)-NH-, -C(O)-NH-, -CH 2 -NH-C(O)-, -(CH 2 ) 2 -C(O)-NH-
- -Y-L-B- is selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O- (CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-C(O)-, -NH-CH 2 -C(O)-NH-, -O-(CH 2 )-C(O)-NH-, -O-(CH 2 ) 3 - C(O)-NH-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -NMe-CH 2 -C(O)-NH-, -C(O)-NH-, -CH 2 -NH- C(O)- and -O-piperidinyl-C(O)-; or
- -Y-L-B- is selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O- (CH 2 ) 2 -NH-C(O)-, -O-(CH 2 ) 2 -N(CH 3 )-C(O)-, -NH-CH 2 -C(O)-NH-, and -O-piperidinyl-C(O)- .
- -Y-L-B- is absent or selected from the group consisting of -O-CH 2 -, -S-CH 2 -, and -S-(CH 2 ) 3 -.
- A is a ring selected from the group consisting of a 6-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
- A can be a ring selected from the group consisting of a phenyl, a morpholinyl, a piperazinyl, a piperidinyl and a cyclohexyl, said ring being optionally substituted.
- A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a methyl, an iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl or -CH 2 -NH-C(O)-CH 3 in para, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl.
- A is a ring selected from the group consisting of a phenyl substituted by a chlorine in para and optionally further substituted in ortho by a group selected from an iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, and a cyclohexyl.
- A is a 9-membered heteroaryl.
- A is a substituted 9-membered heteroaryl, preferably by a halogen, more preferably a chlorine.
- A when A is a 9-membered heteroaryl, A is benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably substituted by a halogen, more preferably a chlorine, preferably in position 6.
- A is benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, more preferably a chlorine, preferably in position 6.
- the compound of formula (C) has a formula (C-2) and one of X 7 and X 8 is N and the other is CH, Xg is CH or N and Xio is CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being independently H or a C1-C3 alkyl; R 7 is H; -Y-L-B- is selected from the group consisting of -O-CH2-, -O-(CH2h-NH-C(O)-, -S-(CH2)2-NH-CO-, -O- (CH2)2-N(CH3)-C(O)-, -O-CH2-C(O)-NH-, and -S-CH2-C(O)-NH-, preferably selected from the group consisting of -O-CH 2 -, -O-(
- A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, a cyclohexyl and a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6, preferably selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl
- X 7 , Xg, and Xio are CH and Xg is N; or Xg, Xg, and Xio are CH and X 7 is N;
- -Y-L-B- is selected from the group consisting of -O-CH2-, -O-(CH2h-NH-C(O)-, -S- (CH 2 ) 2 -NH-CO-, -O-(CH 2 )2-N(CH 3 )-C(O)-, -O-CH 2 -C(O)-NH-, and -S-CH 2 -C(O)-NH-, preferably selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, and -S-(CH2)2-NH-C(O)-.
- A is a ring selected from the group consisting of a 6-membered aryl or heteroaryl substituted by a chlorine in para; and a 9-membered heteroaryl substituted by a chlorine, preferably in position 5 or 6.
- A is a ring selected from the group consisting of a phenyl substituted by a chlorine in para; and a benzoxazolyl substituted by a chlorine, preferably in position 5 or 6.
- the compound of formula (C) has a formula (C-3) and Xu is S, O or NH, X12 and X13 are independently N or CH; Rg is H, a phenyl or a pyridinyl, in particular a 2-pyridinyl;
- -Y-L-B- is absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-;
- A is selected in the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
- Xu is S, X12 and X13 are CH, and Rg is H, a phenyl or a pyridinyl.
- -Y-L-B- is absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-.
- A is a ring selected in the group consisting of a phenyl optionally substituted by a chlorine in para, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
- the compound of formula (C) is selected from the compounds as shown in Tables
- the compound of formula (C) is selected from the compounds as shown in Tables
- the compound of the invention is as disclosed above and has an appetite suppressor effect as measured in the assay disclosed in the example section.
- the food intake reduction in % compared to vehicle is of at least 10, 15, 20, 25, 30, 35, 40, 45 or 50%.
- compositions and the uses thereof are provided.
- the present invention relates to a pharmaceutical or veterinary composition comprising any new compound according to the present invention.
- the pharmaceutical or veterinary composition further comprises a pharmaceutically or veterinary acceptable carrier or excipient.
- the present invention relates to the use of any new compound according to the invention as a drug or as a medicine.
- the invention further relates to a method for treating a disease in a subject, wherein a therapeutically effective amount of any new compound according to the invention, is administered to said subject in need thereof.
- the invention also relates to the use of any new compound according to the invention, for the manufacture of a medicine.
- the invention also relates to a pharmaceutical composition comprising any new compound according to the invention for use as a drug.
- the present invention provides compounds having an appetite-suppressor effect as shown by their capacity to reduce the food intake.
- Beneficial or desired clinical results from the compound of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or solvate thereof include, without limitation, reduced body weight, decreased weight-gain, reduced appetite, weight loss, management of weight, suppression of an appetite for food, controlled food intake, reduced or stabilized body fat content, reduced or stabilized blood or serum glucose and blood or serum insulin levels, amelioration, palliation, stabilization, diminishment of extent of obesity- related diseases, or a delay or slowing of obesity related disease progression.
- treatment is meant inhibiting or reducing an increase in obesity-related symptoms (e.g. weight gain) when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of the relevant condition.
- the compounds of the present invention are of interest as appetite suppressant. Accordingly, the present invention relates to any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for use as appetite suppressant.
- the present invention relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it as appetite suppressant.
- the invention further relates to a method for treating a disease in a subject, wherein a therapeutically effective amount of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it is administered to said subject in need thereof.
- the invention also relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the manufacture of a medicine for use as appetite suppressant.
- the present invention also relates to any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for use for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain.
- the present invention relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain.
- the invention further relates to a method for treating a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain in a subject, wherein a therapeutically effective amount of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it is administered to said subject in need thereof.
- the invention also relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the manufacture of a medicine for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain.
- the metabolic disease can be selected from the non-exhaustive list comprising obesity, diabetes (type 1 or type 2 diabetes), hypertension, non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD), insulin resistance, coronary heart disease, cardiovascular diseases (such as congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, or peripheral artery disease), and dyslipidemia.
- the eating disorders can be selected from the non-exhaustive list comprising bulimia nervosa, binge eating disorder, night eating syndrome, compulsive overeating, anxiety, depression, Gourmand syndrome, Prader-Willi syndrome.
- the syndromes can be selected from metabolic syndrome, Cohen syndrome, Bardet-Biedl syndrome, polycystic ovary syndrome and MOMO syndrome.
- the subject to be treated may have a disorder that leads to weight gain through excessive consumption of food, such as a disorder selected from binge eating disorder, subclinical binge eating, Prader-Willi syndrome and metabolic syndrome (also known as syndrome X or insulin-resistance syndrome).
- a disorder selected from binge eating disorder, subclinical binge eating, Prader-Willi syndrome and metabolic syndrome (also known as syndrome X or insulin-resistance syndrome).
- the subject may have other excess weight-related metabolic disorders. Examples of these include insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), glucagonomas, stroke, respiratory dysfunction, or renal disease.
- Body mass index is a simple index of weight-for-height that is commonly used for human adults to assess whether a patient is "overweight” or "obese”. It is defined as an individual's weight in kilograms divided by the square of his or her height in meters (kg/m2).
- the compounds of the present invention are also of interest in order to promote weight loss in a subject.
- the invention may relate to a method for promoting weight loss or preventing weight gain comprising administering a compound of the present invention or a composition comprising it to the subject.
- the subject can be obese.
- the Body Mass Index (BMI) is higher or equal to 30.
- the subject can be overweight.
- the overweight can be only minor, e.g. unsightly but without any threat to the health.
- the Body Mass Index (BMI) is lower than 30.
- the method is a non-therapeutic method. For instance, the goal could be improved the physical appearance by reducing the weight.
- the subject may have a normal body mass index (up to 25).
- the compound according to the invention or the pharmaceutical composition according to the invention may be administered by any conventional route of administration.
- the compound or the pharmaceutical composition of the invention can be administered by a topical, enteral, oral, parenteral, intranasal, intravenous, intraperitoneal, intra-arterial, intramuscular, intratumoral, subcutaneous or intraocular administration and the like.
- the compound according to the invention or the pharmaceutical composition according to the invention can be formulated for a topical, enteral, oral, parenteral, intranasal, intravenous, intraperitoneal, intraarterial, intramuscular, intratumoral, subcutaneous or intraocular administration and the like.
- the compound according to the invention or the pharmaceutical composition according to the invention is administered by enteral or parenteral route of administration.
- the compound according to the invention or the pharmaceutical composition according to the invention is preferably administered by intravenous or intraperitoneal route of administration.
- the compound according to the invention or the pharmaceutical composition according to the invention is preferably administered by oral route of administration.
- composition comprising the molecule is formulated in accordance with standard pharmaceutical practice (Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York) known by a person skilled in the art.
- the composition can be formulated into conventional oral dosage forms such as tablets, capsules, powders, granules and liquid preparations such as syrups, elixirs, and concentrated drops.
- Nontoxic solid carriers or diluents may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
- binders which are agents which impart cohesive qualities to powdered materials, are also necessary.
- starch, gelatine, sugars such as lactose or dextrose, and natural or synthetic gums can be used as binders.
- Disintegrants are also necessary in the tablets to facilitate break-up of the tablet.
- Disintegrants include starches, clays, celluloses, algins, gums and crosslinked polymers.
- lubricants and glidants are also included in the tablets to prevent adhesion to the tablet material to surfaces in the manufacturing process and to improve the flow characteristics of the powder material during manufacture.
- Colloidal silicon dioxide is most commonly used as a glidant and compounds such as talc or stearic acids are most commonly used as lubricants.
- composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
- nasal sprays for transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used.
- the active compound can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
- compositions according to the invention may be formulated to release the active drug substantially immediately upon administration or at any predetermined time or time period after administration.
- the compound according to the invention or the pharmaceutical composition according to the invention may be administered as a single dose or in multiple doses.
- the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day.
- the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day. The treatment may last as long as the disease persists.
- the amount of compound according to the invention or of pharmaceutical composition according to the invention to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient.
- the total compound dose for each administration of the compound according to the invention or of the pharmaceutical composition according to the invention is comprised between 0.00001 and 1 g.
- compositions can be adjusted by the man skilled in the art according to the type and severity of the disease, and to the patient, in particular its age, weight, sex, and general physical condition.
- the present invention also relates to the combined use of a compound of the present invention with at least another active ingredient or with an appropriate dietary regimen.
- 2-chloro-5-phenylpyrimidine is commercially available.
- 2-Chloro-5-(pyrid-2-yl)pyrimidine was prepared by Negishi cross-coupling according to a known procedure (Organic Process Research & Development 2007, 11, 237-240). The same procedure was followed for pyridyls with additional substituents.
- 2-Chloro-5-(pyrid-2-yl)pyrimidine was prepared by Negishi cross-coupling according to a known procedure (Organic Process Research & Development 2007, 11, 237-240). The same procedure was followed for pyridyls with additional substituents.
- 4-Chloro-N-(2-hydroxyethyl)benzamide was prepared as previously described from 4-chlorobenzoyl chloride and 2-aminoethanol in DCM.
- Route Rl In an additional example of route Rl, the amide coupling is performed after Boc- deprotection, synthesis exemplified on compound 118
- IJAIH4 (1.32 g, 34.9 mmol) was suspended in Et20 (50 mL). The suspension was cooled to 0 °C. To the suspension was added a solution of the above prepared 2-([l,l'-biphenyl]-4-yloxy)acetonitrile (3.65 g, 17.4 mmol) in Et20 (100 mL). The resulting mixture was stirred at 0 °C for 1 h, then at room temperature for 20 h. The reaction mixture was cooled to 0 °C and H2O was added carefully. After 15 min, EtOAc (150 mL) was added.
- the reaction mixture was stirred at room temperature under argon for 18 h and then filtered through a celite pad.
- the celite pad was washed with EtOAc (20 mL) the combined filtrates were evaporated and the residue was purified by flash column chromatography (DCM/MeOH).
- the product-containing fractions were combined and concentrated and the residue was suspended in DCM, extracted with 2M HCI (15 mL) and NaHCO 3 solution (5% aqueous, 15 mL). Concentration of the organic layer afforded the title compound as white solid (65 mg, 33%).
- compound 215 was prepared starting from (2R,4R)-2-aminomethyl-4- hydroxypyrrolidine-l-carboxylate to afford the title compound as white solid.
- Boc-L-Pro (1.00 g, 4.65 mmol), 4-chloroaniline hydrochloride (838 mg, 5.11 mmol), EDC*HCI (2.22 g, 11.6 mmol) and HOBt (1.07 g, 6.98 mmol) were suspended in anhydrous CH2CI2 (30 mL). The suspension was cooled to 0°C, and EtaN (2.33 mL, 16.7 mmol) was added. The resulting light brown solution was stirred at room temperature under argon for 3h. To the mixture was added H2O (15 mL), the resulting mixture was extracted with CH2CI2 (3x20 mL), the organic layer was dried over Na2SO4 and evaporated.
- LiAIH4 (742 mg, 19.54 mmol) was suspended in anhydrous Et20 (150 mL). The suspension was cooled to 0 °C. To the suspension was added a solution of 2-(quinolin-7-yloxy)acetonitrile (1.80 g, 9.77 mmol) in Et20 (150 ml). The reaction mixture was stirred 1 hour at 0 °C, then at room temperature for 18h. The resulting mixture was cooled to 0 °C and H2O (20 ml) was added dropwise. The mixture was extracted with EtOAc (3x30 mL). The organic layer was washed with brine, H2O, dried over Na2SO4, and evaporated.
- N-Methylisatin (369 mg, 2.29 mmol) was dissolved in TFA (3 mL). To the dark red solution was added ethyl 2-hydrazineyl-2-iminoacetate (300 mg, 2.29 mmol). The dark red solution was stirred at room temperature for 30 min., then concentrated in vacuo. The dark red sticky residue was dissolved in POCI3 (2.1 mL, 22.9 mmol) and the brown solution was stirred at 140 °C under argon for 16 h. The resulting black solution was slowly poured in MeOH at 0°C and the resulting solution was evaporated.
- Nitrile derivative M4 (1.11 g, 5.31 mmol) was suspended in HCI (g.) saturated anhydrous MeOH (60 mL). The resulting yellow suspension was stirred at 60 °C under argon for 48 h. To the suspension was added H2O (40 mL), the resulting mixture was stirred at room temperature for 1 h. The yellow precipitate was filtered, washed with H2O, and dried under vacuum (806 mg, 63%).
- UPLC- ESI m/z: 243 [M+H] + .
- Benzo[b]thiophene-2-carboxylic acid (900 mg, 5.05 mmol), 4-chloroaniline hydrochloride (870 mg, 5.30 mmol) and DMAP (250 mg, 2.02 mmol) were dissolved in CH2CI2 (30 mL).
- NMM 920 mg, 9.09 mmol
- 3- (Ethyliminomethyleneamino)-/V,/ ⁇ /-dimethylpropan-l-amine hydrochloride (1.45 g, 7.58 mmol) was added in one portion and the resulting solution was stirred at room temperature for 16 h. The resulting suspension was evaporated in vacuo and the residue suspended in a small amount of CH2CI2.
- N3 (1.05 g, 2.86 mmol), 4-phenylboronic acid (420 mg, 3.43 mmol), K2CO3 (470 mg, 3.43 mmol) and Pd PPhah (160 mg, 0.140 mmol) were suspended in a mixture of 1,4-dioxane (10 mL) and water (10 mL). The suspension was stirred at 100 °C for 16 h. The reaction mixture was cooled to ambient temperature and water was added. The resulting precipitate was filtered and washed with water and EtOAc several times. Crystallization from CHCU/MeOH yielded the desired product as a yellowish solid (750 mg, 72%).
- Tables A and B The effect of the compounds on the food intake in diet-induced obese mice over 24h is provided in Tables A and B.
- This animal model is recognized as being a predictive model for obesity and food intake in human as illustrated for instance by Kleinert et al (Nat Rev Endocrinol. 2018 Mar;14(3):140-162). Accordingly, the utility of the compounds of the present invention as appetite suppressant is well shown.
- Table A
- mice Four-month-old male C57BL/6J mice (Charles River, Sulzfeld, Germany) were individually housed in wire- mesh hanging cages or in standard mice cages at room temperature (21° ⁇ 1°C) and at an artificial 12-hour light/12-hour dark cycle. Animals were able to see, hear, and smell their conspecifics in neighboring cages and were not socially isolated. Water, food (60% high-fat diet, Sniff Spezialdiaten GmbH, Germany), and bedding were provided ad libitum, if not indicated differently. All procedures for mice handling and experimental interventions were according to Swiss Animal Welfare laws, approved by the "Kantonales Veterinaramt Zurich," and conform to the principles of UK regulations. Animals were adapted to novel housing situations and feeding schedules at least for 1 week. All experiments were conducted three times with saline injections before drug administration to habituate the animals to the experimental procedure. Mice compound application
- Food intake reduction in % compared to vehicle in mice is calculated as following: 100-(mean(veh)-mean(cpd))/mean(veh)*100
Abstract
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
Description
COMPOUNDS FOR USE AS APPETITE SUPPRESSANT
FIELD OF THE INVENTION
The present invention relates to new compounds, in particular compounds capable of ameliorating the metabolic syndrome, and their uses, especially for the treatment of diseases and disorders.
BACKGROUND OF THE INVENTION
Today millions of people are obese. At the individual level, obesity reduces life expectancy by 3-4 years causing complications such as type 2 diabetes, psychosocial disorders, cancers among many others. Therapeutic options for weight loss exist in the form of lifestyle therapy, weight-lowering drugs and/or bariatric surgeries depending on the disease severity and complications. Unfortunately, all offer a poor benefit/risk ratio to reduce obesity and to prevent the onset of obesity-associated complications.
Anti-obesity or weight loss drugs are pharmacological agents that reduce or control weight. These drugs may alter either appetite, absorption of calories and/or energy expenditure.
In the United States, orlistat (Xenical) is currently approved by the FDA for long-term use. It reduces intestinal fat absorption by inhibiting pancreatic lipase. However, severe liver damage has been reported as side effects. Rimonabant (Acomplia), a second drug, works via a specific blockade of the endocannabinoid system. It had been approved in Europe for the treatment of obesity but has not received approval in the United States or Canada due to safety concerns. The European Medicines Agency in October 2008 recommended the suspension of the sale of rimonabant as the risks seem to be greater than the benefits. Sibutramine (Meridia), which acts in the brain to inhibit deactivation of the neurotransmitters, thereby decreasing appetite, was withdrawn from the United States and Canadian markets in October 2010 due to cardiovascular concerns. Lorcaserin, marketed under the brand name Belviq, is a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating a type of serotonin receptor known as the 5-HT2C receptor in a region of the brain called the hypothalamus, which is known to control appetite. However, it was removed from the market in the United States in 2020 due to its increased risk of cancer. Qsymia (phentermine-topiramate) was approved by the FDA in 2012 for the chronic treatment of obesity. Combining the appetite suppressant amphetamine-like properties of phentermine to topiramate, an anticonvulsive drug bearing weight loss potential, provides modest results on obesity treatments. However, common adverse effects such as insomnia, constipation, dizziness, paresthesia, dysgeusia and dry mouth are associated to its use and, even more cardiovascular risks and possible kidney alterations have been reported. Contrave is the combination of naltrexone, an opioid antagonist, with bupropion, originally prescribed as an antidepressant, and was recently approved by FDA and EMA for the treatment of obesity. Common side effects are nausea, constipation, headache, dizziness, vomiting, insomnia, dry mouth and diarrhea. Its use is contraindicated in case of hypertension, seizure and alimentary disorder antecedents. Liraglutide is a GLP-1 receptor mono-agonist. It was approved by FDA and EMA for the
treatment of obesity. Liraglutide treatment is frequently associated with gastrointestinal side effects, nausea, diarrhea, constipation and vomiting.
Because of potential side effects, and limited evidence of benefits in weight reduction, anti-obesity drugs are only prescribed for obesity where it is hoped that the benefits of the treatment outweigh its risks.
Therefore, there is a strong need of an appetite suppressor with a high efficacy and a good safety profile.
SUMMARY OF THE INVENTION
The present invention relates to compounds capable of reducing food intake and their uses for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain. In addition, the present invention relates to new compounds, a pharmaceutical or veterinary composition comprising a new compound according to the disclosure and their uses as a drug.
More particularly, the present invention relates to a compound of formula (A) for use as appetite suppressant, in particular for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain, wherein the compound has the formula (A) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
Cy-Y-L-B-A (A) wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen;
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, and a C1-C3 alkoxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy; c)
with X7, Xg, and Xg being independently N or CRb and at least one of X7, Xg, and Xg is N, and X10 being
CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy; d)
with Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N; Rg being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy;
- Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, - C(O)-NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)- and -NRe-SfCh)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-C=CH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a particular embodiment, the present invention relates to a compound for use as mentioned above, wherein the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy
optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen;
- Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, - S(O2)-, -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
The present application also relates to a new compound having the formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
wherein
- Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen, with at least two among Xi, X2 and X3 being N; preferably Xi is CH and X2 and X3 are N;
- Y is present or absent and is selected from the group consisting of S, NH, O, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, - S(O2)-, -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH- C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen; and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound.
More particularly, the compound of formula (B) has -Y-L-B- selected in the group consisting of -NH- C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2- C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-
NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -
O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-
S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-
(CH2)2-N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2-
N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2-N(CH3)-
S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-
CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-
CH(CH3)-NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)-
NH-S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH-C(O)-, -S-CH2-
CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH-
S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-
CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-
NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-
C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O)-, -
NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O2)-, -NH-CH2-
CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-
(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-
, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-
, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S-cyclopentyl-NH-S(O)-, -
S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-
S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH-cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O- piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH-piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-,
-NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S-piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-
NH-C(O)-, -piperidinyl-NH-S(O)-, -piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-
NH-, -NH-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -N H-pyrrolidinyl-
S(O)-NH-, -O-pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -o- pyrrolidinyl-CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -o- pyrrolidinyl-CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -o- pyrrolidinyl-CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -o- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -s- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -o- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-),
tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., -O-
1,4,5,6-Tetrahydropyrimidinyl-), -NH-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -
O-CH2-; -S-CH2-; and -NH-CH2-.
More particularly, the compound of formula (B) has
Ri selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, by a C1-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen; a C3-C7 cycloalkyl, preferably a C5-Cs cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least
one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a C2-C6 alkyl optionally substituted by at least one halogen, and an ethynyl (-CECH),
XI, X2 and X3 selected in one of the following combinations: Xi, X2 and X3 are CH; Xi is CH and X2 and X3 are N; Xi is N and X2 and X3 are CH, and Xi and X2 are CH and X3 is N; preferably Xi is CH and X2 and X3 are N;
- -Y-L-B- selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)- NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)- NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -0-CH2- S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O- (CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O- (CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-(CH2)2- N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2- N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2- N(CH3)-S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)- NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH- S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O- CH2-CH(CH2-OCH3)-NH-S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2- CH(CH2-OH)-NH-C(O)-, -S-CH2-CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)- CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH-S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)- NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH- S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, - NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, - NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, - NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)- , -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH- (CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-, -O- cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH- C(O)-, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S- cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-
S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH-cyclopentyl-NH-S(O)-, -NH- cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH-piperidinyl-C(O)-, -O- piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S- piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, - piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-
C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O- pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-
CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-
CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O-pyrrolidinyl-
CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., - O-1,4,5,6-Tetrahydropyrimidinyl-), -NH-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-; -S-CH2-; and -NH-CH2-.; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-CH2- CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, piperidinyl-NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
A being a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci-
Cg alkyl, preferably said Ci-Cg alkyl being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound.
In a more particular aspect, the compound of formula (B) has
Ri selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a Ci-C3 alkyl optionally substituted by at least one halogen, by a Ci-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen; a C3-C7 cycloalkyl, preferably a C5-Cg cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or
by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a C2-C6 alkyl optionally substituted by at least one halogen, and an ethynyl (-CECH),
XI being CH and X2 and X3 being N;
- -Y-L-B- selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)- NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)- NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -0-CH2- S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O- (CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O- (CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-(CH2)2- N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2- N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2- N(CH3)-S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)- NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH- S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O- CH2-CH(CH2-OCH3)-NH-S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2- CH(CH2-OH)-NH-C(O)-, -S-CH2-CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)- CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH-S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)- NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH- S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, - NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, - NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, - NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)- , -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH- (CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-, -O- cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-
C(O)-, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S- cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-
S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH-cyclopentyl-NH-S(O)-, -NH- cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH-piperidinyl-C(O)-, -O- piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S- piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, - piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-
C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O- pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-
CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-
CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O-pyrrolidinyl-
CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., - O-1,4,5,6-Tetrahydropyrimidinyl-), -NH-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-; -S-CH2-; and -NH-CH2-; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-CH2- CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, piperidinyl-NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
A being a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group,
a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci- Cg alkyl, preferably said Ci-Cg alkyl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound.
In a more particular aspect, the compound of formula (B) has
Ri being selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a Ci-C3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a cyclohexyl, said cyclohexyl being optionally bridged and/or optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an
isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; preferably a bridged cyclohexyl; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; a C4-C6 alkyl optionally substituted by at least one halogen, preferably an isobutyl, an isopropyl or an isohexyl, and an ethynyl (-CECH),
XI being CH and X2 and X3 being N;
- Y-L-B- selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH- C(O)-, -NH-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2- OCH3)-NH-C(O)-, - -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-cyclohexyl-NH- C(O)-, -O-cyclopentyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, -O- piperidinyl-C(O)-, -piperidinyl-NH-C(O)-, -O-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-CH2-NH- C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, and -S-CH2-; and
A being a ring selected from the group consisting of phenyl, benzoxazolyl, 2-pyridinyl, 3- pyridinyl, isoindolinonyl, and thiophenyl, said ring being optionally substituted by a halogen, preferably a chlorine and/or a fluorine, by a hydroxy, by a nitro, by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably a methoxy, by a pyridinyl, preferably a 2- pyridinyl, by a morpholinyl, by a pyrrolidonyl, by a Co-C3alkyl-C(0)-OR, by a C1-C3 alkyl optionally substituted by at least one halogen, a guanidinyl, a Co-Csalkyl-NRR, a Co-Csalkyl-NH- C(O)-OR, a C0-C3alkyl-NH-C(O)-R, a C0-C3alkyl-NH-C(O)-NRR, with R being H or a C1-C4 alkyl optionally substituted by a group -NR'R' or OR', with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, preferably Ci-C2alkyl-NH2, Ci-C2alkyl-NH-C(O)- O-C1-C4 alkyl, Ci-C2alkyl-NH-C(O)-Ci-C4 alkyl, Ci-C2alkyl-NH-C(O)-NH2, Ci-C2alkyl-NH-C(O)-Ci- C4alkyl-NH2, and Ci-C2alky l-NH-C(O)-Ci-C2alkyl- N(CH3)2.
In particular, the compound of formula (B) may have one of the following formulae:
with Ri, Y and A as defined above, Z being O, N or S, and n being an integer from 0 to 4, preferably being 1.
In a very specific aspect, the compound is selected in any of the Tables 1, 2 and 3.
In another a particular embodiment, the present invention relates to a compound for use as mentioned above, wherein the compound has a formula (C) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
Cy-Y-L-B-A (C)
Wherein
- Cy is a ring selected from the group consisting of
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3 being H or a C1-C3 alkyl optionally substituted by at least one halogen; and R4 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with X7, Xg, and Xg being independently N or CR and at least one of X7, Xg, and Xg is N, and X10 being CR, with R being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with Xu being a heteroatom, preferably S, O or NH, more preferably S, and X12 being N or CH and X13 being CH or N; Rs being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
- Y-L-B- is absent or selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH- CH2-C(O)-NH-, -O-CH2-, -O-(CH2)2-, -S-(CH2)3-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -
CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and - O-(CH2)-C(O)-N(CH3)-;
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, a 5-10- membered heteroaryl, preferably a 9-membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of halogen, a cyano, hydroxy, an ethynyl (-CECH), nitro, amino, amido, a Ci-Cg alkyl optionally substituted by at least one halogen, an amino group, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)-OR, Co-C3alkyl-NH-C(0)- NRR, Co-C3alkyl-C(0)-R, Co-C3alkyl-C(0)-OR, or Co-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a particular aspect, the compound of formula (C) for use as mentioned above may have a formula (C-l)
with X4, X5 and Xg being N or CH; R2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 being H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH- , -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2- NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)- C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)- NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-,
and -O-(CH2)-C(O)-N(CH3)-; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)- CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-C(O)-, -C(O)- piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, - NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, -piperazinyl-C(O)-, -O-2-oxo- pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and -O- piperidinyl-C(O)-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2- C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-CO-, -C(O)- piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, - NH-CH2-C(O)-NH-, and -O-piperidinyl-C(O)- , and
A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co- C3alkyl-NH-C(O)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A being benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, in particular a chlorine, preferably in position 6.
The present application also relates to a new compound having the formula (C-l) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
with X4, X5 and Xg being N or CH; R2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 being H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of - C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, - NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, - N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -O-(CH2)3-
C(O)-NH-, and -O-(CH2)-C(O)-N(CH3)-; preferably selected from the group consisting of -C(O)- piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, -O- (CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -NMe-CH2-C(O)-NH-, - C(O)-NH-, -CH2-NH-C(O)- and -O-piperidinyl-C(O)-; more preferably selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2- C(O)-NH-, and -O-piperidinyl-C(O)- , and
A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co- C3alkyl-NH-C(O)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A being a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6.
In another particular aspect, the compound of formula (C) for use as mentioned above may have a formula (C-2)
with one of X7 and X8 being N and the other is CH, , Xg being CH or N and X10 being CRb, with Rb being H or a Ci-C3 alkyl optionally substituted by a halogen, a hydroxy, a Ci-C3 alkyloxy, or a NR'R' with R' being independently H or a Ci-C3 alkyl; R7 being H; with -Y-L-B- being selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, -S-(CH2)2-NH-CO- , -O-(CH2)2-N(CH3)-C(O)-, -O-CH2-C(O)-NH-, and -S-CH2-C(O)-NH-, preferably selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, and -S-(CH2)2-NH-C(O)-; and with A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (- CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, a cyclohexyl and a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6, preferably selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para optionally substituted by an a C2-C3 acyl.
In another particular aspect, the compound of formula (C) for use as mentioned above may have a formula (C-3)
with Xu being S, O or NH, X12 and X13 being N or CH; Rs being H, a phenyl or a pyridinyl, in particular a 2-pyridinyl; with -Y-L-B- being absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-; and with A being selected in the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
In another particular aspect, the compound of formula (C) for use as mentioned above is selected in any of the Tables 4, 5 and 6.
The present invention further relates to a new compound selected in Table 7, 8 or 9.
Finally, the present invention relates to a pharmaceutical composition comprising a new compound according to the present invention and to a new compound according to the present invention for use as a medicament.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compounds capable of reducing food intake and their uses as appetite suppressant, in particular for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication-induced weight gain. In addition, the present invention relates to new compounds, a pharmaceutical or veterinary composition comprising a new compound according to the disclosure and their uses as a drug.
Definitions
According to the present invention, the terms below have the following meanings:
The terms mentioned herein with prefixes such as for example Ci-Cg, can also be used with lower numbers of carbon atoms such as C1-C2. If, for example, the term Ci-Cg is used, it means that the corresponding hydrocarbon chain may comprise from 1 to 6 carbon atoms, especially 1, 2, 3, 4, 5, or 6 carbon atoms. If, for example, the term C1-C4 is used, it means that the corresponding hydrocarbon chain may comprise from 1 to 4 carbon atoms, especially 1, 2, 3 or 4 carbon atoms. If, for example, the term C1-C3 is used, it means that the corresponding hydrocarbon chain may comprise from 1 to 3 carbon atoms, especially 1, 2, or 3 carbon atoms. C0-C3 means that the corresponding hydrocarbon
chain may comprise from 0 to 3 carbon atoms, especially 0, 1, 2 or 3 carbon atoms. In particular, when in the context of Co, the hydrocarbon chain is absent.
The term "alkyl" refers to a saturated, linear or branched aliphatic group. The term "(Ci-Cg)alkyl" more specifically means methyl, ethyl, propyl, isopropyl, butyl, pentyl, or hexyl. The term "(Ci-C4)alkyl" more specifically means methyl, ethyl, propyl, or isopropyl. The term "(Ci-Csjalkyl" more specifically means methyl, ethyl or propyl. In a particular aspect, the "alkyl" is a methyl. By "Me", it refers to a methyl. The term "alkoxy" or "alkyloxy" corresponds to the alkyl group as above defined bonded to the molecule by an -O- (ether) bond. (Ci-Cg)alkoxy includes methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, pentyloxy, or hexyloxy. (Ci-C4)alkoxy includes methoxy, ethoxy, propyloxy, isopropyloxy or butyloxy. (Ci-Csjalkoxy includes methoxy, ethoxy, propyloxy or isopropyloxy. In a particular aspect, the "alkoxy" or "alkyloxy" is a methoxy.
The term "cycloalkyl" corresponds to a saturated or unsaturated mono-, bi- or tri-cyclic alkyl group comprising between 3 and 20 atoms of carbons. It also includes fused, bridged, or spiro-connected cycloalkyl groups. The term "cycloalkyl" includes for instance cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, preferably cyclopropyl. The term "spirocycloalkyl" includes for instance a spirocyclopentyl. In a particular aspect, the term "cycloalkyl" corresponds to a saturated monocycloalkyl group comprising between 3 and 7 atoms of carbons. In a particular aspect, the cycloalkyl group is cyclohexyl. The term "heterocycloalkyl" corresponds to a saturated or unsaturated cycloalkyl group as above defined further comprising at least one heteroatom such as nitrogen, oxygen, or sulphur atom, preferably at least one nitrogen atom or oxygen atom. It also includes fused, bridged, or spiro- connected heterocycloalkyl groups. Representative heterocycloalkyl groups include, but are not limited to dioxolanyl, benzo [1,3] dioxolyl, azetidinyl, oxetanyl, pyrazolinyl, pyranyl, thiomorpholinyl, pyrazolidinyl, piperidyl, piperazinyl, 1,4-dioxanyl, imidazolinyl, phthalimidyl, pyrrolinyl, pyrrolidinyl, piperidinyl, imidazolidinyl, morpholinyl, 1,4-dithianyl, pyrrolidonyl, oxozolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothiazolidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydroisoquinoline, methyl-tetrahydroisoquinoline, isoindolinonyl, tetrahydrofuranyl, and tetrahydrothiophenyl. In a particular aspect, the heterocycloalkyl group is for instance azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or pyrrolidonyl. In another particular aspect, the heterocycloalkyl group is morpholinyl.
The term "aryl" corresponds to a mono- or bi-cyclic aromatic hydrocarbons having from 6 to 12 carbon atoms. For instance, the term "aryl" includes phenyl, naphthyl, or anthracenyl. In a particular aspect, the aryl is a phenyl.
The term "heteroaryl" as used herein corresponds to an aromatic, mono- or poly-cyclic group comprising between 5 and 14 atoms and comprising at least one heteroatom such as nitrogen, oxygen or sulphur atom. As used herein, the term "heteroaryl" further includes the "fused arylheteroaryl",
"fused arylheterocycloalkyl" and "fused heteroarylcycloalkyl". The terms "fused arylheteroaryl" may for instance include non-exhaustively quinolinyl, indole, or benzoxazole. The terms "fused arylheterocycloalkyl" and "fused heteroarylcycloalkyl" correspond to a bicyclic group in which an aryl as above defined or a heteroaryl is respectively bounded to the heterocycloalkyl or the cycloalkyl as above defined by at least two carbons. In other terms, the aryl or the heteroaryl shares a carbon bond with the heterocycloalkyl or the cycloalkyl. Examples of such mono- and poly-cyclic heteroaryl group, fused arylheterocycloalkyl and fused arylcycloalkyl may be: pyridinyl, thiazolyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienopyridinyl, benzofuranyl, thianaphthalenyl, indolyl, indolinyl, quinolinyl, isoquinolinyl, benzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, triazinyl, thianthrenyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthinyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, indazolyl, purinyl, quinolizinyl, phtalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, p- carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, indolinyl, isoindolinyl, oxazolidinyl, benzotriazolyl, benzoisoxazolyl, oxindolyl, benzoxazolyl, benzothiazolyl, benzothiphenyl, benzoxazolinyl, benzoxazinyl, benzothienyl, benzothiazolyl, benzodiazepinyl, benzazepinyl, benzoxazepinyl, isatinyl, dihydropyridyl, pyrimidinyl, s- triazinyl, oxazolyl, or thiofuranyl. In a particular aspect, the heteroaryl is for instance pyridinyl, pyrimidyl, 1,2,4-triazinyl or benzoxazolyl. In a particular aspect, the heteroaryl is for instance tetrazolyl or 1,2,3-trizolyl. In a particular aspect, the heteroaryl is for instance thiophenyl.
The term "fused" when applied to the description of two rings corresponds to a bicyclic group in which the first ring is respectively bounded to the second ring by at least two carbons.
The term "halogen" corresponds to a fluorine, chlorine, bromine, or iodine atom, preferably a fluorine, a chlorine or an iodine.
The expression "substituted by at least" or "substituted by" means that the group is substituted by one or several substituents of the list. For instance, the expression "a (Ci-Cg)alkyl substituted by at least one halogen" or "a (Ci-Cg)alkyl substituted by a halogen" may include a fluoromethyl (-CH2F), a difluoromethyl (-CHF2), or a trifluoromethyl (-CF3).
By "-CO-" or "-C(O)-", it refers to an oxo group. By "-SO-" or "-S(O)-", it refers to a sulfinyl group. By "- SO2-" or "-S(O2)-", it refers to a sulfonyl group.
The expression "optionally substituted" means that the group is not substituted or substituted by one or several substituents of the list.
The "stereoisomers" are isomeric compounds that have the same molecular formula and sequence of bonded atoms, but differ in the 3D-dimensional orientations of their atoms in space. The stereoisomers include enantiomers, diastereoisomers, Cis-trans and E-Z isomers, conformers, and
anomers. In a preferred embodiment of the invention, the stereoisomers include diastereoisomers and enantiomers.
The "tautomers" are isomeric compounds that differ only in the position of the protons and the electrons.
The "pharmaceutically salts" include inorganic as well as organic acids salts. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, maleic, methanesulfonic and the like. Further examples of pharmaceutically inorganic or organic acid addition salts include the pharmaceutically salts listed in J. Pharm. Sci. 1977, 66, 2, and in Handbook of Pharmaceutical Salts: Properties, Selection, and Use edited by P. Heinrich Stahl and Camille G. Wermuth 2002. In a preferred embodiment, the salt is selected from the group consisting of maleate, chlorhydrate, bromhydrate, and methanesulfonate. The "pharmaceutically salts" also include inorganic as well as organic base salts. Representative examples of suitable inorganic bases include sodium or potassium salt, an alkaline earth metal salt, such as a calcium or magnesium salt, or an ammonium salt. Representative examples of suitable salts with an organic base includes for instance a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. In a preferred embodiment, the salt is selected from the group consisting of sodium and potassium salt.
As used herein, the terms "treatment", "treat" or "treating" refer to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of a disease. In certain aspects, such terms refer to the amelioration or eradication of the disease, or symptoms associated with it. In other aspects, this term refers to minimizing the spread or worsening of the disease, resulting from the administration of one or more therapeutic agents to a subject with such a disease.
As used herein, the terms "subject", "individual" or "patient" are interchangeable and refer to an animal, preferably to a mammal, even more preferably to a human, including adult and child. However, the term "subject" can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep and non-human primates, among others.
The terms "quantity," "amount," and "dose" are used interchangeably herein and may refer to an absolute quantification of a molecule.
As used herein, the terms "active principle", "active ingredient" and "active pharmaceutical ingredient" are equivalent and refers to a component of a pharmaceutical composition having a therapeutic effect. As used herein, the term "therapeutic effect" refers to an effect induced by an active ingredient, or a pharmaceutical composition according to the invention, capable to prevent or to delay the appearance or development of a disease or disorder, or to cure or to attenuate the effects of a disease or disorder.
As used herein, the term "effective amount" refers to a quantity of an active ingredient or of a pharmaceutical composition which prevents, removes or reduces the deleterious effects of the disease. It is obvious that the quantity to be administered can be adapted by the man skilled in the art according to the subject to be treated, to the nature of the disease, etc. In particular, doses and regimen of administration may be function of the nature, of the stage and of the severity of the disease to be treated, as well as of the weight, the age and the global health of the subject to be treated, as well as of the judgment of the doctor. In particular, an amount is effective, for example, when its administration results in one or more of weight loss, management of weight, suppression of appetite for food, control of food intake, loss of body fat, prevention or modulation of hypoglycaemia, prevention or modulation of hyperglycaemia, promotion of insulin synthesis, or reduction in food intake.
As used herein, the term "pharmaceutically acceptable excipient" refers to any ingredient except active ingredients which are present in a pharmaceutical composition. Its addition may be aimed to confer a particular consistency or other physical or gustative properties to the final product. A pharmaceutically acceptable excipient must be devoid of any interaction, in particular chemical, with the active ingredients.
In a particular aspect of the present disclosure, the compound has the formula (A)
Cy-Y-L-B-A (A) and any pharmaceutical salt, stereoisomer, tautomer or solvate thereof wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen; b)
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, and a C1-C3 alkoxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy; c)
with X7, Xg, and Xg being independently N or CRb and at least one of X7, Xg, and Xg is N, and X10 being
CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy;
with Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N; Rg being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy;
- Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, -
C(O)-NRd-, and -C(0)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)- and -NRe-SfCh)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a particular aspect of the present disclosure, the compound has the formula (B)
and any pharmaceutical salt, stereoisomer, tautomer or solvate thereof wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen;
- Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, - C(O)-NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(C>2)-NRe-, -NRe-S(O)- and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a more particular aspect, the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, - S(O2)-, -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen, and
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido (- C(O)-NH2), guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, C0-C3alkyl-NH-C(O)-R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl- C(O)-OR, or Co-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a more particular aspect, the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a Ci-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen.
In another more particular aspect, the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof and
- Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a Ci-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear Ci-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a Ci-C3 alkyl, the Ci-C3 alkyl being
optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, - S(O2)-, -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen, and
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
YLB
In a particular aspect of the compounds of formula (B), -Y-L-B- is selected in the group consisting of - NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S- CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2- C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)- NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2- NH-S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S- (CH2)2-N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2- N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2-N(CH3)- S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O- CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-
CH(CH3)-NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)- NH-S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH-C(O)-, -S-CH2- CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH-
S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-
CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-
NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-
C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O)-, -
NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O2)-, -NH-CH2-
CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-
(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-
, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-
, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S-cyclopentyl-NH-S(O)-, -
S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-
S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH-cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O- piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH-piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-,
-NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S-piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-
NH-C(O)-, -piperidinyl-NH-S(O)-, -piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-
NH-, -NH-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -N H-pyrrolidinyl-
S(O)-NH-, -O-pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O- pyrrolidinyl-CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O- pyrrolidinyl-CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O- pyrrolidinyl-CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -s- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., -O-
1,4,5,6-Tetrahydropyrimidinyl-), -NH-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -
O-CH2-; -S-CH2-; and -NH-CH2-.
In a more specific aspect of the compounds of formula (B), -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-CH2-CH(CH2-OH)-NH-
C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O- cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, piperidinyl-NH-C(O)-, -O-
tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-.
In a very specific aspect of the compounds of formula (B), -Y-L-B- is selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-, more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O- CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-.
When -Y-L-B- includes a cyclohexyl, the two connecting bonds can be in positions 1 and 2, 1 and 3 or 1 and 4. When -Y-L-B- includes a cyclohexyl and the two connecting bonds are in positions 1 and 4, the two connecting bonds are in trans or cis configuration, preferably trans configuration. When -Y-L-B- includes a cyclohexyl and the two connecting bonds are in positions 1 and 2 or 1 and 3, the two connecting bonds are in trans configuration.
When -Y-L-B- includes a cyclopentyl, the two connecting bonds can be in positions 1 and 2 or 1 and 3, preferably 1 and 3. Preferably, the two connecting bonds are in trans configuration.
When -Y-L-B- includes a moiety -piperidinyl-C(O)-, -piperidinyl-C(O)- may have the following structure
When -Y-L-B- includes a moiety -piperidinyl-NH-, -piperidinyl-NH- has the following structure -Y-L-B- is -piperidinyl-NH-C(O)-, it may have the following structure
When -Y-L-B- includes a moiety -tetrahydropyrimidyl-, -tetrahydropyrimidyl- may have the following structure
When -Y-L-B- includes a moiety -pyrrolidinyl-C(O)-NH-, -pyrrolidinyl-C(O)-NH- has the following structure
When -Y-L-B- includes a moiety -pyrrolidinyl-CH2-NH-, -pyrrolidinyl-CH2-NH has the following structure
In a particular aspect, when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)-NH-, -O-C(O)-NH-, -O-S(O)- NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)- NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2- N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-(CH2)2-N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH- C(O)-, -NH-(CH2)2-N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, - NH-(CH2)2-N(CH3)-S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2- CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH- S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2- CH(CH2-OCH3)-NH-S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)- NH-C(O)-, -S-CH2-CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2- CH(CH2-OH)-NH-S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH- S(O)-, -S-CH2-CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S- CH(CH3)-CH2-NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2- CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2- OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH- S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O- (CH2)2-NH-, -S-(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O- cyclohexyl-NH-S(O2)-, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S- cyclohexyl-NH-C(O)-, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S- cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-S(O)-, - NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH-cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH- S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH-piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S- piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S-piperidinyl-S(O2)-, -NH-piperidinyl- S(O2)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, -piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, - S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-,
-NH-pyrrolidinyl-S(O)-NH-, -O-pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-
NH-, -O-pyrrolidinyl-CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O- pyrrolidinyl-CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O- pyrrolidinyl-CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., -O-
1,4,5,6-Tetrahydropyrimidinyl-), and -NH-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-).
In another particular aspect, when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O- CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, piperidinyl- NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), and -O-CH2-CH2-NH-.
In a more particular aspect, when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-S(O2)- , -O-CH2-CH2-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH- C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -NH-C(O)-NH-, -NH-CH2-CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH- cyclohexyl-NH-C(O)-, -piperidinyl-NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l, 4,5,6- Tetrahydropyrimidinyl-NH-C(O)-), and -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-).
In a very particular aspect, when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-.
In another particular aspect, when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or -S-
CH2-.
Ri definition
Ri can be selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (- CECH), an amino, and/or a halogen.
In a particular aspect, Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a Ci- C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen.
In a more particular aspect, Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, by a C1-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen; a C3-C7 cycloalkyl, preferably a C5-Cg cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen,
preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; and an ethynyl (-CECH).
In another particular aspect, Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a C1-C3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in particular a fluorine, iodine or chorine, more preferably a fluorine; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a cyclohexyl, said cyclohexyl being optionally bridged and/or optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a Ci- C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; preferably a bridged cyclohexyl; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; and an ethynyl (-CECH).
In a more specific aspect, Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
In a very specific aspect, Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
Definition of Xi, X2 and X3
Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen.
In one aspect, Xi, X2 and X3 are N. In another aspect, Xi, X2 and X3 are CRa and Ra is H. In another aspect, Xi and X2 are CRa with Ra being H and X3 is N. In an addition aspect, Xi is CRa with Ra being H and X2 and X3 are N. In another addition aspect, X2 is CRa with Ra being H and Xi and X3 are N. In a further additional aspect, Xi is CRa with Ra being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N.
In a preferred aspect, Xi, X2 and X3 are as following:
Xi, X2 and X3 are CH; or
Xi is CH and X2 and X3 are N; or
Xi and X2 are CH and X3 is N.
In a preferred aspect, Xi, X2 and X3 are as following:
Xi, X2 and X3 are CH; or
Xi is CH and X2 and X3 are N.
In a very preferred aspect, Xi is CH and X2 and X3 are N.
Definition of A
A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group
consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci- Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a particular aspect, A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10-membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, C0-C3alkyl-NH-C(O)-R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl- C(O)-OR, or Co-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In one aspect, A is a ring selected from the group consisting of a phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl, a 9-membered heteroaryl and a 10-membered heteroaryl, wherein the 5- membered heteroaryl can be preferably selected from the group consisting of thiophenyl, furanyl, and pyrrolyl; the 6-membered heteroaryl can be pyridinyl or pyrimidinyl, preferably pyridinyl; the 9- membered heteroaryl can be preferably selected from the group consisting of benzoxazolyl, benzimidazolyl, benzothiophenyl, indolyl, isoindolinonyl, and benzothiazolyl; and the 10-membered heteroaryl can be preferably selected from the group consisting of quinolinyl, isoquinolinyl,
quinoxalinyl, quinazolinyl, and quinolinonyl, isoquinolinonyl, tetrahydroisoquinoline, and methyltetrahydroisoquinoline.
In a preferred aspect, A is substituted ring.
In a preferred aspect, A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2- pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl a phthalimidyl and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl.
In a very particular aspect, A is an optionally substituted phenyl, thiophenyl, an isoindolinonyl, 2- pyridinyl or 3- pyridinyl, preferably a substituted phenyl, thiophenyl, 2- pyridinyl or 3- pyridinyl.
The substitution of the ring A can be selected from a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, C0-C3alkyl-NH-C(O)-R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl- C(O)-OR, or Co-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen.
Preferably, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound. More preferably, this substitution is in para position of the ring with respect to the connecting bound of A to the rest of the compound.
More particularly, the substitution of the ring A can be selected from the group consisting of a halogen, optionally a chlorine, a iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl; a guanidinyl; -NRR, -NH-C(O)-R, -NH-C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl;
a Ci-Cg alkyloxy optionally substituted by at least one halogen; and a heterocycloalkyl such as morpholinyl, or pyrrolidinyl, or pyrrolidonyl.
In a very specific embodiment, A is a phenyl, a 5-membered heteroaryl, a 6-membered heteroaryl, or a 9-membered heteroaryl substituted by a chlorine. For instance, A can be a phenyl, a thiophenyl, a 2- pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, a phthalimidyl and a benzothiophenyl substituted by a chlorine, preferably in position para.
For instance, A could be a phenyl, optionally substituted by one or several substituents selected from the group consisting of a halogen, especially a chlorine, a fluorine or an iodine, preferably a chlorine, in particular in position para; optionally with an addition substitution by a halogen, preferably in meta, more preferably a fluorine in meta, or by a hydroxy, preferably in ortho; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl or pyrrolidonyl,; a guanidinyl; -NRR, -NH-C(O)-R, -NH- C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl; a Ci-Cg alkyloxy optionally substituted by a halogen, preferably a methoxy, a nitro, and a hydroxy, preferably in ortho.
A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C3alkyl-C(0)-OR, Co-C3alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl optionally substituted by NR'R' or OR' with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen.
Accordingly, A could be selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH2-NH2, -(CH2)2-NH2, -CH2-N(CH3)2, -CH2-pyrrolidinyl, -CH2-morpholinyl, -CH2-guanidinyl, by -CH2-C(O)-NH2, -C(O)-NH2, a methoxy, -CH2-NH-C(O)-CH3, -CH2- NH-C(O)-CH2-NH2, -CH2-NH-C(O)-CH(iPr)-NH2, -CH2-NH-C(O)-CH2-N(CH3)2, nitro, -(CH2)2-NH-C(O)-CH3; a phenyl substituted in para by a chlorine and in meta by a fluorine or a methoxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a cyano or a methyl; a phenyl substituted in meta by a chlorine; a 2-pyridinyl; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl; a 3-pyridinyl substituted in para by a chlorine; a 4-pyridinyl; a piperidinyl; a piperidinyl substituted by a methyl; a morpholinyl; a thiophenyl substituted by a halogen, preferably a chlorine; a thiophenyl substituted by a methyl; a benzoxazolyl substituted by a chlorine; a benzothiazolyl substituted by a chlorine; an indolyl substituted by a chlorine; a phthalimidyl and a thienopyridinyl.
In a more particular aspect, A could be selected from the group consisting of a phenyl, a phenyl substituted in para by a chlorine; a phenyl substituted in para by a chlorine and in meta by a fluorine, a methoxy, or a hydroxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a
methoxy, a fluorine, or a methyl; a phenyl substituted in para by a fluorine, a methyl, a methoxy, -CH2- NH-C(O)-CH3, -CH2-CH2-NH-C(O)-CH3,-CH2-NH2, -CH2-morpholinyl, -CH2-guanidinyl, -C(O)-NH2, -CH2-NH- C(O)-CH(iPr)-NH2, a morpholinyl, or a nitro; a phenyl substituted in meta by a chlorine; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl substituted in para by a chlorine; a benzoxazolyl substituted by a chlorine; thiophenyl substituted by a chlorine; a benzothiophenyl substituted by a halogen, preferably a chlorine, an indolyl substituted by a chlorine; a benzothiazolyl substituted by a chlorine; and a phthalim idyl.
In a very specific aspect, A could be selected from the group consisting of a phenyl substituted in para by a chlorine, a phenyl substituted in para by a chlorine and in meta by a fluorine, a phenyl substituted in para by a chlorine and by a hydroxy in ortho, a phenyl substituted in para by -CH2-NH-C(O)-CH3, a phenyl substituted in para by a nitro, a 2- pyridinyl substituted in para by a chlorine, and a thiophenyl substituted by a halogen, preferably a chlorine.
In a particular aspect, the compound of formula (B) has
Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, by a C1-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen; a C3-C7 cycloalkyl, preferably a C5-Cg cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl
optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; and an ethynyl (-CECH);
XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are N; Xi, X2 and X3 are CH; Xi and X2 are CH and X3 is N; Xi is CH and X2 and X3 are N; X2 is CH and Xi and X3 are N; and Xi is CRa with Ra being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N;
-Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)-NH-, -O-C(O)-NH-, - O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH-, -S(O)- CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)- NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, - O-(CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)- , -O-(CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(o)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH- S(O)-, -S-(CH2)2-N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2- NH-C(O)-, -NH-(CH2)2-N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, - NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2-N(CH3)-S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -0-CH2- CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -0-CH2- CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, -O- CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)-NH-
S(O2)-, -O-CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH- C(O)-, -S-CH2-CH(CH2-OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH- C(O)-, -S-CH2-CH(CH2-OH)-NH-S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)- NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2- OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-NH-S(O2)-, -NH-CH2- CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-C(O)-, -
NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)- NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2- OH)-NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH- CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl- NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-, -S- cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S- cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-C(O)-, -NH- cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH- cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl- C(O)-, -NH-piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl- S(O)-, -O-piperidinyl-S(O2)-, -S-piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl- NH-C(O)-, -piperidinyl-NH-S(O)-, -piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S- pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-S(O)-NH-, -S- pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O-pyrrolidinyl-S(O2)-NH-, -S- pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-CH2-NH-C(O)-, -S- pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-CH2-NH- S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O-pyrrolidinyl- CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), - NH-tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), and -NH- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-); or when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of - O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or - S-CH2-, and
A is a ring selected from the group consisting of a phenyl, a 5-membered heteroaryl, a 6- membered heteroaryl and a 9-membered heteroaryl, wherein the 5-membered heteroaryl is selected from the group consisting of thiophenyl, furanyl, and pyrrolyl, preferably thiophenyl; the 6-membered heteroaryl is pyridinyl or pyrimidinyl, preferably pyridinyl; and the 9- membered heteroaryl is selected from the group consisting of benzoxazolyl, benzothiophenyl, indolyl, phthalimidyl and benzothiazolyl, preferably a substituted ring; the substitution being selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)- R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or Co- C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen.
In another particular aspect, the compound of formula (B) has
Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a Ci-C3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in particular a fluorine, iodine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano;
a morpholinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a cyclohexyl, said cyclohexyl being optionally bridged and/or optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; preferably a bridged cyclohexyl; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; and an ethynyl (-CECH);
XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are CH; Xi and X2 are CH and X3 is N; Xi is CH and X2 and X3 are N; X2 is CH and Xi and X3 are N; and Xi is CRa with Ra being a C1-C3 alkyl, especially a methyl, and X2 and X3 are N;
-Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2- NH-S(O2)-, -O-CH2-CH2-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH- C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -NH-C(O)-NH-, -NH-CH2- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -piperidinyl-NH- C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1,4,5,6-Tetrahydropyrimidinyl-NH- C(O)-), and -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-); or when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of - O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or - S-CH2-; and
A is a ring selected from the group consisting of a phenyl, a 5-membered heteroaryl, a 6- membered heteroaryl, and a 9-membered heteroaryl; the ring being substituted by one or several substitution(s) selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a
heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)- R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or Co- C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen.
In another particular aspect, the compound of formula (B) has
Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a Ci-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl;
Xi, X2 and X3 are as following: Xi, X2 and X3 are CH; or Xi is CH and X2 and X3 are N; or Xi and X2 are CH and X3 is N; preferably Xi, X2 and X3 are CH; or Xi is CH and X2 and X3 are N; more preferably Xi is CH and X2 and X3 are N;
-Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2- NH-S(O2)-, -O-CH2-CH2-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH- C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -NH-C(O)-NH-, -NH-CH2- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -piperidinyl-NH- C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1,4,5,6-Tetrahydropyrimidinyl-NH- C(O)-), and -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-); preferably selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; or
when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of - O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or - S-CH2-;
A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3- pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl, and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl; the ring being substituted by being substituted by one or several substitution(s) selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)- R, C0-C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or Co- C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen.
In another particular aspect, the compound of formula (B) has
Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a Ci-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl;
Xi, X2 and X3 are as following: Xi, X2 and X3 are CH; or Xi is CH and X2 and X3 are N; or Xi and X2 are CH and X3 is N; preferably Xi, X2 and X3 are CH; or Xi is CH and X2 and X3 are N; more preferably Xi is CH and X2 and X3 are N;
-Y-L-B- is such that
when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2- NH-S(O2)-, -O-CH2-CH2-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH- C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -NH-C(O)-NH-, -NH-CH2- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -piperidinyl-NH- C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1,4,5,6-Tetrahydropyrimidinyl-NH- C(O)-), and -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-); preferably selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; or when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of - O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or - S-CH2-;
A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3- pyridinyl, an isoindolinonyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl; the ring being substituted by one or several substituents selected from the group consisting of a halogen, optionally a chlorine, an iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl; a guanidinyl; -NRR, -NH-C(O)-R, -NH- C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl; a Ci-Cg alkyloxy optionally substituted by at least one halogen; and a heterocycloalkyl such as morpholinyl, pyrrolidonyl or pyrrolidinyl.
A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C3alkyl-C(0)-OR, Co-C3alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl optionally substituted by a group -NR'R' or OR', with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen.
In another particular aspect, the compound of formula (B) has
Ri is selected from the group consisting of a phenyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a Ci-C3 alkyl optionally substituted by a halogen, preferably a
methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a pyridinyl, preferably 2-pyridinyl or 3-pyridinyl, optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a C1-C3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; an iodine, a chlorine, a fluorine or a bromine, preferably a chlorine or a fluorine, a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by a halogen, a C1-C3 alkyloxy optionally substituted by a halogen and/or a halogen; a C3-C7 cycloalkyl, preferably a C5-Cs cycloalky, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a C1-C3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a C1-C3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; a C1-C3 alkyl optionally substituted by a halogen, preferably a methyl or an isopropyl; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; and an ethynyl (-CECH),
XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are CH; Xi is CH and X2 and X3 are N; and Xi and X2 are CH and X3 is N;
-Y-L-B- is such that when A is a phenyl or a 5- or 6-membered heteroaryl, -Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -O-CH2-CH2- NH-S(O2)-, -O-CH2-CH2-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH- C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -NH-C(O)-NH-, -NH-CH2- CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -piperidinyl-NH- C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1,4,5,6-Tetrahydropyrimidinyl-NH- C(O)-), and -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-); preferably selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; or
when A is a 9-membered heteroaryl, -Y-L-B- is selected from the group consisting of - O-CH2-CH2-NH-C(O)-, -O-CH2-CH2-NH-, -O-CH2- and -S-CH2-, preferably is -O-CH2- or - S-CH2-;
A is selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH2-NH2, -(CH2)2-NH2, -CH2-N(CH3)2, -CH2-pyrrolidinyl, - CH2-morpholinyl, -CH2-guanidinyl, by -CH2-C(O)-NH2, -C(O)-NH2, a methoxy, -CH2-NH-C(O)-CH3, -CH2-NH-C(O)-CH2-NH2, -CH2-NH-C(O)-CH(iPr)-NH2, -CH2-NH-C(O)-CH2-N(CH3)2, nitro, -(CH2)2- NH-C(O)-CH3; a phenyl substituted in para by a chlorine and in meta by a fluorine or a methoxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a cyano or a methyl; a phenyl substituted in meta by a chlorine; a 2-pyridinyl; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl; a 3-pyridinyl substituted in para by a chlorine; a 4-pyridinyl; a piperidinyl; a piperidinyl substituted by a methyl; a morpholinyl; a thiophenyl substituted by a halogen, preferably a chlorine; a thiophenyl substituted by a methyl; a benzoxazolyl substituted by a chlorine; a benzothiazolyl substituted by a chlorine; an indolyl substituted by a chlorine; a phthalimidyl and a thienopyridinyl; preferably selected from the group consisting of a phenyl, a phenyl substituted in para by a chlorine; a phenyl substituted in para by a chlorine and in meta by a fluorine, a methoxy, or a hydroxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a methoxy, a fluorine, or a methyl; a phenyl substituted in para by a fluorine, a methyl, a methoxy, -CH2-NH-C(O)-CH3, -CH2-CH2-NH-C(O)-CH3,-CH2-NH2, - CH2-morpholinyl, -CH2-guanidinyl, -C(O)-NH2, -CH2-NH-C(O)-CH(iPr)-NH2, a morpholinyl, or a nitro; a phenyl substituted in meta by a chlorine; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl substituted in para by a chlorine; a benzoxazolyl substituted by a chlorine; thiophenyl substituted by a chlorine; a benzothiophenyl substituted by a halogen, preferably a chlorine, an indolyl substituted by a chlorine; a benzothiazolyl substituted by a chlorine; and a phthalimidyl; and more preferably selected from the group consisting of a phenyl substituted in para by a chlorine, a phenyl substituted in para by a chlorine and in meta by a fluorine, a phenyl substituted in para by a chlorine and by a hydroxy in ortho, a phenyl substituted in para by -CH2-NH-C(O)-CH3, a phenyl substituted in para by a nitro, a 2- pyridinyl substituted in para by a chlorine, and a thiophenyl substituted by a halogen, preferably a chlorine.
with Ri, Y and A as defined above in any one of the particular aspects, Z being O, NH or S, and n being an integer from 0 to 4, preferably being 1, and any pharmaceutical salt, stereoisomer, tautomer or solvate thereof.
In a particularly preferred aspect, the compound of formula (B) has one of the following formulae:
with Ri, Y and A as defined above in any one of the particular aspects and any pharmaceutical salt, stereoisomer, tautomer thereof.
Preferably, in formulae (B-l), (B-2), (B-3), (B-3a) or (B-4), Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, by a C1-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen; a C3-C7 cycloalkyl, preferably a C5-Cs cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; an ethynyl (-CECH).
More preferably, in formulae (B-l), (B-2), (B-3), (B-3a) or (B-4), Ri is selected from the group consisting of
a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted, preferably in para or ortho, by one or two halogens, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
Still more preferably, in formulae (B-l), (B-2), (B-3), (B-3a) or (B-4), Ri is selected from the group consisting of a 2-pyridinyl, optionally substituted in ortho or para by a halogen, in particular a fluorine; or a C1-C3 alkyloxy optionally substituted by a halogen, preferably methoxy or isopropyloxy; a phenyl, optionally substituted in para by a halogen, in particular a fluorine, or by an alkyloxy, preferably a methyloxy or an isopropyloxy, more preferably an isopropyloxy; a pyrimidyl, preferably a 2-pyrimidyl, a morpholinyl; and a cyclohexyl.
In a particular aspect of compounds of formulae (B-l), (B-3), (B-3a) or (B-4), A is a ring selected from optionally substituted a phenyl, a thiophenyl, a 2-pyridinyl, a 3-pyridinyl, a benzoxazolyl, a benzothiazolyl, a thiophenyl, a thienopyridinyl, an indolyl, an isoindolinonyl, a phthalimidyl and a benzothiophenyl, preferably a substituted phenyl, pyridinyl, benzoxazolyl and thiophenyl, the substitution of the ring A being selected from the group consisting of a halogen, optionally a chlorine, an iodine or a fluorine, preferably a fluorine or chlorine, more preferably a chlorine; a hydroxy, a cyano; a nitro; a Ci-Cg alkyl optionally substituted by at least one halogen; an amine; an amido; a nitro; a heterocycloalkyl such as morpholinyl; a guanidinyl; -NRR, -NH-C(O)-R, -NH-C(O)-Ci-C4alk-NR2, with R being independently H or a C1-C4 alkyl; a Ci-Cg alkyloxy optionally substituted by at least one halogen; and a heterocycloalkyl such as morpholinyl, or pyrrolidinyl or pyrrolidonyl.
A could also be a phenyl, optionally substituted by one or several substituents selected from the group consisting of Co-C3alkyl-C(0)-OR, Co-C3alkyl-C(0)-R, with R being independently H or a C1-C4 alkyl
optionally substituted by a group -NR'R' or OR', with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen.
Preferably, in formulae (B-l), (B-3), (B-3a) or (B-4), A is selected from the group consisting of a phenyl; a phenyl substituted in para by a chlorine, a fluorine, a methyl, a morpholinyl, -CH2-NH2, -(Cbhh-NI-h, -CH2-N(CH3)2, -CH2-pyrrolidinyl, -CH2-morpholinyl, -CH2-guanidinyl, by -CH2-C(O)-NH2, -C(O)-NH2, a methoxy, -CH2-NH-C(O)-CH3, -CH2-NH-C(O)-CH2-NH2, -CH2-NH-C(O)-CH(iPr)-NH2, -CH2-NH-C(O)-CH2- N(CH3)2, nitro, -(CH2)2-NH-C(O)-CH3; a phenyl substituted in para by a chlorine and in meta by a fluorine or a methoxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a cyano or a methyl; a phenyl substituted in meta by a chlorine; a 2-pyr idinyl; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl; a 3-pyridinyl substituted in para by a chlorine; a 4-pyridinyl; a piperidinyl; a piperidinyl substituted by a methyl; a morpholinyl; a thiophenyl substituted by a halogen, preferably a chlorine; and a thiophenyl substituted by a methyl.
More preferably, in formulae (B-l), (B-3), (B-3a) or (B-4), A is selected from the group consisting of a phenyl, a phenyl substituted in para by a chlorine; a phenyl substituted in para by a chlorine and in meta by a fluorine, a methoxy, or a hydroxy; a phenyl substituted in para by a chlorine and in ortho by a hydroxy, a methoxy, a fluorine, or a methyl; a phenyl substituted in para by a fluorine, a methyl, a methoxy, -CH2-NH-C(O)-CH3, -CH2-CH2-NH-C(O)-CH3,-CH2-NH2, -CH2-morpholinyl, -CH2-guanidinyl, - C(O)-NH2, -CH2-NH-C(O)-CH(iPr)-NH2, a morpholinyl, or a nitro; a phenyl substituted in meta by a chlorine; a 2-pyridinyl substituted in para by a chlorine; a 3-pyridinyl substituted in para by a chlorine; and a thiophenyl substituted by a chlorine.
Still more preferably, in formulae (B-l), (B-3), (B-3a) or (B-4), A is selected from selected from the group consisting of a phenyl substituted in para by a chlorine, a phenyl substituted in para by a chlorine and in meta by a fluorine, a phenyl substituted in para by a chlorine and by a hydroxy in ortho, a phenyl substituted in para by -CH2-NH-C(O)-CH3, a phenyl substituted in para by a nitro, a 2- pyridinyl substituted in para by a chlorine, and a thiophenyl substituted by a halogen, preferably a chlorine.
Preferably, the compounds of (B-2) has a 9-membered ring which is substituted by a halogen, preferably a chlorine.
In a particular aspect, the compound of formula (B) is selected from the compounds as shown in Tables 1, 2 and 3 and any pharmaceutical salt, stereoisomer, tautomer thereof.
In a particular aspect, the compound of the invention is as disclosed above and has an appetite suppressor effect as measured in the assay disclosed in the example section. Preferably, the food intake reduction in % compared to vehicle is of at least 10, 15, 20, 25, 30, 35, 40, 45 or 50%.
Compounds of formula (C) In a particular aspect of the present disclosure, the compound has the formula (C)
Cy-Y-L-B-A (C) and any pharmaceutical salt, stereoisomer, tautomer or a solvate thereof
wherein
- Cy is a ring selected from the group consisting of
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, and a C1-C3 alkoxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy;
with X7, Xg, and Xg being independently N or CRb and at least one of X7, Xg, and Xg is N, and X10 being CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy; and
with Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N; Rg being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy;
- Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, - C(O)-NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, - C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)- and -NRe-SfCh)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co- C3alkyl-NH-C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
In a more particular aspect of the present disclosure, the compound has the formula (C) Cy-Y-L-B-A (C) and any pharmaceutical salt, stereoisomer, tautomer or a solvate thereof wherein
- Cy is a ring selected from the group consisting of
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a
C1-C3 alkoxy optionally substituted by at least one halogen; R3 being H or a C1-C3 alkyl optionally substituted by at least one halogen; and R4 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with X7, Xg, and Xg being independently N or CR and at least one of X7, Xg, and Xg is N, and X10 being CR, with R being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with Xu being a heteroatom, preferably S, O or NH, more preferably S, and X12 being N or CH and X13 being CH or N; Rg being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
- Y-L-B- is absent or selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH- CH2-C(O)-NH-, -O-CH2-, -O-(CH2)2-, -S-(CH2)3-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, - CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and - O-(CH2)-C(O)-N(CH3)-;
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, a 5-10- membered heteroaryl, preferably a 9-membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of halogen, a cyano, hydroxy, an ethynyl (-CECH), nitro, amino, amido, a Ci-Cg alkyl optionally substituted by at least one halogen, an amino group, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted by a halogen, a cyano, a
hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-Csalkyl-NH- C(O)-OR, Co-C3alkyl-NH-C(0)- NRR, Co-C3alkyl-C(0)-R, Co-C3alkyl-C(0)-OR, or Co-Csalkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
Accordingly, the compound of the formula (C) may have one of the formulae (C-l), (C-2) and (C-3) and any pharmaceutical salt, stereoisomer, tautomer or a solvate thereof
with Xs, Rs, Y, L, B and A being as defined above.
Compound of (C-l)
In a particular aspect, the compound of formula (C) has a formula (C-l) and X4, X5 and Xg are independently N or CH; R2 is selected from the group consisting of a methyl, an ethyl, a n-propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 is H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg are H; and
-Y-L-B- is absent or selected from the group consisting of selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4- C(O)-NH-, -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, - S-CH2-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-
(CH2)3-C(O)-NH-, -S-(CH2)-C(0)-, - piperazinyl-C(O)-, -0-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)- NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)- NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)-C(O)-N(CH3)-; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -S- (CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)- NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, -O- (CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, - S-cyclohexyl-C(O)-NH-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and -O-piperidinyl-C(O)- ; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-CO-, -C(O)- piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)- C(O)-, -NH-CH2-C(O)-NH-, and -O-piperidinyl-C(O)- , and
A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co-C3alkyl-NH-C(0)-R, with R being H or a Ci-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or
-Y-L-B- is absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A is benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, in particular a chlorine, preferably in position 6.
In another particular aspect, the compound of formula (C) has a formula (C-l) and X4, X5 and Xg are independently N or CH; R2 is selected from the group consisting of a methyl, an ethyl, a n-propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 is H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg are H; and
-Y-L-B- is absent or selected from the group consisting of selected from the group consisting of - C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)- CO-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, - piperazinyl-C(O)-, -0-2-oxo- pyrrolidinyl-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH- CH2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)-C(O)-N(CH3)-; preferably selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2- N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -piperazinyl-C(O)-, - 0-2-oxo-pyrrolidinyl-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and -O-piperidinyl-C(O)-
; more preferably selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)- NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, and -O-piperidinyl-C(O)- , and
A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a phenyl substituted in para by a Co-C3alkyl-NH-C(0)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or
-Y-L-B- is absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A is a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6.
R2 is a methyl, ethyl or propyl, optionally substituted by a methoxy or at least one halogen;
R3 and R5 are H;
R4 is H or a halogen, preferably a fluorine; and
Re is H, CH3, or CF3.
X4, X5 and Xg are N, or X4, X5 and Xg are CH,
R2 is a methyl, ethyl or propyl optionally substituted by a methoxy, and
R3 and R4 are H.
In a more particular aspect, when A is a ring selected from the group consisting of a 6-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, -Y-L-B- is absent or selected from the group consisting of selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-, C(O)-NH-, -
S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, - S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2-C(O)-NH-, -O-(CH2)- C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl- C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)-C(O)-N(CH3)-.
Preferably, -Y-L-B- is selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)- NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, - S-cyclohexyl-C(O)-NH-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and -O-piperidinyl-C(O)-.
More preferably, -Y-L-B- is selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH- , -S(O2)-CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-CO-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)- NH-, and -O-piperidinyl-C(O)- .
Optionally, -Y-L-B- is selected in one of the following groups:
-Y-L-B- is absent or selected from the group consisting of selected from the group consisting of C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)- CO-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, - piperazinyl-C(O)-, -O-2-oxo- pyrrolidinyl-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH- CH2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)-C(O)-N(CH3)-;
-Y-L-B- is selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O- (CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3- C(O)-NH-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH- C(O)- and -O-piperidinyl-C(O)-; or
-Y-L-B- is selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O- (CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, and -O-piperidinyl-C(O)- .
In a more particular aspect, when A is a 9-membered heteroaryl, -Y-L-B- is absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3-.
In a particular aspect, A is a ring selected from the group consisting of a 6-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. A can be a ring selected from the group consisting of a phenyl, a morpholinyl, a piperazinyl, a piperidinyl and a cyclohexyl, said ring being optionally substituted.
In a more particular aspect, A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a methyl, an iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl or -CH2-NH-C(O)-CH3 in para,
a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl.
In a very specific aspect, A is a ring selected from the group consisting of a phenyl substituted by a chlorine in para and optionally further substituted in ortho by a group selected from an iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, and a cyclohexyl.
In a particular aspect, A is a 9-membered heteroaryl. Preferably, A is a substituted 9-membered heteroaryl, preferably by a halogen, more preferably a chlorine.
In a particular aspect, when A is a 9-membered heteroaryl, A is benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably substituted by a halogen, more preferably a chlorine, preferably in position 6. Preferably, A is benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, more preferably a chlorine, preferably in position 6.
Compound of (C-2)
In a particular aspect, the compound of formula (C) has a formula (C-2) and one of X7 and X8 is N and the other is CH, Xg is CH or N and Xio is CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being independently H or a C1-C3 alkyl; R7 is H; -Y-L-B- is selected from the group consisting of -O-CH2-, -O-(CH2h-NH-C(O)-, -S-(CH2)2-NH-CO-, -O- (CH2)2-N(CH3)-C(O)-, -O-CH2-C(O)-NH-, and -S-CH2-C(O)-NH-, preferably selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, and -S-(CH2)2-NH-C(O)-; and
A is a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, a cyclohexyl and a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6, preferably selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para optionally substituted by an a C2-C3 acyl.
In a more particular aspect, when Cy is
X7, Xg, and Xio are CH and Xg is N; or Xg, Xg, and Xio are CH and X7 is N; or X7, Xg, Xg, and Xio are
CH;
- R7 is H.
X7, Xg, and Xio are CH and Xg is N; or Xg, Xg, and Xio are CH and X7 is N;
- R7 is H.
In a particular aspect, -Y-L-B- is selected from the group consisting of -O-CH2-, -O-(CH2h-NH-C(O)-, -S- (CH2)2-NH-CO-, -O-(CH2)2-N(CH3)-C(O)-, -O-CH2-C(O)-NH-, and -S-CH2-C(O)-NH-, preferably selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, and -S-(CH2)2-NH-C(O)-.
In a particular aspect, A is a ring selected from the group consisting of a 6-membered aryl or heteroaryl substituted by a chlorine in para; and a 9-membered heteroaryl substituted by a chlorine, preferably in position 5 or 6.
In a very specific aspect, A is a ring selected from the group consisting of a phenyl substituted by a chlorine in para; and a benzoxazolyl substituted by a chlorine, preferably in position 5 or 6.
Compound of (C-3)
In a particular aspect, the compound of formula (C) has a formula (C-3) and Xu is S, O or NH, X12 and X13 are independently N or CH; Rg is H, a phenyl or a pyridinyl, in particular a 2-pyridinyl;
-Y-L-B- is absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-; and
A is selected in the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
Xu is S, X12 and X13 are CH, and Rg is H, a phenyl or a pyridinyl.
-Y-L-B- is absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-.
A is a ring selected in the group consisting of a phenyl optionally substituted by a chlorine in para, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
In a particular aspect, the compound of formula (C) is selected from the compounds as shown in Tables
4, 5 and 6 and any salt, stereoisomer, tautomer or solvate thereof.
In a particular aspect, the compound of formula (C) is selected from the compounds as shown in Tables
7, 8 and 9 and any salt, stereoisomer, tautomer or solvate thereof.
In a particular aspect, the compound of the invention is as disclosed above and has an appetite suppressor effect as measured in the assay disclosed in the example section. Preferably, the food intake reduction in % compared to vehicle is of at least 10, 15, 20, 25, 30, 35, 40, 45 or 50%.
Pharmaceutical or veterinary compositions and the uses thereof
As illustrated by examples, the inventors have demonstrated the therapeutic interest of the new compounds of the invention. Accordingly, the present invention relates to a pharmaceutical or veterinary composition comprising any new compound according to the present invention. Preferably, the pharmaceutical or veterinary composition further comprises a pharmaceutically or veterinary acceptable carrier or excipient. The present invention relates to the use of any new compound according to the invention as a drug or as a medicine. The invention further relates to a method for treating a disease in a subject, wherein a therapeutically effective amount of any new compound according to the invention, is administered to said subject in need thereof. The invention also relates to the use of any new compound according to the invention, for the manufacture of a medicine. The invention also relates to a pharmaceutical composition comprising any new compound according to the invention for use as a drug.
More particularly, the present invention provides compounds having an appetite-suppressor effect as shown by their capacity to reduce the food intake. Beneficial or desired clinical results from the
compound of the present invention, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or solvate thereof, include, without limitation, reduced body weight, decreased weight-gain, reduced appetite, weight loss, management of weight, suppression of an appetite for food, controlled food intake, reduced or stabilized body fat content, reduced or stabilized blood or serum glucose and blood or serum insulin levels, amelioration, palliation, stabilization, diminishment of extent of obesity- related diseases, or a delay or slowing of obesity related disease progression. By treatment is meant inhibiting or reducing an increase in obesity-related symptoms (e.g. weight gain) when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of the relevant condition.
Therefore, the compounds of the present invention are of interest as appetite suppressant. Accordingly, the present invention relates to any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for use as appetite suppressant. The present invention relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it as appetite suppressant. The invention further relates to a method for treating a disease in a subject, wherein a therapeutically effective amount of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it is administered to said subject in need thereof. The invention also relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the manufacture of a medicine for use as appetite suppressant.
The present invention also relates to any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for use for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain. The present invention relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain. The invention further relates to a method for treating a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain in a subject, wherein a therapeutically effective amount of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it is administered to said subject in need thereof. The invention also relates to the use of any compound according to the present invention or a pharmaceutical or veterinary composition comprising it for the manufacture of a medicine for the treatment of a metabolic disease, an eating disorder, a syndrome or a medication-induced weight gain. The metabolic disease can be selected from the non-exhaustive list comprising obesity, diabetes (type 1 or type 2 diabetes), hypertension, non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD), insulin resistance, coronary heart disease, cardiovascular diseases (such as congestive
heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, or peripheral artery disease), and dyslipidemia.
The eating disorders can be selected from the non-exhaustive list comprising bulimia nervosa, binge eating disorder, night eating syndrome, compulsive overeating, anxiety, depression, Gourmand syndrome, Prader-Willi syndrome.
The syndromes can be selected from metabolic syndrome, Cohen syndrome, Bardet-Biedl syndrome, polycystic ovary syndrome and MOMO syndrome.
The subject to be treated may have a disorder that leads to weight gain through excessive consumption of food, such as a disorder selected from binge eating disorder, subclinical binge eating, Prader-Willi syndrome and metabolic syndrome (also known as syndrome X or insulin-resistance syndrome). The subject may have other excess weight-related metabolic disorders. Examples of these include insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), glucagonomas, stroke, respiratory dysfunction, or renal disease.
Body mass index (BMI) is a simple index of weight-for-height that is commonly used for human adults to assess whether a patient is "overweight" or "obese". It is defined as an individual's weight in kilograms divided by the square of his or her height in meters (kg/m2). The most commonly used definitions, established by the World Health Organization (WHO) in 1997 and published in 2000, provide the following classifications based on BMI: overweight = human adult with BMI of between about 25 to about 29.99 kg/m2; class I obesity = a human adult with BMI from between about 30 kg/m2 to about 34.99 kg/m2; severe obesity (class II obesity) = a human adult with BMI of between about 35 kg/m2 to about 39.99 kg/m2; morbid obesity (class III obesity) = a human adult with BMI of between about 40 kg/m2 and 44.99 kg/m2. Some physicians/clinicians/surgeons may also refer to super obesity, being a BMI of greater than about 45 kg/m2 in a human adult subject.
In addition, the compounds of the present invention are also of interest in order to promote weight loss in a subject. Then, the invention may relate to a method for promoting weight loss or preventing weight gain comprising administering a compound of the present invention or a composition comprising it to the subject. In a particular embodiment, the subject can be obese. In this context, for human being, the Body Mass Index (BMI) is higher or equal to 30. In an alternative embodiment, the subject can be overweight. The overweight can be only minor, e.g. unsightly but without any threat to the health. In this context, the Body Mass Index (BMI) is lower than 30. In this aspect, the method is a non-therapeutic method. For instance, the goal could be improved the physical appearance by reducing the weight. The subject may have a normal body mass index (up to 25).
The compound according to the invention or the pharmaceutical composition according to the invention may be administered by any conventional route of administration. In particular, the
compound or the pharmaceutical composition of the invention can be administered by a topical, enteral, oral, parenteral, intranasal, intravenous, intraperitoneal, intra-arterial, intramuscular, intratumoral, subcutaneous or intraocular administration and the like. In particular, the compound according to the invention or the pharmaceutical composition according to the invention can be formulated for a topical, enteral, oral, parenteral, intranasal, intravenous, intraperitoneal, intraarterial, intramuscular, intratumoral, subcutaneous or intraocular administration and the like.
Preferably, the compound according to the invention or the pharmaceutical composition according to the invention is administered by enteral or parenteral route of administration. When administered parenterally, the compound according to the invention or the pharmaceutical composition according to the invention is preferably administered by intravenous or intraperitoneal route of administration. When administered enterally, the compound according to the invention or the pharmaceutical composition according to the invention is preferably administered by oral route of administration.
The pharmaceutical composition comprising the molecule is formulated in accordance with standard pharmaceutical practice (Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York) known by a person skilled in the art.
For oral administration, the composition can be formulated into conventional oral dosage forms such as tablets, capsules, powders, granules and liquid preparations such as syrups, elixirs, and concentrated drops. Nontoxic solid carriers or diluents may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. For compressed tablets, binders, which are agents which impart cohesive qualities to powdered materials, are also necessary. For example, starch, gelatine, sugars such as lactose or dextrose, and natural or synthetic gums can be used as binders. Disintegrants are also necessary in the tablets to facilitate break-up of the tablet. Disintegrants include starches, clays, celluloses, algins, gums and crosslinked polymers. Moreover, lubricants and glidants are also included in the tablets to prevent adhesion to the tablet material to surfaces in the manufacturing process and to improve the flow characteristics of the powder material during manufacture. Colloidal silicon dioxide is most commonly used as a glidant and compounds such as talc or stearic acids are most commonly used as lubricants.
For transdermal administration, the composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
For transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used. The active compound can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan
monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
Pharmaceutical compositions according to the invention may be formulated to release the active drug substantially immediately upon administration or at any predetermined time or time period after administration.
The compound according to the invention or the pharmaceutical composition according to the invention may be administered as a single dose or in multiple doses. Preferably, the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day. In a particular embodiment, the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day. The treatment may last as long as the disease persists.
The amount of compound according to the invention or of pharmaceutical composition according to the invention to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient.
In a preferred embodiment, the total compound dose for each administration of the compound according to the invention or of the pharmaceutical composition according to the invention is comprised between 0.00001 and 1 g.
The form of the pharmaceutical compositions, the route of administration and the dose of administration of the compound according to the invention, or the pharmaceutical composition according to the invention can be adjusted by the man skilled in the art according to the type and severity of the disease, and to the patient, in particular its age, weight, sex, and general physical condition.
The present invention also relates to the combined use of a compound of the present invention with at least another active ingredient or with an appropriate dietary regimen.
Further aspects and advantages of the present invention will be described in the following examples, which should be regarded as illustrative and not limiting.
EXAMPLES
SYNTHESIS
General synthesis of 2-chloro-5-(het)arylpyrimidine
2-chloro-5-phenylpyrimidine is commercially available.
2-Chloro-5-(pyrid-2-yl)pyrimidine was prepared by Negishi cross-coupling according to a known procedure (Organic Process Research & Development 2007, 11, 237-240). The same procedure was followed for pyridyls with additional substituents.
General Synthesis of 2-N- and 2-O-substituted 5-(het)arylpyrimidines
Compound 60
2-Chloro-5-(pyrid-2-yl)pyrimidine was prepared by Negishi cross-coupling according to a known procedure (Organic Process Research & Development 2007, 11, 237-240). The same procedure was followed for pyridyls with additional substituents. 4-Chloro-N-(2-hydroxyethyl)benzamide was prepared as previously described from 4-chlorobenzoyl chloride and 2-aminoethanol in DCM.
4-Chloro-N-(2-hydroxyethyl)benzamide (521 mg, 2.73 mmol) was dissolved in anhydrous THF (25 mL). The solution was cooled to 0°C, and 60% NaH on mineral oil (115 mg, 3.00 mmol) was added. After 15 min 2-chloro-5-(pyrid-2-yl)pyrimidine (500 mg, 2.73 mmol) was added. The resulting mixture was stirred at room temperature under argon for 16h. The mixture was poured into H2O (350 mL). Precipitate was filtered and recrystallized from EtOH/HjO to yield white solid (511 mg, 55%). 1H-NMR (300 MHz, CDCk) 6: 9.11 (s, 2H), 8.76-8.66 (m, 1H), 7.85-7.62 (m, 4H), 7.44-7.35 (m, 2H), 7.34-7.25 (m, 1H), 6.92-6.80 (m, 1H), 4.64 (t, 7=4.9 Hz, 2H); 3.98-3.89 (m, 2H). UPLC-ESI (m/z): 355, 357 [M+H]+.
Route Rl: In an additional example of route Rl, the amide coupling is performed after Boc- deprotection, synthesis exemplified on compound 118
Compound 118-PF6
In a variation of the general route Rl, the following preparation exemplifies the late introduction of amides.
To solution of tert-butyl (2-hydroxyethyl)carbamate (1.94 mL 12.5 mmol) in THF (10 mL), NaH (60 % in mineral oil, 542 mg, 13.6 mmol) was added at 0 °C. After stirring for 20 min at the same temperature, 2-chloro-5-(pyridin-2-yl)pyrimidine (1, 2.00 g, 10.4 mmol) was added. The reaction mixture was stirred at room temperature for 1.5 h. Sat. NH4CI solution (20 mL) was added and the mixture was extracted with EtOAc (2x100 mL). The combined EtOAc extracts were washed with brine (100 mL), dried over NajSC and evaporated. Purification of the residue by column chromatography (eluent DCM/acetone) yielded 01 as slightly yellow powder (2.38 g, 72%). 1H-NMR 300 MHz, CDCI3 6 (ppm): 9.11 (s, 2H), 8.70 (ddd, 7=4.8, 1.7, 0.9 Hz, 1H), 7.79 (dt, 7=7.8, 1.7 Hz, 1H), 7.70-7.64 (m, 1H), 7.29 (ddd, 7=7.8, 4.8, 0.9 Hz, 1H), 5.17-5.00 (m, 1H), 4.55-4.45 (m, 2H), 3.65-3.52 (m, 2H), 1.44 (s, 9H). ESI (m/z): 317 [M+H]+.
To solution of 01 (2.38 g 7.52 mmol) in DCM (15 ml), TFA (3 mL) was added. The reaction mixture was stirred at room temperature for 1 h and then evaporated. MeOH (20 mL) and HCI (5M in iPrOH, 12 mL) was added to the residue and the mixture was stirred at room temperature for 3 h. EtjO (150 mL) was added. Filtration and washing of precipitates with EtjO (2x150 mL) yielded 02 as white powder (1.89 g, 99%). XH-NMR 300 MHz, DMSO-dg 6 (ppm): 9.29 (s, 2H), 8.72 (ddd, 7=4.9, 1.7, 0.9 Hz, 1H), 8.36-8.12 (br s, 2H), 8.13-8.06 (m, 1H), 8.00 (dt, 7=7.6, 1.7 Hz, 1H), 7.48 (ddd, 7=7.6, 4.9, 0.9 Hz, 1H), 7.02-6.21 (m, 3H), 4.63-4.54 (m, 2H), 3.34-3.20 (m, 2H). ESI (m/z): 217 [M+H]+.
To suspension of l-methylpiperidine-4-carboxylic acid (5) (283 mg 1.98 mmol), 02 (500 mg 1.98 mmol) and HATU (752 mg 1.98 mL) in DMF (15 mL) was added diisopropylethylamine (1.03 mL 5.94 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with NaHCOs (50 ml) and diluted with DCM (50 mL). The aqueous layer was separated, extracted with DCM (50 mL), the organic layers combined, washed with water (2x50 mL) and brine (50 mL), dried over Na2SO4 and evaporated. Recrystallization of the residue from EtOH yielded compound 118-PF6 as yellow solid (200 mg, 21%). XH-NMR 300 MHz, DMSO-dg 6 (ppm): 9.25 (s, 2H), 9.16-9.00 (m, 1H), 8.69 (ddd, J=4.8, 1.8, 1.0 Hz, 1H), 8.27 (t, J= 5.5 Hz, 1H), 8.05 (dt, J=8.0, 1.0 Hz, 1H), 7.97-7.90 (m, 1H), 7.42 (ddd, J=7.5, 4.8, 1.1 Hz, 1H), 4.41 (t, J= 5.5 Hz, 2H), 3.53-3.46 (m, 2H), 3.46-3.36 (m, 2H), 3.05-2.80 (m, 2H), 2.75 (s, 3H), 2.44-2.32 (m, 1H), 1.98-1.64 (m, 4H). ESI (m/z): 342 [M-PF6]+. The free base was obtained by column chromatography (eluent EtOH, then EtOH + 0.7% TEA) to afford compound 118 as yellow solid (280 mg, 41%). XH-NMR 300 MHz, DMSO-dg 6 (ppm): 9.23 (s, 2H), 8.69 (ddd, J=4.8, 1.8, 1.0 Hz, 1H), 8.07-7.99 (m, 2H), 7.93 (dt, J=7.7, 1.8 Hz, 1H), 7.41 (ddd, J=7.5, 4.8, 1.0 Hz, 1H), 4.38 (t, J=5.7, 2H), 3.48-3.43 (m, 2H), 3.76-3.70 (m, 2H), 2.10 (s, 3H), 2.08-2.00 (m, 1H), 1.78 (dt, J=11.5, 3.1 Hz, 2H), 1.63-1.48 (m, 4H). ESI (m/z): 342 [M+H]+.
Route R2: Synthesis exemplified on compound 125
Intermediate QI
To solution of N-(2-hydroxyethyl)-4-chlorobenzamide (1.00 g, 5.01 mmol) in anhydrous THF (40 mL), NaH (60% in mineral oil, 220 mg, 5.51 mmol) was added at 0 °C (ice bath). The resulting suspension was stirred at 0 °C for 20 min. 2-Chloro-5-iodopyrimidine (1.20 g, 5.01 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The suspension was poured into water (150 mL). Precipitates were filtered, dissolved in EtOH and the solution was evaporated to afford 4 as beige solid (1.89 g, 94 %). XH-NMR 300 MHz, CDCI3 6 (ppm): 8.68 (s, 2H), 7.78-7.68 (m, 2H), 7.47-7.38 (m, 2H), 6.74-6.60 (m, 1H), 4.58-4.52 (m, 2H), 3.97-3.86 (m, 2H). ESI (m/z): 404 [M+H]+.
Compound 125
A mixture of the above prepared Q2 (600 mg, 1.49 mmol), 2-fluorophenylboronic acid (312 mg, 2.23 mmol), Pd(OAc)2 (3.0 mg, 0.015 mmol) and K3PO4 (631 mg, 2.97 mmol) in ethylene glycol (10 mL) was stirred at 80 °C for 3 h. After cooling to room temperature, brine (100 mL) and EtOAc (150 mL) were added, the organic layer was separated, dried over NajSCU and evaporated. Purification of the residue by column chromatography (eluent DCM/acetone 5/1) yielded the title compound as white powder (500 mg, 90 %). XH-NMR 300 MHz, CDCI3 6 (ppm): 8.74 (d, J=1.4 Hz, 2H), 7.79-7.73 (m, 2H), 7.48-7.38 (m, 4H), 7.33-7.29 (m, 1H), 7.28-7.19 (m, 1H), 6.86-6.70 (m, 1H), 4.69-4.63 (m, 2H), 4.00-3.93 (m, 2H). ESI (m/z): 372 [M+H]+.
Compound 62 4-Phenylphenol (3.00 g, 17.6 mmol) was dissolved in acetone (100 mL). K2CO3 (4.87 g, 35.3 mmol) and bromoacetonitrile (1.42 mL, 21.2 mmol) were added. The reaction mixture was stirred at room
temperature for 20 h before it was concentrated in vacuo. To the crude was added H2O, the resulting mixture was extracted with EtOAc (3x35mL). The combined organic layers were washed with brine and H2O, dried over Na2SO4, and evaporated. The crude was purified by column chromatography on silica gel, eluent EtOAc/petrol ether 1:6 to yield a white solid (3.65 g, 99%). 1H NMR (300 MHz, CDCI3) 6: 7.61-7.55 (m, 4H), 7.47-7.42 (m, 2H), 7.38-7.32 (m, 1H), 7.06 (d, 7=8.7 Hz, 2H), 4.79 (s, 2H). UPLC-ESI (m/z): 210 [M+H]+.
IJAIH4 (1.32 g, 34.9 mmol) was suspended in Et20 (50 mL). The suspension was cooled to 0 °C. To the suspension was added a solution of the above prepared 2-([l,l'-biphenyl]-4-yloxy)acetonitrile (3.65 g, 17.4 mmol) in Et20 (100 mL). The resulting mixture was stirred at 0 °C for 1 h, then at room temperature for 20 h. The reaction mixture was cooled to 0 °C and H2O was added carefully. After 15 min, EtOAc (150 mL) was added. The organic layer was separated, washed with H2O and brine, dried over Na2SO4 and evaporated to yield a light brown solid (3.00 g, 81%). 1H NMR (300 MHz, CDCI3) 6: 7.48-7.41 (m, 4H), 7.35-7.30 (m, 2H), 7.24-7.17 (m, 1H), 6.89 (d, 7=8.7 Hz, 2H), 3.94 (t, 7=5.1 Hz, 2H), 3.02 (br s, 2H). UPLC-ESI (m/z): 214 [M+H]+.
The above prepared 2-([l,l'-Biphenyl]-4-yloxy)ethan-l-amine (3.00 g, 14.06 mmol) and 4- chlorobenzoyl chloride (2.86 mL, 22.5 mmol) were suspended in anhydrous CH2CI2 (100 mL). To the suspension was added NEt3 (3.92 mL, 28.1 mmol). The resulting yellow solution was stirred at room temperature under argon for 16 h. The orange solution was diluted with H2O (100 mL). The resulting mixture was extracted with CH2CI2 (3x100 mL), dried over Na2SC>4 and evaporated. The crude was purified by column chromatography on silica gel, eluent CH2CI2. After concentration of the productcontaining fractions, the residue was washed with hot Et20 to yield the title compound as a white solid (1.95 g, 39 %). Rf=0.21 (CH2CI2). XH NMR (300 MHz, CDCI3) 6: 7.77-7.69 (m, 2H), 7.58-7.50 (m, 4H), 7.46- 7.37 (m, 4H), 7.35-7.28 (m, 1H), 7.03-6.96 (m, 2H), 6.62-6.51 (m, 1H), 4.20 (t, 7=5.0 Hz, 2H), 3.94-3.86 (m, 2H). UPLC-ESI (m/z): 352, 354 [M+H]+.
Compound 621
Compound 62 (500 mg, 1.42 mmol) was dissolved in anhydrous THF (15 mL). The solution was cooled to 0 °C, and 60% NaH in mineral oil (114 mg, 2.84 mmol) was added. The resulting suspension was stirred at 0 °C under argon for 20 min. To the suspension was added Mel (0.22 mL, 3.55 mmol). The resulting suspension was stirred at room temperature under argon for 16 h. The reaction was quenched with H2O (10 mL) and extracted with CH2CI2 (3x15 mL). The organic layer was dried over Na2SC>4 and concentrated. The crude was purified by column chromatography on silica gel (eluent PE:EtOAc 3:2 to 2:3) to yield the title product as a white solid (501 mg, 96%). 1H-NMR (400 MHz, CDCI3) 6: 7.60-7.48 (m, 4H), 7.46-7.29 (m, 7H), 7.06-6.84 (m, 2H), 4.41-4.02 (m, 2H), 3.99-3.63 (m, 2H), 3.24- 3.09 (m, 3H). UPLC-ESI (m/z): 366, 368 [M+H]+.
Compound 203
To the suspension of 186 (prepared according to general Route 1, 400 mg, 1.15 mmol) in DCM (15 mL), acetic anhydride (542 j L, 5.75 mmol) and triethylamine (320 p.1, 2.30 mmol) were added. The reaction mixture was stirred at room temperature for 10 min and then concentrated in vacuo. The residue was recrystallized from water/ethanol (7/1) to afford the title compound as white solid (370 mg, 83%). 1H NMR (300 MHz, DMSO) 6 8.94 (s, 2H), 8.70 (t, J = 5.7 Hz, 1H), 8.40 (t, J = 5.7 Hz, 1H), 7.92 - 7.63 (m, 4H), 7.59 - 7.37 (m, 3H), 7.38 - 7.22 (m, 2H), 4.53 (t, J = 5.7 Hz, 2H), 4.30 (d, J = 5.7 Hz, 2H), 3.70 (q, J = 5.7 Hz, 2H), 1.89 (s, 3H). ESI-MS (m/z): 391.3; 219.1 [M+H]+
Compound 274
In identical fashion as described above, compound274 was prepared from 4-(2- acetamidoethyl)benzoic acid. The title compound was obtained as a white solid after recrystallization from EtOH/H2O (5:1). XH NMR (400 MHz, DMSO) 8.92 (s, 2H), 8.67 (t, J = 5.6 Hz, 1H), 7.90 (t, J = 5.6 Hz, 1H), 7.82 - 7.77 (m, 2H), 7.74 - 7.70 (m, 2H), 7.52 - 7.47 (m, 2H), 7.44 - 7.39 (m, 1H), 7.31 - 7.25 (m, 2H), 4.51 (t, J = 5.6 Hz, 2H), 3.68 (q, J = 5.6 Hz, 2H), 3.29 - 3.23 (m, 2H), 2.74 (t, J = 7.3 Hz, 2H), 1.77 (s, 3H). LC-MS: 405.4 [M+H]+. Elemental analysis (%): Calculated: C 65.39, H 6.20, N 13.24 (with 1.0 molecule of H2O). Found: C 65.34, H 6.05, N 13.24.
Compound 204
186 (400 mg, 1.15 mmol) was suspended in dry DCM (20 mL), then diisopropylethylamine (795 pL, 4.59 mmol) and tert-butyl [(tert-Butoxycarbonyl)amino]{[(trifluoromethyl)- sulfonyl]imino}methylcarbamate (674 mg, 1.72 mmol) was added. The reaction mixture was stirred at RT overnight and then then concentrated in vacuo. The residue was purified by reverse phase column chromatography (eluent 30-100% MeCN/l- O) to afford Boc-protected guanidine as white solid (563 mg, 83%). XH NMR (400 MHz, CDCI3) 6 11.47 (s, 1H), 8.66 (s, 2H), 8.59 (t, J = 5.5 Hz, 1H), 7.72 - 7.67 (m, 2H), 7.47 - 7.39 (m, 4H), 7.38 - 7.33 (m, 1H), 7.32 - 7.27 (m, 2H), 6.72 - 6.67 (m, 1H), 4.61 (d, J = 5.5 Hz, 2H), 4.55 (t, J = 5.5 Hz, 2H), 3.88 (q, J = 5.5 Hz, 2H), 1.44 (s, 9H), 1.41 (s, 9H). ESI-MS (m/z): 591.5 [M+H]+.
The above prepared protected guanidine (563 mg, 0.95 mmol) was dissolved in DCM (10 mL) and cone. HCI (1.50 mL, 47.7 mmol) was added. The reaction mixture was stirred at room temperature for 30 min. Ammonia (25% in water) was added until the pH of the reaction mixture reached 10 (aprox. 7 mL). Precipitates were filtered off, washed with water (3x10 mL) and recrystallized from H2O to afford the title compound as white solid (215 mg, 58%). 1H NMR (400 MHz, DMSO-dg) 6 (ppm): 8.93 (s, 2H), 8.82 (t, J = 5.6 Hz, 1H), 8.31 - 8.38 (m, 1H), 7.90 (d, J = 7.9 Hz, 2H), 7.73 (d, J = 7.6 Hz, 2H), 7.53 - 7.33 (m, 9H), 4.52 (t, J = 5.6 Hz, 2H), 4.47 (d, J = 5.7 Hz, 2H), 3.71 (q, J = 5.6 Hz, 2H). ESI-MS (m/z): 391.3 [M+H]+.
Compound 205
To a solution of 186 (300 mg, 0.86 mmol) in DCM (5 mL) and ethanol (5 mL), trimethylsilyl isocyanate (233 pl, 1.72 mmol) was added. The reaction mixture was stirred at room temperature for 72 h, before it was concentrated in vacuo. The residue was purified by column chromatography (DCM/EtOH) and recrystallization from dioxane to afford the title compound as white solid (270 mg, 80%). 1H NMR (300 MHz, DMSO) 6 8.94 (s, 2H), 8.72 (t, J = 5.6 Hz, 1H), 7.90 - 7.76 (m, 2H), 7.77 - 7.66 (m, 2H), 7.58 - 7.39 (m, 3H), 7.39 - 7.25 (m, 2H), 6.55 (t, J = 6.1 Hz, 1H), 5.60 (s, 2H), 4.53 (t, J = 5.6 Hz, 2H), 4.23 (d, J = 6.1 Hz, 2H), 3.70 (q, J = 5.6 Hz, 2H). ESI-MS (m/z): 392.3; 220.2 [M+H]+
Compound 253
A mixture of 186, 400 mg, 1.15 mmol), /V-Boc-glycine 201 mg, 1.15 mmol), HOBt (233 mg, 1.72 mmol) and NMM (0.25 mL, 2.30 mmol) in DMF (10 mL) was stirred at room temperature for 10 min. EDC-HCI (550 mg, 2.87 mmol) was added in one portion and the resulting solution was stirred at room temperature for 18h. Water (30 mL) was added and the mixture was extracted with EtOAc (3x50 mL). The combined EtOAc extracts were treated with brine (30 mL), dried over Na2SO4 and evaporated. Purification of the residue by column chromatography (eluent DCM/MeOH) yielded the Boc-protected title compound as white solid (560 mg, 96%). 1H-NMR 300 MHz, DMSO-dg 6 (ppm): 8.93 (s, 2H), 8.70 (t, J = 5.4 Hz, 1H), 8.34 (t, J = 5.6 Hz, 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 7.4 Hz, 2H), 7.50 (t, J = 7.4
Hz, 2H), 7.45 - 7.38 (m, 1H), 7.32 (d, J = 8.2 Hz, 2H), 7.01 (t, J = 5.8 Hz, 1H), 4.51 (t, J = 5.6 Hz, 2H), 4.33 (d, J = 6.0 Hz, 2H), 3.69 (q, J = 5.4 Hz, 2H), 3.57 (d, J = 6.0 Hz, 2H), 1.39 (s, 9H). ESI (m/z): 506, 507 [M+H]+.
To solution of the above prepared protected title compound (540 mg, 1.07 mmol) in DCM (20 mL), cone. HCI (aqueous, 1 mL, 32.0 mmol) was added. The reaction mixture was stirred at room temperature for lh. Ammonia (25% in water) was added until the pH of reaction mixture reached 10 (approximately 8 mL). The mixture was extracted with EtOAc (3x20 mL). The organic extracts were combined, dried over NajSC and evaporated. Purification of the residue by column chromatography (eluent DCM/MeOH) yielded the title compound as white solid (330 mg, 76%). 1H-NMR 300 MHz, DMSO-dg 6 (ppm): 8.69 (t, J = 5.6 Hz, 1H), 8.37 (t, J = 5.9 Hz, 1H), 7.85 - 7.77 (m, 2H), 7.75 - 7.69 (m, 2H), 7.54 - 7.45 (m, 2H), 7.45 - 7.38 (m, 1H), 7.33 (d, J = 8.3 Hz, 2H), 4.51 (t, J = 5.6 Hz, 2H), 4.34 (d, J = 5.9 Hz, 2H), 3.69 (q, J = 5.6 Hz, 2H), 3.15 (s, 2H), 2.22 - 1.92 (m, 2H). ESI (m/z): 406 [M+H]+.
Compound 254
A mixture of 186 (400 mg, 1.15 mmol), N,N-dimethylglycine hydrochloride (160 mg, 1.15 mmol), HOBt (233 mg, 1.72 mmol) and NMM (0.32 mL, 2.87 mmol) in DMF (10 mL) was stirred at room temperature for 10 min. EDC-HCI (550 mg, 2.87 mmol) was added in one portion and the resulting solution was stirred at room temperature for 18h. Water (30 mL) was added and the mixture was extracted with EtOAc (3x50 mL). The combined EtOAc extracts were treated with brine (30 mL), dried over Na2SO4 and evaporated. The residue was recrystallized from EtOH to afford the title compound as white powder (300 mg, 60%). XH-NMR 300 MHz, DMSO-dg 6 (ppm): 8.93 (s, 2H), 8.68 (t, J = 5.6 Hz, 1H), 8.35 (t, J = 6.3 Hz, 1H), 7.85 - 7.76 (m, 2H), 7.76 - 7.67 (m, 2H), 7.55 - 7.45 (m, 2H), 7.45 - 7.37 (m, 1H), 7.36 - 7.29 (m, 2H), 4.51 (t, J = 5.6 Hz, 2H), 4.32 (d, J = 6.3 Hz, 2H), 3.68 (q, J = 5.6 Hz, 2H), 2.92 (s, 2H), 2.20 (s, 6H). ESI (m/z): 434 [M+H]+.
Compound 255
In identical fashion to 253, the title compound was prepared with N-Boc-(S)-valine and was obtained as a white solid. %). XH-NMR 300 MHz, DMSO-dg 6 (ppm): 8.93 (s, 2H), 8.69 (t, J = 5.6 Hz, 1H), 8.38 (t, J = 6.0 Hz, 1H), 7.86 - 7.77 (m, 2H), 7.76 - 7.68 (m, 2H), 7.54 - 7.46 (m, 2H), 7.45 - 7.38 (m, 1H), 7.33 (d, J = 8.2 Hz, 2H), 4.51 (t, J = 5.6 Hz, 2H), 4.33 (d, J = 6.0 Hz, 2H), 3.68 (q, J = 5.6 Hz, 2H), 2.98 (d, J = 5.2 Hz, 1H), 1.94 - 1.81 (m, 1H), 1.77 - 1.60 (m, 2H), 0.86 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H). ESI (m/z): 448 [M+H]+.
Compound 256
To the suspension of 123 (prepared according to general Route 1, 350 mg, 1.00 mmol) in DCM (15 mL), acetic anhydride (473 j L, 5.00 mmol) and triethylamine (279 p.1, 2.00 mmol) were added. After stirring at room temperature for 16 hours, the reaction mixture was concentrated in vacuo and the residue was recrystallized from water/EtOH mixture (7/1) and dried in vacuo to afford the title compound as
white solid (345 mg, 88 %). XH-NMR (300 MHz, DMSO-d6) 6 9.26 (s, 2H), 8.77 - 8.66 (m, 2H), 8.40 (t, J = 5.6 Hz, 1H), 8.05 (dt, J = 7.8, 1.1 Hz, 1H), 7.94 (td, J = 7.8, 1.8 Hz, 1H), 7.87 - 7.78 (m, 2H), 7.42 (ddd, J = 7.8, 4.8, 1.1 Hz, 1H), 7.38 - 7.28 (m, 2H), 4.55 (t, J = 5.6 Hz, 2H), 4.30 (d, J = 6.0 Hz, 2H), 3.71 (q, J = 5.6 Hz, 2H), 1.89 (s, 3H). ESI (m/z): 433 [M+H]+.
Miscellaneous Syntheses:
The following compounds were synthesized as described below:
78, 108, 135, 136, 138, 139, 141, 142, 143, 144, 164, 169, 172, 173, 174, 175, 176, 193, 203, 209, 214, 233, 234,
Compound 78
5-(Pyridin-2-yl)pyrimidine-2-thiol (550 mg, 2.91 mmol) and t-BuOK (326 mg, 2.91 mmol) were suspended in anhydrous DMF (10 mL). The yellow solution was stirred at room temperature under argon for 40 min. To the solution was added 6-chloro-2-chloromethylbenzooxazole (587 mg, 2.91 mmol). The resulting brown solution was stirred at room temperature for 3 h. To the mixture was added H2O and a light brown precipitate was filtered and washed with H2O. The solids were recrystallized from acetone to yield the product as a light brown solid (560 mg, 54 %). 1H NMR (300 MHz, DMSO-dg) 6: 9.29 (s, 2H), 8.75-8.63 (m, 1H), 8.13-8.02 (m, 1H), 8.00-7.87 (m, 2H), 7.76-7.62 (m, 1H), 7.48-7.33 (m, 2H), 4.85 (s, 2H). UPLC-ESI (m/z): 355, 357 [M+H+],
Compound 108
Palladium (II) acetate (250 mg, 1.10 mmol) was added to a solution of Xantphos (850 mg, 1.46 mmol) in 1,4-dioxane (40 mL) at room temperature. The mixture was stirred under argon for 1 h and then treated with 2-chloro-5-(pyrid-2-yl)pyrimidine (700 mg, 3.65 mmol), 4-chlorophenylurea (930 mg, 5.48 mmol), potassium tert-butoxide (610 mg, 5.48 mmol) and degassed water (100 mg, 5.48 mmol). The mixture was stirred at 100 °C for 2 h, cooled to room temperature, diluted with EtOAc (100 mL) and filtered through a celite pad. After evaporation in vacuo, the crude material was purified by flash column chromatography, (eluent: 20% MeCN in DCM) to yield the product as a yellow solid. 1H NMR
(300 MHz, DMSO-dg): 11.58 (s, 1H), 10.49 (s, 1H), 9.34 (s, 2H), 8.74-8.67 (m, 1H), 8.10-8.02 (m, 1H), 7.99-7.90 (m, 1H), 7.72-7.63 (m, 2H), 7.46-7.37 (m, 3H). UPLC-ESI (m/z): 326, 328 [M+H]+.
Compound 135
The suspension of 4-chloro-N-(2-((5-cyanopyrimidin-2-yl)oxy)ethyl)benzamide (500 mg, 1.65 mmol), sodium azide (215 mg, 3.30 mmol) and triethylammonium chloride (455 mg, 3.30 mmol) in anhydrous toluene (7 mL) was stirred at 110 °C for 20 h. After cooling to room temperature, IM NaOH (30 mL) was added and the mixture was vigorously stirred for 10 minutes. The resulting suspension was extracted with ethyl acetate (3x25 mL). The pH of the aqueous layer was adjusted to 1 by 3M HCI and extracted with ethyl acetate (3x25 mL). The combined organic layers were dried over NajSCU and evaporated (in the end co-evaporated with toluene) to afford the title compound as white solid (360 mg, 63%). XH NMR (300 MHz, DMSO-d6) 6 9.16 (s, 2H), 8.85 (t, J = 5.5 Hz, 1H), 7.95 - 7.80 (m, 2H), 7.63 - 7.47 (m, 2H), 4.56 (t, J = 5.6 Hz, 2H), 3.71 (q, J = 5.6 Hz, 2H). ESI (m/z): 182.1; 303.2 [M+H]+.
Compound 164
A mixture of QI (1.00 g, 2.48 mmol), trimethylsilylacetylene (686 pL, 4.96 mmol), bis(triphenylphosphine)palladium(ll) chloride (35 mg, 0.050 mmol), copper iodide (9.44 mg, 0.050 mmol) and triethylamine (690 pl, 4.96 mmol) in DMF (5 mL) was stirred at room temperature for 16 h. DCM (50 mL) was added and the organic layer was washed with water (2x30 mL), dried over anhydrous sodium sulfate and evaporated. The residue was purified by flash chromatography (hexanes/EtOAc) to afford Pl as brown solid (871 mg, 94%). XH NMR (400 MHz, CDCI3) 6 8.46 (s, 2H), 7.66 - 7.51 (m, 2H), 7.35 - 7.22 (m, 2H), 6.59 (s, 1H), 4.46 (t, J = 5.5 Hz, 2H), 3.79 (q, J = 5.5 Hz, 2H), 0.15 (s, 9H). ESI (m/z): 374.2; 182.0 [M+H]+.
To solution of the above prepared Pl (550 mg, 1.47 mmol) in DCM (10 mL), tetrabutylammonium fluoride (IM in THF, 1.62 mL, 1.62 mmol) was added at 0 °C. After 10 min, the reaction mixture was diluted with DCM (30 mL), extracted with water (3x20 mL) and evaporated. The residue was purified by column chromatography (hexanes/EtOAc) to afford the title compound as slightly yellow solid (370 mg, 83%). XH NMR (300 MHz, CDCI3) 6 8.54 (s, 2H), 7.73 - 7.57 (m, 2H), 7.39 - 7.27 (m, 2H), 6.59 (s, 1H), 4.51 (t, J = 5.5 Hz, 2H), 3.84 (q, J = 5.5 Hz, 2H), 3.22 (s, 1H). ESI (m/z): 302.1; 182.0 [M+H]+.
Compound 136
A mixture of compound 164 (300 mg, 0.99 mmol), NaNs (193 mg 2.98 mmol), Cui (18.9 mg, 0.099 mmol) and sodium ascorbate (394 mg, 1.99 mmol) in DMF (5 mL) was stirred at 100 °C for 16 h. The reaction mixture was poured into water (50 mL), precipitates were filtered and purified by column chromatography (hexanes/EtOAc) to afford the title compound as slightly yellow solid (300 mg, 87%).1H NMR (300 MHz, DMSO) 6 15.3 (br s, 1H), 9.06 (s, 2H), 8.83 (t, J = 5.6 Hz, 1H), 8.4 (br s, 1H), 7.98 - 7.79 (m, 2H), 7.67 - 7.45 (m, 2H), 4.52 (t, J = 5.6 Hz, 2H), 3.70 (q, J = 5.6 Hz, 2H). ESI (m/z): 345.2; 182.1 [M+H]+
Compound 138
A mixture of 4-chloro-N-(2-((5-iodopyrimidin-2-yl)oxy)ethyl)benzamide (1.00 g, 2.48 mmol), Cui (94 mg, 0.50 mmol), L-proline (57 mg, 0.50 mmol), K2CO3 (685 mg, 4.96 mmol) and morpholine (324 j L, 3.72 mmol) in DMSO (15 mL) was stirred at 70 °C for 40 h. Additional portions of Cui (47 mg, 0.25 mmol), L-proline (28 mg, 0.25 mmol) were added and reaction mixture was stirred at 70 °C for an additional 30 h. EtOAc (50 mL) was added and mixture was extracted with water (3x50 mL) and brine (50 mL). The EtOAc solution was dried over Na2SO4 and concentrated in vacuum. The residue was purified by column chromatography (eluent DCM/acetone) and additionally by washing with EtOH/H2O (10/1, 10 mL) to afford the title compound as white powder (325 mg, 36%). 1H-NMR 300 MHz, CDCk 6 (ppm): 8.18 (s, 2H), 7.75 - 7.68 (m, 2H), 7.43 - 7.35 (m, 2H), 6.77 (s, 1H), 4.50 (dd, J = 5.8, 4.1 Hz, 2H), 3.92 - 3.83 (m, 6H), 3.13 - 3.06 (m, 4H). ESI (m/z): 182.1; 363.3 [M+H]+. HPLC purity 98.8%. In an identical fashion, compound 172, using piperidine instead of morpholine, was prepared: 1H-NMR 300 MHz, CDCk 6 (ppm): 8.78 (t, J = 5.3 Hz, 1H), 8.30 (s, 2H), 7.91 - 7.85 (m, 2H), 7.58 - 7.52 (m, 2H), 4.37 (t, J = 5.7 Hz, 2H), 3.64 (m, 2H), 3.07 (m, 4H), 1.69 - 1.58 (m, 4H), 1.56 - 1.48 (m, 2H). ESI (m/z): 182.1; 361.2 [M+H]+. HPLC purity 96.8%.
In an identical fashion, compound 173, using N-methylpiperazine instead of morpholine, was prepared: XH-NMR 300 MHz, CDCI3 6 (ppm): 8.78 (t, J = 5.4 Hz, 1H), 8.32 (s, 2H), 7.91 - 7.85 (m, 2H), 7.58 - 7.51 (m, 2H), 4.37 (t, J = 5.7 Hz, 2H), 3.64 (m, 2H), 3.10 (m, 4H), 2.48 - 2.43 (m, 4H), 2.22 (s, 3H). ESI (m/z): 182.1; 376.3 [M+H]+. HPLC purity 99.7%.
In an identical fashion, compound 193, using 4,4-difluoropiperidine instead of morpholine, was prepared: XH-NMR (400 MHz, DMSO-dg) 6 (ppm): 8.78 (m, 1H), 8.39 (s, 2H), 7.90-7.85 (m, 2H), 7.57- 7.52 (m, 2H), 4.38 (m, 2H), 3.63 (m, 2H), 3.31-3.24 (m, 4H), 2.13-2.02 (m, 4H). ESI (m/z): 397.2 [M+H]+. HPLC purity 97.7%.
Compound 139
A mixture of 4-chloro-N-(2-((5-iodopyrimidin-2-yl)oxy)ethyl)benzamide (600 mg, 1.49 mmol), Pd(dba)2 (43 mg, 0.074 mmol) and X-Phos (57 mg, 0.119 mmol) in THF (15 mL) was stirred at RT for 5 min, before cyclohexylzinc bromide (3.9 mL, 1.93 mmol) was added. After 18 h, additional Pd(dba (43 mg, 0.074 mmol) and X-Phos (57 mg, 0.119 mmol) and cyclohexylzinc bromide (3.0 mL 1.5 mmol) was added and the reaction mixture was stirred for an additional 24 h. Sat. solution NH4CI (10 mL) and water (10 mL) was added. The aqueous phase was separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried over NazS04 and evaporated. Purification of the residue by column chromatography (eluent DCM/acetone 5/1) yielded the title compound as yellow powder (250 mg, 46%). XH-NMR 300 MHz, CDCI3 6 (ppm): 8.36 (s, 2H), 7.76-7.67 (m, 2H), 7.42-7.36 (m, 2H), 6.92-6.65 (m, 1H), 4.57-4.49 (m, 2H), 3.93-3.83 (m, 2H), 2.56-2.37 (m, 1H), 1.91-1.72 (m, 5H), 1.48-1.23 (m, 5H). ESI (m/z): 360.3 [M+H]+. HPLC purity 99.4%.
In an identical fashion, compound 174, using cyclopropylzinc bromide instead of cyclohexylzinc bromide, was prepared: 1H NMR (300 MHz, Chloroform-d) 6 8.26 (s, 2H), 7.75 - 7.67 (m, 2H), 7.42 - 7.35 (m, 2H), 6.85 - 6.75 (m, 1H), 4.55 - 4.49 (m, 2H), 3.91 - 3.84 (m, 2H), 1.87 - 1.75 (m, 1H), 1.06 - 0.96 (m, 2H), 0.72 - 0.62 (m, 2H). ESI (m/z): 318 [M+H]+.
In an identical fashion, compound 175, using 2-norbonylzinc bromide instead of cyclohexylzinc bromide, was prepared: XH NMR (300 MHz, CDCI3) 6 8.37 - 8.83 (m, 2H), 7.75 - 7.68 (m, 2H), 7.41 - 7.35 (m, 2H), 6.82 (s, 1H), 4.54 (q, J = 4.9 Hz, 2H), 3.93 - 3.85 (m, 2H), 3.16 - 3.08 (m, 0.7H), 2.71 - 2.63 (m, 0.3H), 2.45 - 2.27 (m, 2H), 2.09 - 2.00 (m, 0.7H), 1.85 - 1.75 (m, 0.3H), 1.70 - 1.10 (m, 7H). ESI (m/z): 373.27 [M+H]+.
4-Chloro-/V-(2-((5-iodopyridin-2-yl)oxy)ethyl)benzamide (Rl)
To solution of 4-chloro-/V-(2-hydroxyethyl)benzamide (1.67 g, 8.35 mmol) in anhydrous THF (60 mL), NaH (60% in mineral oil, 0.25 g, 6.26 mmol) was added at 0 °C. The resulting suspension was stirred at 0 °C for 15 min. 2-Chloro-5-iodopyridine (1.00 g, 4.18 mmol) was added and the reaction mixture was stirred at room temperature for 5 days. The suspension was poured into water (250 mL). Precipitates were filtered, washed with water (2x80 mL) and dried in vacuum to afford Rl as white solid (1.5 g 89%). XH NMR (300 MHz, CDCI3) 6 (ppm): 8.36 - 8.26 (m, 1H), 7.82 (dd, J = 8.7, 2.4 Hz, 1H), 7.75 - 7.65
(m, 2H), 7.45 - 7.36 (m, 2H), 6.92 - 6.79 (m, 1H), 6.63 (dd, J = 8.7, 0.6 Hz, 1H), 4.54 - 4.46 (m, 2H), 3.84 (q, J = 5.3 Hz, 2H). ESI (m/z): 403, 405 [M+H]+.
Compound 141
A mixture of R1 (0.50 g, 1.24 mmol), phenylboronic acid (0.15 g, 1.24 mmol), Pd PPhah (72 mg, 0.062 mmol) and NajCOs (0.26 g, 2.48 mmol) in DMF/H2O (10/1 mL) was stirred at 100 °C for 18 h. After cooling to room temperature, DCM (50 mL) was added and the mixture washed with water (2x50 mL), dried over NajSCU, filtered and evaporated. Purification of the residue by column chromatography (eluent PE/EtOAc) yielded the title compound as white solid (350 mg, 80%). 1H NMR (300 MHz, CDCI3) 6 8.41 - 8.31 (m, 1H), 7.84 (dd, J = 8.6, 2.5 Hz, 1H), 7.77 - 7.70 (m, 2H), 7.54 - 7.34 (m, 7H), 7.26 - 7.20 (m, 1H), 6.87 (dd, J = 8.6, 0.6 Hz, 1H), 4.64 - 4.57 (m, 2H), 3.88 (q, J = 5.1 Hz, 2H). ESI (m/z): 355, 353 [M+H]+.
Compound 142
2-bromopyridine (0.18 mL, 1.86 mmol) was added dropwise to a solution of n-BuLi (2M in hexane, 0.74 mL, 1.86 mmol) in THF (5 mL) at -78 °C. A solution of ZnCL (2M in MeTHF, 0.93 mL, 1.86 mmol) was added and the reaction mixture was allowed to reach room temperature. After stirring for 2 h, Pd(PPha)4 (72 mg, 0.062 mmol) and R1 (0.50 g, 1.24 mmol) was added and the mixture was stirred at room temperature for 2 h. EtOAc (10 mL) was added and the reaction mixture was filtered through a celite pad, which was rinsed with EtOAc (45 mL). The combined filtrate was evaporated and the residue was purified by reversed-phase column chromatography (eluent HjO/MeCN) to afford the title compound as white solid (0.27 g 62%). XH NMR (400 MHz, CDCI3) 6 (ppm): 8.73 (dd, J = 2.5, 0.7 Hz, 1H), 8.69 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.28 (dd, J = 8.7, 2.5 Hz, 1H), 7.80 - 7.71 (m, 3H), 7.66 (dt, J = 8.0, 1.0 Hz, 1H), 7.45 - 7.36 (m, 2H), 7.28 - 7.23 (m, 1H), 7.23 - 7.16 (m, 1H), 6.89 (dd, J = 8.7, 0.7 Hz, 1H), 4.65 - 4.58 (m, 2H), 3.88 (q, J = 5.2 Hz, 2H). ESI (m/z): 356, 354 [M+H]+.
tert-butyl (2-((6-bromopyridin-3-yl)oxy)ethyl)carbamate (SI)
A mixture of 6-bromopyridin-3-ol (500 mg, 2.87 mmol), tert-bytyl /V-(2-bromoethyl)carbamate (2, 966 mg, 4.31 mmol) and CS2CO3 (1.40 g, 4.31 mmol) in DMF (5 mL) was stirred at 40 °C for 18h. After cooling to room temperature, water (20 mL) was added. Filtration and washing of the precipitates with water (2x10 mL) afforded SI as white powder (631 mg, 69%). 1H-NMR 300 MHz, CDCI3 6 (ppm): 8.06 (d, J = 3.2 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.10 (dd, J = 8.7, 3.2 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.54 (q, J = 5.2 Hz, 2H), 1.45 (s, 9H). ESI (m/z): 318 [M+H]+.
2-((6-Bromopyridin-3-yl)oxy)ethan-l-amine (S2)
To a solution of SI (795 mg, 2.51 mmol) in DCM (10 ml), TFA (3.85 mL) was added at 0 °C. The reaction mixture was stirred at room temperature for 2 h and then concentrated. The residue was suspended in DCM (20 mL), extracted with NaHCOs (5% aq. 2x25 mL) and dried over Na2SO4. Concentration afforded S2 as yellowish oil which was used without further purification (540 mg, 99%). 1H-NMR 300 MHz, CDCk 6 (ppm): 8.07 (d, J = 3.1 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 7.11 (dd, J = 8.7, 3.1 Hz, 1H), 4.01 (t, J = 5.2 Hz, 2H), 3.28 - 2.97 (s, 2H). ESI (m/z): 218 [M+H]+.
/V-(2-((6-bromopyridin-3-yl)oxy)ethyl)-4-chlorobenzamide (S3)
To suspension of S2 (540 mg, 2.49 mmol) in DCM (40 mL), EtsN (0.347 mL, 2.49 mmol) was added, followed by addition of 4-chlorobenzoyl chloride (0.351 mL, 2.74 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 4 h and concentrated. Purification of the residue by column chromatography (eluent DCM/MeOH) yielded S3 as white solid (810 mg, 92%). 1H-NMR 300 MHz, CDCI3 6 (ppm): 8.12 - 8.06 (m, 1H), 7.77 - 7.69 (m, 2H), 7.44 - 7.34 (m, 3H), 7.12 (dd, J = 8.7, 3.0 Hz, 1H), 6.60 - 6.51 (m, 1H), 4.18 (t, J = 5.2 Hz, 2H), 3.88 (q, J = 5.2 Hz, 2H). ESI (m/z): 357 [M+H]+.
Compound 143
A mixture of S3 (200 mg, 0.562 mmol), phenylboronic acid (103 mg, 0.844 mmol), Pd(0Ac)2 (2.53 mg, 0.011 mmol) and K3PO4 (239 mg, 1.12 mmol) in ethylene glycol (3 mL) was stirred at 80 °C for 3h. After cooling to room temperature, brine (20 mL) and EtOAc (25 mL) were added. The organic layer was separated, dried over NajSC and evaporated. Purification of the residue by flash column chromatography (eluent DCM/MeOH) yielded the title compound as white powder (135 mg, 68%). 1H- NMR 300 MHz, DMSO-dg 6 (ppm): 8.82 (t, J = 5.7 Hz, 1H), 8.40 (d, J = 2.9 Hz, 1H), 8.04 - 7.97 (m, 2H), 7.93 - 7.85 (m, 3H), 7.57 - 7.49 (m, 3H), 7.48 - 7.41 (m, 2H), 7.40 - 7.31 (m, 1H), 4.26 (t, J = 5.7 Hz, 2H), 3.67 (q, J = 5.7 Hz, 2H). ESI (m/z): 354 [M+H]+.
Compound 144
To a solution of t-BuLi (1.7M in pentane, 0.782 mL, 1.33 mmol) in THF (8 mL) at -78 °C, 2-bromopyridine (0.796 ml, 0.831 mmol) was added. After 30 min, a solution of ZnCL (2M in MeTHF, 0.997 mL, 1.99 mmol) was added. The resulting solution was stirred at -78 °C under argon for 10 min, and then allowed to warm to room temperature. After stirring for 2 h, Pd(PPh3)4 (25.6 mg, 0.0222 mmol) was added, followed by addition of S3 (195 mg, 0.548 mmol) in THF (1 mL). The reaction mixture was stirred at room temperature under argon for 18 h and then filtered through a celite pad. The celite pad was washed with EtOAc (20 mL) the combined filtrates were evaporated and the residue was purified by flash column chromatography (DCM/MeOH). The product-containing fractions were combined and concentrated and the residue was suspended in DCM, extracted with 2M HCI (15 mL) and NaHCO3 solution (5% aqueous, 15 mL). Concentration of the organic layer afforded the title compound as white solid (65 mg, 33%). XH-NMR 300 MHz, CD3OD 6 (ppm): 8.59 (d, J = 4.3 Hz, 1H), 8.37 (d, J = 2.6 Hz, 1H), 8.27 - 8.17 (m, 2H), 7.93 - 7.86 (m, 1H), 7.85 - 7.78 (m, 2H), 7.55 (dd, J = 8.8, 2.6 Hz, 1H), 7.50 - 7.43 (m, 2H), 7.41 - 7.34 (m, 1H), 4.32 (t, J = 5.5 Hz, 2H), 3.82 (t, J = 5.5 Hz, 2H). ESI (m/z): 355 [M+H]+.
A mixture of 2-chloro-5-iodopyrimidine (750 mg, 3.12 mmol), 2-(tributylstannyl) pyrimidine (1.18 mL, 3.74 mmol, 1.2 eq), Pd(PPh3)4 (150 mg, 0.13 mmol, 0.04 eq) and Cui (196 mg, 1.03 mmol, 0.33 eq) in dry DMF (10 mL) was stirred at room temperature for 80 min. The solvent was evaporated and the brown residue was purified by column chromatography (eluent petrol ether/EtOAc) to afford 2'-chloro-2,5'-bipyrimidine as orange solid (581 mg, 92%). 1H NMR (300 MHz, Chloroform-d) 6 9.59 (s, 2H), 8.86 (d, J = 4.9 Hz, 2H), 7.33 (t, J = 4.9 Hz, 1H). ESI (m/z): 193.0 [M+H]+.
To solution of 4-chloro-N-(2-hydroxyethyl)benzamide (363 mg, 1.82 mmol) in dry THF (15 mL), NaH (60% in mineral oil, 80 mg, 2.0 mmol, 1.1 eq) was added at 0 °C. After stirring at room temperature for 10 min, 2'-chloro-2,5'-bipyrimidine (350 mg, 1.82 mmol) was added. The reaction mixture was stirred at room temperature for 4h 30min before the solvent was evaporated and the residue was purified by column chromatography (eluent DCM/EtOH) to afford the title compound as white solid (515 mg, 80%). XH NMR (300 MHz, DMSO-dg) 6 9.40 (s, 2H), 8.93 (d, J = 4.9 Hz, 2H), 8.83 (t, J = 5.5 Hz, 1H), 7.90 - 7.85 (m, 2H), 7.56 - 7.49 (m, 3H), 4.56 (t, J = 5.5 Hz, 2H), 3.70 (q, J = 5.5 Hz, 2H). ESI (m/z): 356.1 [M+H]+.
tert-Butyl (2-((5-bromopyrimidin-2-yl)oxy)ethyl)carbamate (Tl)
To a solution of N-Boc-ethanolamine (485 mg, 3 mmol, 1 eq) in dry THF (30 mL) at 0 °C, NaH (60% in mineral oil, 132 mg, 3.30 mmol, 1.1 eq) was added at once and the mixture was stirred for 10 min. 2- chloro-5-bromopyrimidine (580 mg, 3.0 mmol, 1 eq) was added and mixture was stirred at room temperature for lh. Water (100 mL) was added. Precipitates were filtered, washed with water (40 mL) and dried in vacuum to afford T1 as white solid (868 mg, 91%). 1H NMR (300 MHz, DMSO-dg) 6 8.75 (s, 2H), 7.01 (t, J = 5.7 Hz, 1H), 4.27 (t, J = 5.7 Hz, 2H), 3.30 (q, J = 5.7 Hz, 3H), 1.37 (s, 9H). LC-MS (m/z): 316 [M+H]+. tert-Butyl (2-((5-morpholinopyrimidin-2-yl)oxy)ethyl)carbamate (T2)
A mixture of T1 (860 mg, 2.70 mmol), CS2CO3 (1.20 g, 3.70 mmol, 1.55 eq), XPhos (114 mg, 0.24 mmol, 0.1 eq), Pd2(dba)s (109 mg, 0.12 mmol, 0.05 eq) and morpholine (0.47 mL, 5.40 mmol, 2 eq) in dry toluene (10 mL) was stirred at 80 °C for 23 h. After cooling to room temperature, EtOAc (50 mL) and sat. NaCI (40 mL) was added. The aqueous phase was separated and extracted with EtOAc (3x25 mL). The organic extracts were combined, dried with Na2SO4 and evaporated. The residue was purified by column chromatography (hexanes/EtOAc) to afford T2 as yellow oil (745 mg, 75%). 1H NMR (300 MHz, Chloroform-d) 6 8.17 (s, 2H), 5.07 (s, 1H), 4.36 (t, J = 5.4 Hz, 2H), 3.91 - 3.81 (m, 4H), 3.53 (q, J = 5.4 Hz, 2H), 3.14 - 3.02 (m, 4H), 1.43 (s, 9H). ESI (m/z): 325.5 [M+H]+.
2-((5-morpholinopyrimidin-2-yl)oxy)ethan-l-ammonium chloride (T3)
To a solution of T2 (640 mg, 1.73 mmol) in dichloromethane (10 mL), 4M HCI in dioxane (1.50 mL, 6.07 mmol, 3.5 eq) was added and the solution was stirred for 18 h at room temperature before it was concentrated in vacuo. The solid residue was suspended in Et20 (50 mL) and filtered to afford T3 as light yellow solid (521 mg, 94%). 1H NMR (300 MHz, DMSO-d6) 6 8.38 (s, 2H), 8.31 (s, 2H), 4.46 - 4.40 (m, 2H), 3.80 - 3.69 (m, 4H), 3.19 (q, J = 5.6 Hz, 2H), 3.15 - 3.06 (m, 4H). ESI (m/z): 225.3 [M+H]+.
Compound 209
To suspension of T3 (520 mg, 2.0 mmol), 6-chlorosalicylic acid (345 mg, 2.0 mmol) and HATU (836 mg, 2.2 mmol, 1.1 eq) in dry DMF (8 mL), DIPEA (1.0 mL, 6.0 mmol, 3 eq) was added dropwise. After stirring at room temperature for 1 h, water (100 mL) was added. The precipitates were filtered, washed with water (2x30 mL) and crystallized from EtOH to afford the title compound as beige solid (225 mg, 30%). XH-NMR (400 MHz, DMSO-d6) 6 12.76 (s, 1H), 9.03 (t, J = 5.6 Hz, 1H), 8.32 (s, 2H), 7.90 - 7.86 (m, 1H), 7.03 - 6.92 (m, 2H), 4.39 (t, J = 5.6 Hz, 2H), 3.75 - 3.72 (m, 4H), 3.67 (q, J = 5.6 Hz, 2H), 3.09 - 3.05 (m, 4H). ESI (m/z): 379.4 [M+H]+. Elemental analysis (%): Calculated: C 51.46, H 5.40, N 14.00 (with 0.07 molecule of EtOH and 1.0 mol. of water). Found: C 51.44, H 5.16, N 13.75.
tert-Butyl (2S,4R)-2-((4-chlorobenzamido)methyl)-4-hydroxypyrrolidine-l-carboxylate (Ul)
To the solution of tert-butyl (2S,4R)-2-aminomethyl-4-hydroxypyrrolidine-l-carboxylate (415 mg, 1.92 mmol) in DCM (15 mL), p-chlorobenzoyl chloride (403 mg, 2.30 mmol) and EtaN (670 pl, 4.80 mmol) were added. The reaction mixture was stirred at room temperature for 30 min and then was poured into saturated aqueous NH4CI (20 mL). The mixture was extracted with EtOAc (3x15 mL). The organic extracts were combined and evaporated. The residue was purified by column chromatography (DCM/EtOAc) to afford Ul (490 mg, 72%) as a white foam. XH NMR (400 MHz, CDCI3) 6: 8.65 (s, 1H), 7.87 - 7.73 (m 2H), 7.43 - 7.35 (m, 2H), 4.50 - 4.42 (m, 1H), 4.36 - 4.22 (m, 1H), 3.74 - 3.63 (m, 1H), 3.60 - 3.52 (m, 1H), 3.45 (dd, J = 12.0, 4.6 Hz, 1H), 3.33 - 3.18 (m, 1H), 2.23 - 2.12 (m, 1H), 1.93 - 1.82 (m, 1H), 1.48 (s, 9H). LC-MS (m/z): 355.9 [M+H]+. tert-Butyl (2S,4R)-2-((4-chlorobenzamido)methyl)-4-((5-phenylpyrimidin-2-yl)oxy) pyrrolidine-1- carboxylate (U2)
To the solution of Ul (480 mg, 1.35 mmol) in DMF (15 mL) at 0°C, NaH (60% in mineral oil, 60 mg, 1.49 mmol, 1.1 eq) was added. The reaction mixture was stirred at 0°C for 15 min. 2-Chloro-5- phenylpyrimidine (260 mg, 1.35 mmol) was added and the reaction mixture was stirred at room temperature. After 20h, the mixture was poured onto ice. Precipitates were filtered, washed with water (50 mL) and dried to afford U2 (580 mg, 84%) as white solid. 1H NMR (400 MHz, CDCI3) 6: 8.72 (s, 2H), 8.64 (s, 1H), 7.87 - 7.78 (m, 2H), 7.56 - 7.35 (m, 7H), 5.58 - 5.52 (m, 1H), 4.84 - 3.82 (m, 1H), 4.43 - 4.34 (m, 1H), 3.89 - 3.82 (m, 1H), 3.78 - 3.65 (m, 2H), 3.44 (m, 1H), 2.58 - 2.47 (m, 1H), 2.22 - 2.09 (m, 1H), 1.46 (s, 9H). LC-MS (m/z): 509.8 [M+H]+
Compound 214
To the solution of U2 (580 mg, 1.14 mmol) in DCM (15 mL), HCI (2M in EtjO, 10 mL) was added. The reaction mixture was stirred at room temperature for 16 h. The precipitates were filtered and washed with DCM to afford the title compound as white solid (340 mg, 73%). 1H NMR 6 8.87 (s, 2H), 7.94 - 7.87 (m, 2H), 7.67 - 7.61 (m, 2H), 7.56 - 7.48 (m, 4H), 7.47 - 7.41 (m, 1H), 5.82 - 5.75 (m, 1H), 4.23 - 4.12 (m, 1H), 3.90 - 3.74 (m, 3H), 3.63 (d, J = 13.1 Hz, 1H), 2.58 (dd, J = 14.5, 6.3 Hz, 1H), 2.28 (ddd, J = 14.5, 11.6, 4.8 Hz, 1H). LC-MS (m/z): 409.3 [M+H]+. Elemental analysis: Calculated: C 53.50, H 5.00, N 11.29 (with 0.8 molecule of water). Found: C 53.50, H 5.11, N 11.21. [a]D 20 -3.50 (1.0, MeOH).
Compound 215
In a similar fashion compound 215 was prepared starting from (2R,4R)-2-aminomethyl-4- hydroxypyrrolidine-l-carboxylate to afford the title compound as white solid.
1H NMR 6 8.87 (s, 2H), 7.92 - 7.84 (m, 2H), 7.68 - 7.60 (m, 2H), 7.56 - 7.40 (m, 5H), 5.78 - 5.73 (m, 1H), 4.13 - 4.02 (m, 1H), 3.91 - 3.83 (m, 1H), 3.82 - 3.72 (m, 2H), 3.73 - 3.67 (m, 1H), 2.87 - 2.77 (m, 1H), 2.32 -2.22 (m, 1H). LC-MS (m/z): 409.3 [M+H]+. Elemental analysis: Calculated: C 52.12, H 5.13, N 11.05 (with 1.4 molecule of water). Found: C 52.10, H 4.93, N 10.92. [a]D20 -21.1 (0.5, MeOH).
Dimethyl (4-chlorobenzoyl)carbonimidodithioate (VI)
To solution of 4-chlorobenzamide (1, 1.00 g, 6.43 mmol), carbon disulfide (1.55 mL, 25.7 mmol) and iodomethane (1.28 mL, 20.6 mmol) in DMF (15 mL), NaH (60% in mineral oil, 514 mg, 12.9 mmol) was added and the mixture was stirred at room temperature for 5 h. Cold water (30 mL) was added and mixture was extracted with EtOAc (2x50 mL). The organic extracts were combined, dried over Na2SO4 and evaporated. The residue was purified by column chromatography (eluent EtOAc/hexanes) to afford VI as white solid (700 mg, 42%). XH NMR (300 MHz, DMSO) 6 8.09 - 7.99 (m, 2H), 7.63 - 7.57 (m, 2H), 2.61 (s, 6H).
4-Chloro-N-(5-hydroxytetrahydropyrimidin-2(lH)-ylidene)benzamide (V2)
To solution of l,3-diamino-2-hydroxypropane (3, 505 mg, 5.60 mmol) in anhydrous DMF (15 mL), VI (485 mg, 1.87 mmol) was added. The reaction mixture was stirred at 85 °C for 3 h and then evaporated.
The residue was purified by RP column chromatography (MeCN/water) to afford V2 as white solid (336 mg, 71%). XH NMR (400 MHz, DMSO) 6 8.75 (s, 2H), 8.08 - 7.95 (m, 2H), 7.48 - 7.36 (m, 2H), 5.29 - 5.17 (m, 1H), 4.00 (t, J = 4.3 Hz, 1H), 3.39 - 3.33 (m, 2H), 3.19 - 3.07 (m, 2H). ESI (m/z): 254.2 [M+H]+.
Compound 233
To solution of V2 ( 336 mg, 1.32 mmol) and 2-chloro-5-phenylpirimidine (5, 253 mg, 1.32 mmol) in THF (20 mL), NaH (60% on mineral oil, 106 mg, 2.65 mmol) was added at once. The resulting yellow suspension was stirred at room temperature for 14 h, and then poured into cold water (50 mL). Precipitates were filtered and re-crystallized from ethanol/water mixture (5/1) to afford the title compound as white solid (205 mg, 38%). XH NMR (400 MHz, DMSO) 6 8.98 (s, 2H), 8.91 (s, 2H), 8.08 - 8.03 (m, 2H), 7.77 - 7.73 (m, 2H), 7.54 - 7.48 (m, 2H), 7.46 - 7.40 (m, 3H), 5.52 - 5.47(m, 1H), 3.69 - 3.60 (m, 4H). ESI (m/z): 408.4 [M+H]+. Elemental analysis (%): Calculated: C 62.03, H 4.72, N 16.74 (with 0.1 molecule of H2O and 0.1 molecule of hexane). Found: C 61.93, H 4.46, N 16.67.
2-(4-Chlorophenyl)-l,4,5,6-tetrahydropyrimidin-5-ol hydrogen chloride (Wl)
The solution of l,3-diaminopropan-2-ol (788 mg, 8.74 mol) and 4-chlorothiobenzamide (1.50 g, 8.74 mol) in ethylene glycol dimethyl ether (15 mL) was stirred at reflux for 18 h, and then concentrated in vacuo. The residue was purified by RP column chromatography (MeCN/water/0.1 % HCI) to afford Wl as white solid (794 mg, 37%). XH NMR (400 MHz, DMSO) 6 10.27 (s, 2H), 7.87 - 7.81 (m, 2H), 7.74 - 7.67 (m, 2H), 4.27 - 4.19 (m, 1H), 3.56 - 3.49 (m, 2H), 3.41 - 3.34 (m, 2H). ESI (m/z): 211.1 [M+H]+.
Compound 234
To solution of Wl ( 774 mg, 3.21 mmol) and 2-chloro-5-phenylpirimidine (612 mg, 3.21 mmol) in THF (30 mL), NaH (60% on mineral oil, 257 mg, 6.43 mmol) was added at once. The resulting suspension was stirred at room temperature for 16 h. The suspension was poured into cold water (50 mL) and extracted with EtOAc (2x30 mL). The organic extracts were combined, dried over NajSC and evaporated. The residue was purified by flash chromatography (eluent EtOH/DCM/O.1% HCI). Product containing fractions were combined and evaporated. The residue was dissolved in DMSO (1 mL) and solution was poured into cold water (10 mL). Filtration of the precipitates yielded the title compound as white solid (335 mg, 26%). XH NMR (400 MHz, DMSO) 6 10.42 (s, 2H), 9.00 (s, 2H), 7.89 - 7.83 (m, 2H), 7.79 - 7.73 (m, 4H), 7.55 - 7.49 (m, 2H), 7.47 - 7.41 (m, 1H), 5.77 - 5.68 (m, 1H), 3.92 - 3.79 (m, 4H). ESI (m/z): 365.4 [M+H]+. Elemental analysis (%): Calculated: C 56.56, H 4.89, N 13.19 (with 1.3
molecule of H2O). Found: C 56.52, H 4.69, N 13.02. General synthesis of 3H-l,2,4-triazino[5,6- b]indole-3-thione compounds
Isatin derivatins were reacted with thiosemicarbazide according to ACS Infect. Dis. 2018, 4, 1030 and the products used without purification unless otherwise noted. /V-substituted 2-chloroacetamides were synthesized from 2-chloroacetyl chloride and the corresponding amine or aniline, using one equivalent of base such as NEts in organic solvent such as dichloromethane. After aqueous work-up, the intermediates were used without further purification.
Intermediate Al
7-trifluoromethylisatin (2.00 g, 9.30 mmol) and K2CO3 (1.54 g, 11.2 mmol) were suspended in anhydrous DMF (10 mL). The brown suspension was stirred at room temperature under argon for 40 min. To the brown suspension was added Mel (0.87 mL, 13.9 mmol). The resulting brown suspension was stirred at room temperature under argon for 16 h. To the brown suspension was added H2O (10 mL) and aq. 10% HCI. The orange precipitate was filtered off, washed with H2O and dried under vacuum to afford Al (1.77 g, 83%). XH-NMR (300 MHz, DMSO-dg) 6: 8.00-7.93 (m, 1H), 7.86-7.80 (m, 1H), 7.34- 7.25 (m, 1H), 3.27 (q, 7=2.5 Hz, 3H). UPLC-ESI (m/z): 230 [M+H]+.
Intermediate Bl
Intermediate Al (1.76 g, 7.68 mmol), thiosemicarbazide (700 mg, 7.68 mmol) and K2CO3 (2.65 g, 19.2 mmol) were suspended in H2O (60 mL). The yellow suspension was stirred at 120 °C. for 16 h. The resulting mixture was acidified with aqueous 10% HCI. The yellow precipitate was filtered off and dried under vacuum to afford Bl (1.96 g, 89%). XH-NMR (300 MHz, DMSO-dg) 6: 14.86 (s, 1H), 8.41-8.32 (m, 1H), 8.09-8.01 (m, 1H), 7.61-7.52 (m, 1H), 3.78-3.73 (m, 3H). UPLC-ESI (m/z): 285 [M+H]+.
Intermediate Cl
To a solution of 4-chloroaniline HCI salt (10.0 g, 61.0 mmol) in anhydrous CH2CI2 (100 mL) was added NEta (10.2 mL, 73.2 mmol). The solution was cooled to 0 °C and chloroacetylchloride (5.80 mL, 73.2 mmol) was added dropwise. The light brown suspension was stirred at room temperature under argon for 16 h. The reaction mixture was washed with H2O (2x30 mL) and 0.5 N HCI solution (1x25 mL). The organic layer was dried over NaaSO4 and concentrated to yield Cl as a light grey solid (12.0 g, 97%). 1H- NMR (300 MHz, CDCIa) 6: 8.21 (br s, 1H), 7.54-7.47 (m, 2H), 7.36-7.29 (m, 2H), 4.19 (s, 2H). UPLC-ESI (m/z): 204, 206, 208 [M+H]+.
Compound 15
Bl (1.00 g, 3.52 mmol) and Cl (754 mg, 3.69 mmol) were suspended in MeOH (25 mL). To the suspension was added NEta (0.98 mL, 7.04 mmol). The resulting orange mixture was stirred at 60 °C for 18 h. The yellow precipitate was filtered off and washed with MeOH. The crude product was recrystallized from EtOAc to yield compound 15 as a white solid (1.04 g, 65 %). 1H-NMR (300 MHz, DMSO-dg) 6: 10.58 (s, 1H), 8.73-8.66 (m, 1H), 8.17-8.10 (m, 1H), 7.70-7.60 (m, 3H), 7.41-7.33 (m, 2H), 4.31 (s, 2H), 3.91-3.86 (m, 3H). UPLC-ESI (m/z): 452, 454 [M+H]+. In a similar manner, the following compounds were prepared with the appropriate starting materials.
Oxidations of compound 1
Compound 1 (100 mg, 0.261 mmol) was suspended in anhydrous CH2CI2 (5 mL). To the suspension was added m-CPBA (90 mg, 0.365 mmol). The initially white suspension was stirred at room temperature for 30 min. The resulting yellow suspension was washed with aq. sat. NaHCO3 (3x3 mL). The organic layer was dried over Na2SO4 and evaporated. The crude was suspended in EtOAc (2 mL) and filtered to yield 1-SO as a yellow solid (73 mg, 70%). XH NMR (CDCI3, 300 MHz) 6: 9.57 (s, 1H), 8.43-8.38 (m, 1H), 7.85-7.78 (m, 1H), 7.56-7.45 (m, 4H), 7.23-7.16 (m, 2H), 4.31 (q, 7=14.62 Hz, 2H), 3.80 (s, 3H). UPLC-ESI (m/z): 400, 402 [M+H]+.
Compound 1 (1.80 g, 4.70 mmol) was suspended in dioxane (30 mL) and magnesium monoperoxyphthalate hexahydrate (4.40 g, 14.1 mmol) was added. The yellow suspension was stirred at room temperature for 20h. The resulting yellow solution was evaporated. The crude was purified by reversed flash column chromatography on C-18-SH modified silica gel (30-70 % CH3CN in H2O) to yield the product 1-SO2 as a yellow solid (500 mg, 26%). XH NMR (300 MHz, DMSO-d6) 6: 10.67 (s, 1H), 8.59-8.52 (m, 1H), 8.01-7.93 (m, 2H), 7.67-7.60 (m, 1H), 7.55-7.48 (m, 2H), 7.39-7.31 (m, 2H), 4.95 (s, 2H), 3.94 (s, 3H). UPLC-ESI (m/z): 416, 418 [M+H]+.
General Synthesis of 3-ether- and 3-aminoalkyl-5H-[l,2,4]triazino[5,6-b]indol compounds
Intermediate E2
4-Chloroaniline hydrochloride (1.50 g, 9.14 mmol) was dissolved in anhydrous THF (35 mL). The solution was cooled to -78°C and 2.5M n-BuLi solution in hexanes (9.2 mL, 22.9 mmol) was added dropwise. The resulting light brown solution was stirred at -78°C under argon for 30 min. To the mixture was added y-butyrolactone (1.12 mL, 13.7 mmol). The resulting solution was stirred at room temperature for 1.5 h. The reaction was quenched by addition of aq. sat. NH4CI solution (20 mL). The resulting mixture was extracted with EtOAc (3xl5mL), the organic layer was dried over NajSCU and evaporated. The crude was recrystallized from EtjO to yield DI as a white solid (1.57 g, 80%). 1H NMR (CDCk, 300 MHz) 6: 7.64 (s, 1H), 7.49-7.42 (m, 2H), 7.30-7.24 (m, 2H), 3.77 (t, 7=5.7 Hz, 2H), 2.53 (t, 7=6.9 Hz, 2H), 2.23-2.10 (m,), 2.03-1.92 (m, 2H). UPLC-ESI (m/z): 214, 216 [M+H]+.
Intermediate D2
Compound B2 (10.0 g, 46.2 mmol) and K2CO3 (7.67 g, 55.5 mmol) were suspended in THF (50 mL). The yellow suspension was stirred at room temperature for 40 min. To the suspension was added Mel (7.2 mL, 116 mmol). The resulting green suspension was stirred at room temperature for 4 h. To the suspension was added H2O (35 mL). The resulting mixture was extracted with CH2CI2 (4x40 mL) and the organic layer was washed with sat. NaCI (35 mL), dried over Na2SO4 and concentrated to yield D2 as a brown solid (9.91 g, 93%) which was used without further purification in the next step.
To the suspension of above methylthioether in MeOH (70 mL) and H2O (70 mL) was added oxone (52.9 g, 86.1 mmol) slowly. The resulting yellow suspension was stirred at room temperature for 16 h. The before it was filtered. The yellow solid was dissolved in MeCN and the insoluble part (impurities) was filtered off. The filtrate was evaporated to yield D2 as a yellow solid (8.03 g, 71 %). 1H-NMR (300 MHz,
DMSO-dg) 6: 8.56-8.50 (m, 1H), 7.99-7.90 (m, 2H), 7.65-7.57 (m, 1H), 3.95 (s, 3H), 3.58 (s, 3H). UPLC- ESI (m/z): 263 [M+H]+.
Compound 14
60% NaH dispersion on mineral oil (0.26 g, 6.48 mmol) was suspended in anhydrous DMF (5 mL). The suspension was cooled to 0 °C and compound E2 (1.38 g, 6.48 mmol) was added. The resulting light brown suspension was stirred at 0 °C under argon for 40 min. To the suspension was added compound D2 (1.00 g, 3.81 mmol) and the resulting mixture was stirred at room temperature under argon for 16 h. The orange mixture was evaporated in vacuo and the residue was washed with H2O (5 mL) and hot MeCN (3x10 mL). The light yellow precipitate was filtered off and dried under vacuum to obtain 14 (1.18 g, 78 %). XH NMR (CDCI3, 300 MHz) 6: 10.10 (s, 1H), 8.31-8.25 (m, 1H), 7.76-7.67 (m, 2H), 7.65- 7.56 (m, 2H), 7.50-7.40 (m, 1H), 7.36-7.28 (m, 2H), 4.59 (t, 7=6.3 Hz, 2H), 3.75 (s, 3H), 2.56 (t, 7=7.5 Hz, 2H), 2.21-2.09 (m, 2H). UPLC-ESI (m/z): 396, 398 [M+H]+.
Intermediate F2
Compound D2 (6.70 g, 25.5 mmol) and NaOH (5.11 g, 128 mmol) were suspended in H2O (120 mL). The yellow suspension was stirred at room temperature for 3 h. The resulting brown solution was acidified with aq. 10% HCI solution to pH = 1. The yellow precipitate was filtered off and dried under vacuum (4.97 g, 97%) and used without further purification in the next step.
The above prepared crude intermediate (7.30 g, 36.5 mmol) was suspended in POCI3 (20 mL). The yellow suspension was stirred at 85 °C for 2 h. The resulting brown suspension was poured into ice/HjO. The aq. layer was extracted with CHCU/'PrOH 3:1 (3x70 mL). The organic layer was dried over NajSC and concentrated. The brown sticky residue was crystallized from MeOH, the brown precipitate was filtered and dried under vacuum to afford F2 (5.84 g, 73%). 1H-NMR (300 MHz, DMSO- d6) 6: 8.45-8.39 (m, 1H), 7.90-7.82 (m, 2H), 7.60-7.51 (m, 1H), 3.85 (s, 3H). UPLC-ESI (m/z): 219, 221 [M+H]+.
Intermediate G1
Boc-L-Pro (1.00 g, 4.65 mmol), 4-chloroaniline hydrochloride (838 mg, 5.11 mmol), EDC*HCI (2.22 g, 11.6 mmol) and HOBt (1.07 g, 6.98 mmol) were suspended in anhydrous CH2CI2 (30 mL). The suspension was cooled to 0°C, and EtaN (2.33 mL, 16.7 mmol) was added. The resulting light brown solution was stirred at room temperature under argon for 3h. To the mixture was added H2O (15 mL), the resulting mixture was extracted with CH2CI2 (3x20 mL), the organic layer was dried over Na2SO4 and evaporated. The crude product was purified by reversed phase column flash chromatography on C-18-SH modified silica gel (10 - 85 % MeCN in H2O) to yield G1 as a white solid (931 mg, 62%). 1H NMR (CDCk, 300 MHz) 6: 9.62 (s, 1H), 7.49-7.42 (m, 2H), 7.29-7.19 (m, 2H), 4.53-4.34 (m, 1H), 3.52-3.28 (m, 2H), 2.61-2.40 (m, 1H), 2.06-1.84 (m, 3H), 1.49 (s, 9H). UPLC-ESI (m/z): 323, 325 [M-H]’.
Intermediate Hl
The above prepared G2 (931 mg, 2.87 mmol) was dissolved in anhydrous CH2CI2 (6 mL). The solution was cooled to 0°C, and TFA (4 mL) was added dropwise. The solution was stirred at room temperature for 1 h. The resulting light brown solution was washed with sat. NaHCOs (3x3 mL), the organic layer was evaporated and dried under vacuum to yield Hl as a light brown solid (550 mg, 86%). 1H NMR (CDCk, 300 MHz) 6: 9.79 (s, 1H), 7.61-7.51 (m, 2H), 7.31-7.23 (m, 2H), 3.91-3.81 (m, 1H), 3.15-3.04 (m, 1H), 3.02-2.93 (m, 1H), 2.29-2.17 (m, 1H), 2.15-2.09 (m, 1H), 2.08-1.97 (m, 1H), 1.83-1.69 (m, 2H). UPLC-ESI (m/z): 225, 227 [M+H]+.
Compound 40-(R)
Intermediates F2 (452 mg, 2.07 mmol) and Hl (605 mg, 2.69 mmol) were dissolved in anhydrous 1,4- dioxane (15 mL). To the solution was added DIPEA (0.55 mL, 3.19 mmol). The dark green solution was stirred at 110°C under argon for 16h. To the resulting brown solution was added H2O (10 mL) and the mixture was extracted with EtOAc (3x10 mL). The organic layer was dried over NajSC and evaporated. The crude was purified by reversed phase column chromatography on C-18-SH modified silica gel (15 to 85 % MeOH in H2O) and recrystallized from MeCN to yield 40-(R) light yellow solid (623 mg, 74%). [a]= -3.91 (IM CHCI3). XH NMR (300 MHz, DMSO-dg) 6: 10.36 (s, 1H), 8.17-8.04 (m, 1H), 7.70-7.51 (m, 4H), 7.40-7.29 (m, 3H), 4.99-4.52 (m, 1H), 4.01-3.40 (m, 5H), 2.52-2.29 (m, 1H), 2.21-1.94 (m, 3H). UPLC-ESI (m/z): 407, 409 [M+H]+.
Intermediate 11
Compound D2 (6.70 g, 25.5 mmol) and NaOH (5.11 g, 128 mmol) were suspended in H2O (120 mL). The yellow suspension was stirred at room temperature for 3 h. The resulting brown solution was acidified with aq. 10% HCI solution to pH = 1. The yellow precipitate was filtered off and dried under vacuum to afford 11 (4.97 g, 97%). XH-NMR (300 MHz, DMSO-dg) 6: 13.01 (s, 1H), 7.94-7.88 (m, 1H), 7.65-7.57 (m, 1H), 7.55-7.49 (m, 1H), 7.35-7.27 (m, 1H), 3.55 (s, 3H). UPLC-ESI (m/z): 201 [M+H]+.
Compound 71
Compound 11 (673 mg, 3.36 mmol), 6-chloro-2-chloromethylbenzooxazole (1.02 g, 5.04 mmol) and K2CO3 (512 mg, 3.70 mmol) were suspended in anhydrous DMF (44 mL). The resulting yellow suspension was stirred at room temperature under argon for 18 h. The suspension was poured into H2O and acidified to pH = 1 with aq. 10% HCI. The yellow precipitate was filtered and recrystallized from MeOH to yield 71 as a yellow solid (929 mg, 76%). XH-NMR (300 MHz, DMSO-dg) 6: 7.98-7.90 (m, 2H), 7.75-7.62 (m, 2H), 7.61-7.54 (m, 1H), 7.46-7.40 (m, 1H), 7.38-7.30 (m, 1H), 5.71 (s, 2H), 3.59 (s, 3H). UPLC-ESI (m/z): 366, 368 [M+H]+.
2-(Quinolin-7-yloxy)acetonitrile
7-Hydroxyquinoline (1.72 g, 11.8 mmol) was dissolved in acetone/DMF 10:1 mixture (55 mL) and K2CO3 (3.27 g, 23.69 mmol) followed by bromoacetonitrile (0.95 ml, 14.21 mmol) was added. The mixture was stirred at room temperature for 20 hours. Solvents were evaporated and to the residue was added H2O (30 mL). The mixture was extracted with EtOAc (3x40 mL), the combined organic layers were washed with brine and H2O, dried over Na2SO4 and evaporated. The residue was purified by column chromatography on silica gel (eluent: EtOAc/petrol ether 1:2 to 1:1). The title compound was isolated as a light yellow solid (1.80 g, 82%). XH NMR (300 MHz, CDCI3) 6: 8.88 (dd, 7=4.5 Hz, 1.8 Hz, 1H), 8.14 (dd, 7=8.4 Hz, 1.2 Hz, 1H), 7.79 (d, 7=9.3 Hz, 1H), 7.52 (d, 7=2.7 Hz, 1H), 7.36 (m, 1H), 7.25-7.29 (m, 1H), 4.92 (s, 2H). UPLC-ESI (m/z): 185 [M+H]+.
2-(Quinolin-7-yloxy)ethan-l-amine (JI)
LiAIH4 (742 mg, 19.54 mmol) was suspended in anhydrous Et20 (150 mL). The suspension was cooled to 0 °C. To the suspension was added a solution of 2-(quinolin-7-yloxy)acetonitrile (1.80 g, 9.77 mmol) in Et20 (150 ml). The reaction mixture was stirred 1 hour at 0 °C, then at room temperature for 18h. The resulting mixture was cooled to 0 °C and H2O (20 ml) was added dropwise. The mixture was extracted with EtOAc (3x30 mL). The organic layer was washed with brine, H2O, dried over Na2SO4, and evaporated. The crude was washed with Et20 and dried under vacuum to yield light brown oil which was used without further purification (1.15 g, 62%). 1H NMR (300 MHz, CDCI3) 6: 8.76 (dd, 7=4.2, 1.5
Hz, 1H), 8.01 (d, 7=9.0 Hz, 1H), 7.63 (d, 7=9.0 Hz, 1H), 7.34 (d, 7=2.4 Hz, 1H), 7.22-7.13 (m, 2H), 3.11 (t, 7=5.1 Hz, 2H), 2.71-7.21 (m, 2H).
Compound 57
The above prepared 2-(Quinolin-7-yloxy)ethan-l-amine (1.15 g, 6.11 mmol) and 4-chlorobenzoyl chloride (0.93 ml, 7.33 mmol) were suspended in anhydrous CH2CI2 (100 mL). To the yellow suspension was added NEt3 (1.70 mL, 12.2 mmol). The resulting yellow solution was stirred at room temperature under argon for 16 h. The orange solution was diluted with H2O (15 mL) and the resulting mixture was extracted with CH2CI2 (2x100 mL), dried over NajSCU and evaporated. The crude was purified by column chromatography on silica gel (eluent PE/EtOAc l:5->100% EtOAc gradient, then C^CL/MeOH 20:1). The combined product-containing fractions were concentrated and the residue was washed with Et20 to yield the product as light yellow solid (650 mg, 33 %), Rf=0.22 (C^CL/MeOH 1:9). 1H NMR (300 MHz, DMSO-dg) 6: 8.89-8.76 (m, 2H), 8.30-8.22 (m, 1H), 7.94-7.82 (m, 3H), 7.57-7.49 (m, 2H), 7.45-7.41 (m, 1H), 7.40-7.33 (m, 1H), 7.30-7.23 (m, 1H), 4.30 (t, 7=5.8 Hz, 2H), 3.77-3.67 (m, 2H). UPLC-ESI (m/z): 327, 329 [M+H]+.
Compound 571
Cmpd 57 (190 mg, 0.580 mmol) was dissolved in anhydrous THF (8 mL). The solution was cooled to 0 °C and 60% NaH in mineral oil (35 mg, 0.87 mmol) was added. The resulting suspension was stirred at 0 °C under argon for 20 min. To the suspension was added Mel (0.04 mL, 0.70 mmol). The resulting mixture was stirred at room temperature under argon for 16h. The reaction was quenched with H2O (15 mL) and extracted with CH2CI2 (3x20 mL). The organic layer was dried over Na2SO4 and concentrated. Purification by column chromatography on silica gel (eluent PE:EtOAc:MeOH 3:1:1 to 0:10:1) gave the product as an orange oil (193 mg, 97%). 1H-NMR (400 MHz, CDCI3) 6: 8.89-8.80 (m, 1H), 8.16-8.07 (m, 1H), 7.74 (d, 7=9.0 Hz, 1H), 7.55-7.28 (m, 6H), 7.27-7.13 (m, 1H), 4.52-4.11 (m, 2H), 4.08-3.68 (m, 2H), 3.16 (s, 3H). UPLC-ESI (m/z): 341, 343 [M+H]+.
In a similar manner, the following compounds were prepared with the appropriate starting materials.
Miscellaneous Syntheses:
The following compounds were synthesized as described below:
4, 11, 20, 20-SO, 20-SO2, 65, 66, 67, 75, 76
2-Bromo-9-methyl-9H-carbazole (KI)
2-bromocarbazole (3.00 g, 12.2 mmol) was dissolved in DMSO (10 mL). To the solution was added NaOH (0.975 g, 24.4 mmol) as a solution in H2O (2 mL). To the resulting light brown solution was slowly added Mel (1.50 mL, 24.4 mmol). The resulting mixture was stirred at room temperature for 18h. To the mixture was added aq. sat. NaCI solution (10 mL). The resulting mixture was extracted with CH2CI2 (4xl5mL). The combined organic layers were dried over Na2SO4 and concentrated. To the resulting brown solution (product + DMSO) was added H2O (10 mL) and the light brown precipitate was filtered off. The crude was recrystallized from MeOH to yield the title product as a white solid (1.88 g, 60%). XH NMR (300 MHz, CDCI3) 6: 8.09-8.02 (m, 1H), 7.97-7.90 (m, 1H), 7.58-7.46 (m, 2H), 7.43-7.30 (m, 2H), 7.29-7.21 (m, 1H), 3.81 (s, 3H).
9-Methyl-9H-carbazole-2-thiol (K2)
The above prepared 2-bromo-9-methyl-9H-carbazole (1.86 g, 7.15 mmol) was dissolved in anhydrous THF (40 mL). The solution was cooled to -78 °C and 1.9 M t-BuLi solution in pentane (8.94 mL, 14.3 mmol) was added dropwise. The resulting light green suspension was stirred at -78 °C under argon for 30 min. To the suspension was added elemental sulfur (0.252 g, 7.87 mmol). The resulting yellow suspension was stirred at room temperature under argon for 18 h. To the suspension was added sat. NH4CI (20mL). The resulting mixture was extracted with EtOAc (3x20mL). The combined organic layer were dried over Na2SO4 and evaporated to yield a yellow solid (mixture of title product, disulfide K3, and unidentified byproducts). Disulfide K3 was separated by dissolving the mixture in hot MeOH (15 ml) and filtration. The solids were collected and reduced by reduction with LiAl H4. The filtrate and the crude reduced product K2 were combined, concentrated and used without further purificiation (554 mg; mixture contains title compound as general component "'0.320 g, 54% by LC-MS peak areas).
Compound 20
The above prepared crude K2 (870 mg, 4.08 mmol) was dissolved in anhydrous DMF (8 mL). The light yellow solution was cooled to 0 °C and 60% NaH in mineral oil (0.196 g, 4.89 mmol) was added. The resulting mixture was stirred at 0 °C under argon for 40 min. To the resulting yellow solution was added Cl (0.916 g, 4.49 mmol). The mixture was stirred at 65 °C under argon for 16 h. To the resulting dark brown suspension was added H2O (10 mL) and the liquid decanted. The brown sticky residue was purified by column chromatography on silica gel (eluent: 0 - 7% MeOH in DCM). The light brown solid thus obtained was washed with hot MeOH (7 mL) and the crude was recrystallized from acetone to yield the product as a white solid (684 mg, 44 %). 1H NMR (DMSO-dg, 300 MHz) 6: 10.37 (s, 1H), 8.14- 8.06 (m, 2H), 7.67-7.55 (m, 4H), 7.48-7.42 (m, 1H), 7.38-7.32 (m, 2H), 7.26-7.26 (m, 2H), 3.96 (s, 2H), 3.83 (s, 3H). UPLC-ESI (m/z): 381, 383 [M+H]+.
Compound 20-SO
Compound 20 (1.00 g, 2.63 mmol) was suspended in chloroform (20 mL) and heated until a clear solution was obtained. To the warm solution, 75% m-chloroperoxybenzoic acid (478 mg, 1.97 mmol) was added. The resulting yellow suspension was stirred at room temperature for 20 min. The yellow solution was evaporated and the residue was purified by flash column chromatography (0-10 % EtOH in CH2CI2) to yield the product as a yellowish solid (716 mg, 92%). 1H NMR (300 MHz, CDCI3) 6: 9.17 (s, 1H), 8.19-8.16 (m, 1H), 8.11-8.07 (m, 1H), 7.73-7.70 (m, 1H), 7.57-7.51 (m, 1H), 7.48-7.42 (m, 2H), 7.41- 7.36 (m, 1H), 7.35-7.32 (m, 1H), 7.31-7.27 (m, 1H), 7.26-7.22 (m, 2H), 3.99 (d, J=14.4 Hz, 1H), 3.70 (s, 3H), 3.65 (d, J=14.4 Hz, 1H). UPLC-ESI (m/z): 397, 399 [M+H]+.
Cmpd 20-SO2
Compound 20 (761 mg, 2.00 mmol) was suspended in chloroform (20 mL) and heated until a clear solution was obtained. To the warm solution of 75% meto-chloroperoxybenzoic acid (1.033 g, 4.50 mmol) was added. The yellow suspension was stirred at room temperature for 20 min. The resulting yellow suspension was stirred at room temperature for 20 min. The yellow solution was evaporated and the residue was purified by flash column chromatography (0-15 % EtOH in CH2CI2). The productcontaining fractions were evaporated and the residue recrystallized from EtOH to yield the product as a brownish solid (365 mg, 44%). XH NMR (400 MHz, CDCI3) 6: 8.66 (s, 1H), 8.24 (d, 7=8.2 Hz, 1H), 8.15
(d, 7=7.8 Hz, 1H), 7.98-7.95 (m, 1H), 7.76-7.71 (m, 1H), 7.64-7.58 (m, 1H), 7.52-7.45 (m, 3H), 7.36-7.28
(m, 3H), 4.24 (s, 2H), 3.86 (s, 3H). UPLC-ESI (m/z): 413, 415 [M+H]+.
Ethyl (E)-3-(5-methyl-5H-[l,2,4]triazino[5,6-b]indol-3-yl)acrylate (LI)
3-Chloro-5-methyl-5H-[l,2,4]triazino[5,6-b]indole (F2, 1.72 g, 7.82 mmol), ethyl 3-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)acrylate (2.12 g, 9.38 mmol), Pd(dppf)Cl2 (400 mg, 0.547 mmol) and K3PO4 (4.98 g, 23.5 mmol) were suspended in anhydrous 1,4-dioxane (15 mL). The brown suspension was stirred at 120°C under argon for 16 h. The resulting brown suspension was filtered through a celite pad, which was washed with EtOAc (120 mL). The combined filtrate was evaporated. The crude was purified by column chromatography on silica gel; eluent - PE/EtOAc 10:1 to 2:1 to yield LI as yellow solid (728 mg, 33%). Rf=0.42 (PE/EtOAc 1:1). XH-NMR (300 MHz, DMSO-dg) 6: 8.47-8.42 (m, 1H), 7.89-7.84 (m, 2H), 7.83 (d, 7=15.7 Hz, 1H), 7.58-7.49 (m, 1H), 7.26 (d, 7=15.7 Hz, 1H), 4.27 (q, 7=7.1 Hz, 2H), 3.91 (s, 3H), 1.31 (t, 7=7.1 Hz, 3H). UPLC-ESI (m/z): 283 [M+H]+.
Ethyl 3-(5-methyl-5H-[l,2,4]triazino[5,6-b]indol-3-yl)propanoate (L2)
Compound 9 (2.65 g, 9.39 mmol) was suspended in EtOAc (120 mL). To the yellow suspension was added 10% palladium on carbon (999 mg, 0.939 mmol). The resulting black suspension was stirred at room temperature in a presence of H2 (1 atm, bubbling through mixture) for 16 h. The dark suspension was filtered through a celite pad which was washed with EtOAc (60 mL). The combined filtrate was concentrated to yield L2 as a light yellow solid which was used without further purification (2.59 g, 97%). XH-NMR (300 MHz, DMSO-dg) 6: 8.43-8.37 (m, 1H), 7.85-7.76 (m, 2H), 7.55-7.45 (m, 1H), 4.07 (q, 7=7.1 Hz, 2H), 3.85 (s, 3H), 3.41 (t, 7=7.1 Hz, 2H), 2.96 (t, 7=7.1 Hz, 2H), 1.16 (t, 7=7.1 Hz, 3H). UPLC-ESI (m/z): 285 [M+H]+.
3-(5-Methyl-5H-[l,2,4]triazino[5,6-b]indol-3-yl)propanoic acid (L3)
Compound L2 (2.56 g, 9.00 mmol) and LiOH*H2O (2.65 g, 63.0 mmol) were suspended in EtOH (150 mL). The yellow suspension was stirred at 90 °C for 3h before the mixture was concentrated in vacuo. The crude was dissolved in H2O, acidified with IM HCI solution in H2O to pH=l. The aqueous layer was saturated with NaCI and extracted with CHCU/'PrOH 3:1 (4x70 mL). The organic layer was dried over Na2SO4 and concentrated to yield L3 as a yellow solid which was used without further purification (1.91 g, 83%). XH-NMR (300 MHz, DMSO-dg) 6: 8.46-8.40 (m, 1H), 7.92-7.84 (m, 2H), 7.62-7.54 (m, 1H), 3.91 (s, 3H), 3.41 (t, 7=7.1 Hz, 2H), 2.94 (t, 7=7.1 Hz, 2H). UPLC-ESI (m/z): 257 [M+H]+.
Compound 4
Compound L3 (549 mg, 2.14 mmol), 4-chloroaniline (410 mg, 3.22 mmol) and HATU (1.30 g, 3.43 mmol) were suspended in anhydrous DMF (18 mL). To the suspension was added NEt3 (0.90 mL, 6.43 mmol). The resulting dark purple solution was stirred at room temperature under argon for 16 h. Volatiles were evaporated. To the black residue was added EtOAc (35 mL) and H2O (20 mL). Insoluble black sticky precipitates (impurities) was filtered off and the filtrate layers were separated. The organic layer was washed with IM HCI (1x20 mL) and brine (1x20 mL), dried over NajSC and concentrated. The crude was purified by column chromatography on silica gel (eluent PE/EtOAc 10:1 to 1:5) to yield the title compound as a light brown solid (321 mg, 41%). Rf=0.42 (EtOAc). 1H-NMR (300 MHz, DMSO-dg) 6: 10.24 (s, 1H), 8.44-8.37 (m, 1H), 7.86-7.78 (m, 2H), 7.69-7.61 (m, 2H), 7.56-7.47 (m, 1H), 7.39-7.31 (m, 2H), 3.85 (s, 3H), 3.47 (t, 7=7.3 Hz, 2H), 3.02 (t, 7=7.3 Hz, 2H). UPLC-ESI (m/z): 366, 368 [M+H]+.
Ethyl 5-methyl-5H-[l,2,4]triazino[5,6-b]indole-3-carboxylate (Ml)
N-Methylisatin (369 mg, 2.29 mmol) was dissolved in TFA (3 mL). To the dark red solution was added ethyl 2-hydrazineyl-2-iminoacetate (300 mg, 2.29 mmol). The dark red solution was stirred at room temperature for 30 min., then concentrated in vacuo. The dark red sticky residue was dissolved in POCI3 (2.1 mL, 22.9 mmol) and the brown solution was stirred at 140 °C under argon for 16 h. The resulting black solution was slowly poured in MeOH at 0°C and the resulting solution was evaporated. The crude was purified by column chhromatography on silica gel, eluent PE/EtOAc 10:1 to 1:10 (gradient). The resulting brown oily crude was dissolved in EtOAc (20 mL) and washed with H2O (3x10 mL). The organic layer was dried over Na2SO4 and concentrated to yield a brown solid (101 mg, 17%). Rf = 0.28 (PE/EtOAc 1:2). XH-NMR (300 MHz, CDCI3) 6: 8.65-8.58 (m, 1H), 7.88-7.79 (m, 1H), 7.62-7.51 (m, 2H), 4.63 (q, 7=7.2 Hz, 2H), 4.01 (s, 3H), 1.53 (t, 7=7.2 Hz, 3H). UPLC-ESI (m/z): 257 [M+H]+.
5-Methyl-5H-[l,2,4]triazino[5,6-b]indole-3-carboxylic acid (M2)
Compound Ml (95 mg, 0.371 mmol) and LiOH (53 mg, 2.22 mmol) were suspended in EtOH (3 mL). The brown suspension was stirred at room temperature for 1 h, then concentrated. The crude was suspended in H2O, and acidified with 10% HCI to pH=l. Precipitates (impurities) were filtered off and the aqueous layer was extracted with CHCU/z-PrOH 3:1 (3x20 mL). The organic layer was dried over Na2SO4 and evaporated to yield a yellow solid which was used without further purification (59 mg, 70%). XH-NMR (300 MHz, DMSO-dg) 6: 8.53-8.48 (m, 1H), 7.94-7.86 (m, 2H), 7.61-7.53 (m, 1H), 3.93 (s, 3H). UPLC-ESI (m/z): 229 [M+H]+.
Compound 11
Compound M2 (59 mg, 0.259 mmol), 2-amino-/V-(4-chlorophenyl) acetamide trifluoroacetate salt (57 mg, 0.259 mmol), H0Bt*H20 (48 mg, 0,310 mmol) and EDC*HCI (59 mg, 0,310 mmol) were suspended in anhydrous CH2CI2 (4 mL). To the suspension was added NEta (108 pL, 0.776 mmol). The resulting yellow suspension was stirred at room temperature under argon for 16 h. The yellow precipitate was filtered and dried under vacuum to afford the title compound (31 mg, 30 %). 1H-NMR (300 MHz, DMSO- d6) 6: 10.26 (s, 1H), 9.45 (t, 7=5.8 Hz, 1H), 8.55-8.48 (m, 1H), 7.95-7.87 (m, 2H), 7.69-7.62 (m, 2H), 7.61- 7.54 (m, 2H), 7.42-7.34 (m, 2H), 4.22 (d, 7=5.8 Hz, 2H), 3.96 (s, 3H). UPLC-ESI (m/z): 395, 397 [M+H]+.
5-Methyl-5H-[l,2,4]triazino[5,6-b]indole-3-carbonitrile (M4)
Sulfone derivative D2 (2.00 g, 7.62 mmol) and NaCN (419 mg, 8.54 mmol) were suspended in anhydrous DMF (10 mL). The resulting suspension was stirred at room temperature under argon for 1 h. The resulting brown suspension was diluted with H2O (20 mL). The light brown precipitate was filtered and dried under vacuum (1.19 g, 75%). XH NMR (300 MHz, DMSO-d6) 6: 8.56-8.51 (m, 1H), 8.00- 7.92 (m, 2H), 7.68-7.57 (m, 1H), 3.93 (s, 3H). UPLC-ESI (m/z): 210 [M+H]+.
Methyl 5-methyl-5H-[l,2,4]triazino[5,6-b]indole-3-carboxylate (M5)
Nitrile derivative M4 (1.11 g, 5.31 mmol) was suspended in HCI (g.) saturated anhydrous MeOH (60 mL). The resulting yellow suspension was stirred at 60 °C under argon for 48 h. To the suspension was added H2O (40 mL), the resulting mixture was stirred at room temperature for 1 h. The yellow precipitate was filtered, washed with H2O, and dried under vacuum (806 mg, 63%). 1H NMR (300 MHz, DMSO-dg) 6: 8.56-8.48 (m, 1H), 8.00-7.84 (m, 2H), 7.65-7.53 (m, 1H), 4.01 (s, 3H), 3.93 (s, 3H). UPLC- ESI (m/z): 243 [M+H]+.
Compound 38 l-(4-Chlorophenyl)piperazine (M6, 750 mg, 3.81 mmol) and AICI3 (573 mg, 7.95 mmol) were suspended in anhydrous CH2CI2 (35 mL). The yellow suspension was stirred at room temperature under argon for 1 h. To the mixture was added compound M5 (770 mg, 3.18 mmol). The resulting orange suspension was stirred at room temperature under argon for 24 h. To the mixture was added 50 mL aq. IM HCI. The yellow precipitate was filtered off and recrystallized from DMSO/H2O mixture to yield the title compound as a yellow solid (134 mg, 10%). XH NMR (300 MHz, DMSO-dg) 6: 8.51-8.45 (m, 1H), 7.93-
7.84 (m, 2H), 7.61-7.52 (m, 1H), 7.30-7.21 (m, 2H), 7.04-6.95 (m, 2H), 3.93-3.84 (m, 5H), 3.46-3.38 (m, 2H), 3.32-3.24 (m, 2H), 3.15-3.07 (m, 2H). UPLC-ESI (m/z): 407, 409 [M+H]+.
Synthesis of Compound 65
Compound 65
Benzo[b]thiophene-2-carboxylic acid (900 mg, 5.05 mmol), 4-chloroaniline hydrochloride (870 mg, 5.30 mmol) and DMAP (250 mg, 2.02 mmol) were dissolved in CH2CI2 (30 mL). NMM (920 mg, 9.09 mmol) was added and reaction mixture was stirred 10 min at room temperature. 3- (Ethyliminomethyleneamino)-/V,/\/-dimethylpropan-l-amine hydrochloride (1.45 g, 7.58 mmol) was added in one portion and the resulting solution was stirred at room temperature for 16 h. The resulting suspension was evaporated in vacuo and the residue suspended in a small amount of CH2CI2. The solids were collected by filtration and washed with a minimum of CH2CI2 to give desired product as a white solid (1.23 g, 85%). 1H-NMR (300 MHz, DMSO-dg): 10.63 (s, 1H), 8.38-8.35 (m, 1H), 8.10-7.98 (m, 2H), 7.85-7.77 (m, 2H), 7.54-7.40 (m, 4H). UPLC-ESI (m/z): 288, 290 [M+H]+.
Compound 66 l-Benzothiophen-2-ylmethamine hydrochloride (930 mg, 4.66 mmol) was suspended in anhydrous CH2CI2 (12 mL) and cooled to 0 °C. To the suspension were added 4-chlorobenzoyl chloride (980 mg, 5.58 mmol) and EtaN (1.40 g, 14.0 mmol). The suspension was stirred at rom temperature under argon for 1 h. To the mixture was added H2O (10 mL). The resulting mixture was extracted with CH2CI2 (3x10ml). The combined organic layers were dried over Na2SC>4 and concentrated. The crude was recrystallized from EtOAc/PE to yield the title product as a white solid (520 mg, 37%). 1H-NMR (300 MHz, DMSO-dg): 9.34 (t, 7=5.8 Hz, 1H), 7.96-7.85 (m, 3H), 7.81-7.75 (m, 1H), 7.60-7.52 (m, 2H), 7.38- 7.25 (m, 3H), 4.74 (d, 7=5.8 Hz, 2H). UPLC-ESI (m/z): 302, 304 [M+H]+.
Compound 67
Benzo[b]thiophene-2-boronic acid (1.14 g, 6.38 mmol), 2,6-dichlorobenzoxazole (1.00 g, 5.32 mmol),
KOAc (1.04 g, 10.6 mmol) and Pd(Amphos)Cl2 (190 mg, 0.270 mmol) were suspended in a mixture of
1,4-dioxane (20 mL) and H2O (2 mL) and the suspension was stirred at 100 °C for 16 h. After the reaction mixture was cooled to ambient temperature, H2O was added. The precipitate was filtered and washed with H2O and EtOAc several times. Purification by flash column chromatography on silica gel with CH2CI2 as eluent yielded the desired product (550 mg, 36%) as a light grey solid. 1H NMR (300 MHz, CDCk) 6: 8.15 (s, 1H), 7.95-7.87 (m, 2H), 7.68 (d, 7=8.5 Hz, 1H), 7.62-7.58 (m, 1H), 7.50-7.41 (m, 2H), 7.36 (dd, 7=8.5, 1.9 Hz, 1H). UPLC-ESI (m/z): 286, 288 [M+H]+.
Methyl 5-(pyridin-2-yl)benzo[b]thiophene-2-carboxylate (Nl)
Methyl 5-bromobenzo[b]thiophene-2-carboxylate (2.00 g, 7.40 mmol) and Pd(PPha)4 (852 mg, 0.74 mmol) were charged in a MW tube and flushed with Argon. Anhydrous toluene (30 mL) was added followed by 2-(tributylstannyl)pyridine (2.87 mL, 8.85 mmol). The mixture was heated to 120 °C for 3 hours. The reaction mixture was concentrated and the residue purified by column chromatography on silica gel (eluent PE:EtOAc 9:1 to 1:1). The product-containing fractions were evaporated and the residue was recrystallized from Pet:EtOAc to give a light yellow solid (1.57 g, 79%). 1H-NMR (300 MHz, CDCk) 6: 8.76-8.69 (m, 1H), 8.54-8.49 (m, 1H), 8.15-8.08 (m, 2H), 7.99-7.92 (m, 1H), 7.83-7.76 (m, 2H), 7.31-7.24 (m, 1H), 3.96 (s, 3H). UPLC-ESI (m/z): 270 [M+H]+.
5-(pyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (N2)
Ester Nl (1.55 g, 5.70 mmol) and LiOH monohydrate (966 mg, 23.0 mmol) were dissolved in 80 mL H2O/THF 1:1 mixture and stirred at room temperature for 16 h. 50 mL H2O was added and mixture was washed with 50 mL CH2CI2. The aqueous layer was acidified to pH 3 by addition of aq. 10% HCI. The resulting precipitate was filtered and dried to give N2 as off-white solid (1.28 g, 87%). 1H-NMR (300 MHz, DMSO-dg) 6: 8.82-8.71 (m, 2H), 8.28-8.08 (m, 5H), 7.61-7.53 (m, 2H). UPLC-ESI (m/z): 256 [M+H]+. Compound 75
N2 (800 mg, 3.13 mmol), HATU (1.43 g, 3.76 mmol) and 4-chloraniline hydrochloride (617 mg, 3.76 mmol) were suspended in anhydrous DMF (15 mL). To the suspension NEts (1.53 mL, 10.97 mmol) was added. The resulting red suspension was stirred at room temperature under argon for 16 h. To the red suspension was added H2O. The resulting white precipitate was filtered and recrystallized from EtOAc/PE to yield the title product as a white solid (871 mg, 76 %). 1H-NMR (300 MHz, DMSO-dg) 6: 10.72 (s, 1H), 8.78-8.63 (m, 2H), 8.43 (s, 1H), 8.32-8.02 (m, 3H), 7.99-7.88 (m, 1H), 7.87-7.76 (m, 2H), 7.52-7.32 (m, 3H). UPLC-ESI (m/z): 365, 367 [M+H]+.
Synthesis of Compound 76
5-bromo-N-(4-chlorophenyl)thieno[2,3-b]pyridine-2-carboxamide (N3)
5-Bromothieno[2,3-b]pyridine-2-carboxylic acid (1.00 g, 3.87 mmol), 4-chloroaniline hydrochloride (700 mg, 4.26 mmol) and HOBt-F O (300 mg, 1.94 mmol) were suspended in anhydrous CH2CI2 (20 mL). N-methyl morpholine (780 mg, 7.75 mmol) was added and the reaction mixture was stirred at room temperature for 10 min. 3-(Ethyliminomethyleneamino)-/V,/\/-dimethylpropan-l-amine hydrochloride
(1.11 g, 5.81 mmol) was added in one portion and the resulting solution was stirred at room temperature for 16 h. The resulting suspension was evaporated under reduced pressure, and the residue was suspended in a small amount of 1,2-dichloromethane. The solids were collected by filtration and washed with minimum CH2CI2 to give the desired product as a white solid (1.14 g, 80%). XH NMR (300 MHz, DMSO-dg) 6: 10.81 (s, 1H), 8.79 (s, 2H), 8.31 (s, 1H), 7.83-7.77 (m, 2H), 7.49-7.41 (m, 2H).
Compound 76
N3 (1.05 g, 2.86 mmol), 4-phenylboronic acid (420 mg, 3.43 mmol), K2CO3 (470 mg, 3.43 mmol) and Pd PPhah (160 mg, 0.140 mmol) were suspended in a mixture of 1,4-dioxane (10 mL) and water (10 mL). The suspension was stirred at 100 °C for 16 h. The reaction mixture was cooled to ambient temperature and water was added. The resulting precipitate was filtered and washed with water and EtOAc several times. Crystallization from CHCU/MeOH yielded the desired product as a yellowish solid (750 mg, 72%). XH NMR (300 MHz, DMSO-dg) 6: 10.80 (s, 1H), 9.01 (d, 7=2.2 Hz, 1H), 8.71 (d, 7=2.2 Hz, 1H), 8.40 (s, 1H), 7.88-7.78 (m, 4H), 7.61-7.51 (m, 2H), 7.51-7.41 (m, 3H). UPLC-ESI (m/z): 365, 367
[M+H]+.
BIOLOGICAL ACTIVITY
Results
The effect of the compounds on the food intake in diet-induced obese mice over 24h is provided in Tables A and B. This animal model is recognized as being a predictive model for obesity and food intake in human as illustrated for instance by Kleinert et al (Nat Rev Endocrinol. 2018 Mar;14(3):140-162). Accordingly, the utility of the compounds of the present invention as appetite suppressant is well shown.
Table A
Materials and Methods
Mice
Four-month-old male C57BL/6J mice (Charles River, Sulzfeld, Germany) were individually housed in wire- mesh hanging cages or in standard mice cages at room temperature (21° ± 1°C) and at an artificial 12-hour light/12-hour dark cycle. Animals were able to see, hear, and smell their conspecifics in neighboring cages and were not socially isolated. Water, food (60% high-fat diet, Sniff Spezialdiaten GmbH, Germany), and
bedding were provided ad libitum, if not indicated differently. All procedures for mice handling and experimental interventions were according to Swiss Animal Welfare laws, approved by the "Kantonales Veterinaramt Zurich," and conform to the principles of UK regulations. Animals were adapted to novel housing situations and feeding schedules at least for 1 week. All experiments were conducted three times with saline injections before drug administration to habituate the animals to the experimental procedure. Mice compound application
Individual compounds were injected intraperitoneally as solutions or suspensions in 0.2% Tween 80 in saline (10 ml/kg), a minimum of n>8 animals were dosed per group.
Mice feeding behavior
Ad libitum fed or 16-hour-fasted mice received an intraperitoneal injection of candidate compounds within 15 min before dark onset. Food was made available at dark onset to the 16-hour-fasted mice. Food intake was measured continuously in undisturbed mice using an automated system (BioDAQ, Research Diets, NJ, USA). This system measures food hopper weight (±0.01 g) at 1-Hz resolution. The microstructure of feeding was analyzed using proprietary software (BioDAQ Monitoring Software) as follows: Absolute food hopper weight changes smaller than 0.02 g within a 5-s time interval were counted as food-seeking bouts. Absolute food hopper weight changes of 0.02 g or larger represent a meal and were summed into a single meal based on a 10-min intermeal interval.
Food intake reduction in % compared to vehicle in mice is calculated as following: 100-(mean(veh)-mean(cpd))/mean(veh)*100
Claims
1- A compound of formula (A) for use as appetite suppressant, in particular for the treatment of a disease, disorder or condition selected from the group consisting of metabolic syndrome including obesity, diabetes, hypertension, NASH, dyslipidemia, eating disorders including Prader-Willi syndrome, Bardet- Biedl syndrome, Cohen syndrome and MOMO syndrome, cardiovascular diseases, and medication- induced weight gain, wherein the compound has the formula (A) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
Cy-Y-L-B-A (A) wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, a C1-C3 alkyl optionally substituted by at least one halogen, and a halogen;
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by a halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3, R4, Rs and Rg being independently selected from the group consisting of H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or by a
C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, and a C1-C3 alkoxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy; c)
with X7, Xg, and Xg being independently N or CRb and at least one of X7, Xg, and Xg is N, and X10 being CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 alkyloxy; d)
with Xu being a heteroatom, preferably S, O or NRc with Rc being H or a Ci-Cg alkyl optionally substituted by at least one halogen, more preferably S, X12 being N or CH and X13 being CH or N; Rg being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen or a C1-C3 alkyloxy, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen or a C1-C3 a Iky I oxy;
- Y is present or absent and is selected from the group consisting of -S-, -NRd-, -O-, sulfinyl, sulfonyl, -C(O)- NRd-, and -C(O)-, with Rd being H or C1-C3 alkyl optionally substituted by at least one halogen;
- L is present or absent and is selected from the group consisting of a linear C1-C4 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl, a heterocycloalkyl, an aryl and a heteroaryl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl, especially a 5- or 6-membered heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -C(O)-NRe-, -NRe-C(O)-, -C(O)-, sulfinyl, sulfonyl, S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)- and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, and a 5-10- membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a
guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH-C(0)-OR, Co- C3alkyl-NH-C(O)-NRR, Co-C3alkyl-C(0)-R, Co-C3alkyl-C(0)-OR, or Co-Csalkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', - OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
2- The compound for use of claim 1, wherein the compound has a formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
wherein
- Ri is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen;
- Y is present or absent and is selected from the group consisting of S, -NH-, -O-, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound, and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, preferably a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, -S(O2)- , -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH-C(0)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being independently H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
3- The compound for use of claim 1, wherein the compound has a formula (C) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof Cy-Y-L-B-A (C)
Wherein
- Cy is a ring selected from the group consisting of
with X4, X5 and Xg being independently N or CH; R2 being a Ci-Cg alkyl, linear, branched or cyclic, optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen; R3 being H or a C1-C3 alkyl optionally substituted by at least one halogen; and R4 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with X7, Xg, and Xg being independently N or CR and at least one of X7, Xg, and Xg is N, and Xio being CR, with R being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being H or a C1-C3 alkyl; R7 being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
with Xu being a heteroatom, preferably S, O or NH, more preferably S, and X12 being N or CH and X13 being CH or N; Rs being H, an aryl, a heteroaryl, a Ci-Cg alkyl optionally substituted by at least one halogen, a hydroxy, a cyano, an ethynyl (-CECH), an amino, or a C1-C3 alkoxy optionally substituted by at least one halogen;
- Y-L-B- is absent or selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)- CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH- C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2- C(O)-NH-, -0-CH2-, -O-(CH2)2-, -S-(CH2)3-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2- NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)- C(O)-N(CH3)-;
-A is a ring selected from the group consisting of a cycloalkyl, a heterocycloalkyl, an aryl, a 5-10-membered heteroaryl, preferably a 9-membered heteroaryl, said ring being optionally substituted by substitution(s) selected from the group consisting of halogen, a cyano, hydroxy, an ethynyl (-CECH), nitro, amino, amido, a Ci-Cg alkyl optionally substituted by at least one halogen, an amino group, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl- NH- C(O)-OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group - NR'R', -OR', -C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a C1-C3
alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the ring can be fused to the cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
4- A compound having the formula (B) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
wherein
- Ri is selected from the group consisting of aryl, 6-10-membered heteroaryl, cycloalkyl, heterocycloalkyl, and ethynyl (-CECH), said aryl, heteroaryl, cycloalkyl, and heterocycloalkyl being optionally substituted by a Ci-Cg alkyl optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a Ci-Cg alkyloxy optionally substituted by at least one halogen or by a C1-C3 alkyloxy, a cyano, a hydroxy, an ethynyl (-CECH), an amino, and/or a halogen;
- Xi, X2 and X3 are independently N or CRa with Ra being independently selected from the group consisting of H, C1-C3 alkyl optionally substituted by at least one halogen and a halogen, with at least two among Xi, X2 and X3 being N; preferably Xi is CH and X2 and X3 are N;
- Y is present or absent and is selected from the group consisting of S, NH, O, sulfinyl, and sulfonyl,
- L is present or absent and is selected from the group consisting of a linear C1-C2 alkylenyl, optionally comprising a double or triple bound and optionally substituted by a C1-C3 alkyl, the C1-C3 alkyl being optionally substituted by a hydroxy, a methoxy, or a halogen, or by two substituents forming together a cycloalkyl or a heterocycloalkyl, a cycloalkyl and a heterocycloalkyl, in particular a 5- or 6-membered cycloalkyl or heterocycloalkyl,
- B is present or absent and is selected from the group consisting of -NRe-, -NRe-C(O)-, -C(O)-, -S(O)-, -S(O2)- , -C(O)-NRe-, -S(O)-NRe-, -S(O2)-NRe-, -NRe-S(O)-and -NRe-S(O2)-, with Re being H or a C1-C3 alkyl optionally substituted by at least one halogen,
- A is a ring selected from the group consisting of a phenyl, a 5-10-membered heteroaryl and a 5-10- membered heterocycloalkyl, said ring being optionally substituted by the substitution(s) being selected from the group consisting of halogen, cyano, hydroxy, ethynyl (-CECH), amino group, nitro, amido, a guanidinyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, said ring, Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, preferably said Ci-Cg alkyl, Ci-Cg alkyloxy, a cycloalkyl, a heterocycloalkyl, an aryl, and a heteroaryl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a
Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)- OR, C0-C3alkyl-NH-C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', - C(O)-NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen; and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound.
5- The compound according to claim 4 or the compound for use according to claim 2, wherein -Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)-NH-, -O-C(O)-NH- , -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH-, -S(O)-CH2-C(O)-NH-, - S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2- S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2- N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, -S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S- (CH2)2-NH-S(O)-, -S-(CH2)2-N(CH3)-S(O)-, -S-(CH2)2-NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2-N(CH3)-C(O)-, -NH-(CH2)2-NH-S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2- N(CH3)-S(O2)-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, - O-CH(CH3)-CH2-NH-C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-CH(CH3)- NH-S(O)-, -O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)-NH-S(O2)-, -O- CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH-C(O)-, -S-CH2-CH(CH2-OCH3)- NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH-S(O)-, -S-CH2-
CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2-CH(CH2-OH)-NH- S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)-CH2-NH-S(O2)-, -NH-CH2- CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2-CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2- NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, - NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2- CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH-(CH2)2-NH-, -O- cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-S(O)-, -O-cyclohexyl-NH-S(O2)-, -O-cyclopentyl-NH-C(O)-, -O- cyclopentyl-NH-S(O)-, -O-cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-, -S-cyclohexyl-NH-S(O)-, -S- cyclohexyl-NH-S(O2)-, -S-cyclopentyl-NH-C(O)-, -S-cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH- cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, - NH-cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH- piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-S(O2)-, -S- piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, -piperidinyl-NH- S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-S(O)-
NH-, -S-pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O-pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-
NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-CH2-NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH- pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-CH2-NH-S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-
CH2-NH-S(O)-, -O-pyrrolidinyl-CH2-NH-S(O2)-, -S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-
S(O2)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-
NH-S(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O)- (e.g., -O- l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O)- (e.g., -O-l, 4, 5, 6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O2)- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -S- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -NH-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6- Tetrahydropyrimidinyl-), -O-CH2-; -S-CH2-; and -NH-CH2-.
6- The compound for use according to claim 2 or 5, wherein
Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, by a C1-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen;
a C3-C7 cycloalkyl, preferably a C5-Cg cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; and an ethynyl (-CECH),
XI, X2 and X3 are selected in one of the following combinations: Xi, X2 and X3 are CH; Xi is CH and X2 and X3 are N; Xi is N and X2 and X3 are CH, and Xi and X2 are CH and X3 is N; preferably Xi is CH and X2 and X3 are N;
-Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(C>2)-NH-, -S-C(O)- NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH- , -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)- C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, - S-(CH2)2-NH-C(o)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-(CH2)2-N(CH3)-S(O)-, -S-(CH2)2- NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2-N(CH3)-C(O)-, -NH-(CH2)2-NH- S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2-N(CH3)-S(O2)-, -O-CH2-CH(CH2- OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH- C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, - O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)-NH-S(O2)-, -O- CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH-C(O)-, -S-CH2-CH(CH2- OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH- S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2- CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)- CH2-NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2- CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2-
OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)-
NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-
S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-
S(O)-, -O-cyclohexyl-NH-S(O2)-, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O- cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-SfCh)-, -
S-cyclopentyl-NH-C(O)-, -S-cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-
C(O)-, -NH-cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH- cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH- piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-
S(02)-, -S-piperidinyl-S(02)-, -NH-piperidinyl-S(02)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, - piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-C(O)-
NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O- pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-CH2-
NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-CH2-NH-
S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O-pyrrolidinyl-CH2-NH-S(O2)-,
-S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O-tetrahydropyrimidyl-NH-C(O)-
(e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-C(O)- (e.g., -O- l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -NH- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -O-CH2-; -S-CH2-; and -NH-CH2-.; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-
NH-C(O)-, -NH-C(O)-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-
CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -
O-CH2-CH2-NH-S(O2)-, piperidinyl-NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -O-l, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
A is a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci-Cg alkyl, preferably said Ci-Cg alkyl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)-OR, Co-C3alkyl-NH- C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)- NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound. - The compound according to claim 4 or 5, wherein
Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl , optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a Ci-C3 alkyl optionally substituted by at least one halogen, by a Ci-C3 alkyloxy optionally substituted by at least one halogen and/or by a halogen;
a C3-C7 cycloalkyl, preferably a C5-Cs cycloalkyl, more preferably a cyclohexyl, said cycloalkyl being optionally bridged and/or optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; and an ethynyl (-CECH),
XI is CH and X2 and X3 are N;
-Y-L-B- is selected in the group consisting of -NH-C(O)-NH-, -NH-S(O)-NH-, -NH-S(O2)-NH-, -S-C(O)- NH-, -O-C(O)-NH-, -O-S(O)-NH-, -O-S(O2)-NH-, -S-CH2-C(O)-NH-, -S-CH2-S(O)-NH-, -S-CH2-S(O2)-NH- , -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-S(O)-NH-, -O-CH2-S(O2)-NH-, -NH-CH2-C(O)-NH-, -NH-CH2-S(O)-NH-, -NH-CH2-S(O2)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)- C(O)-, -O-(CH2)2-NH-S(O)-, -O-(CH2)2-N(CH3)-S(O)-, -O-(CH2)2-NH-S(O2)-, -O-(CH2)2-N(CH3)-S(O2)-, - S-(CH2)2-NH-C(O)-, -S-(CH2)2-N(CH3)-C(O)-, -S-(CH2)2-NH-S(O)-, -S-(CH2)2-N(CH3)-S(O)-, -S-(CH2)2- NH-S(O2)-, -S-(CH2)2-N(CH3)-S(O2)-, -NH-(CH2)2-NH-C(O)-, -NH-(CH2)2-N(CH3)-C(O)-, -NH-(CH2)2-NH- S(O)-, -NH-(CH2)2-N(CH3)-S(O)-, -NH-(CH2)2-NH-S(O2)-, -NH-(CH2)2-N(CH3)-S(O2)-, -O-CH2-CH(CH2- OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH- C(O)-, -O-CH2-CH(CH2-OH)-NH-S(O)-, -O-CH2-CH(CH2-OCH3)-NH-S(O)-, -O-CH2-CH(CH3)-NH-S(O)-, - O-CH(CH3)-CH2-NH-S(O)-, -O-CH2-CH(CH2-OH)-NH-S(O2)-, -O-CH2-CH(CH2-OCH3)-NH-S(O2)-, -O- CH2-CH(CH3)-NH-S(O2)-, -O-CH(CH3)-CH2-NH-S(O2)-, -S-CH2-CH(CH2-OH)-NH-C(O)-, -S-CH2-CH(CH2- OCH3)-NH-C(O)-, -S-CH2-CH(CH3)-NH-C(O)-, -S-CH(CH3)-CH2-NH-C(O)-, -S-CH2-CH(CH2-OH)-NH- S(O)-, -S-CH2-CH(CH2-OCH3)-NH-S(O)-, -S-CH2-CH(CH3)-NH-S(O)-, -S-CH(CH3)-CH2-NH-S(O)-, -S-CH2- CH(CH2-OH)-NH-S(O2)-, -S-CH2-CH(CH2-OCH3)-NH-S(O2)-, -S-CH2-CH(CH3)-NH-S(O2)-, -S-CH(CH3)- CH2-NH-S(O2)-, -NH-CH2-CH(CH2-OH)-NH-C(O)-, -NH-CH2-CH(CH2-OCH3)-NH-C(O)-, -NH-CH2- CH(CH3)-NH-C(O)-, -NH-CH(CH3)-CH2-NH-C(O)-, -NH-CH2-CH(CH2-OH)-NH-S(O)-, -NH-CH2-CH(CH2- OCH3)-NH-S(O)-, -NH-CH2-CH(CH3)-NH-S(O)-, -NH-CH(CH3)-CH2-NH-S(O)-, -NH-CH2-CH(CH2-OH)- NH-S(O2)-, -NH-CH2-CH(CH2-OCH3)-NH-S(O2)-, -NH-CH2-CH(CH3)-NH-S(O2)-, -NH-CH(CH3)-CH2-NH-
S(O2)-, -O-(CH2)2-NH-, -S-(CH2)2-NH-, -NH-(CH2)2-NH-, -O-cyclohexyl-NH-C(O)-, -O-cyclohexyl-NH-
S(O)-, -O-cyclohexyl-NH-S(O2)-, -O-cyclopentyl-NH-C(O)-, -O-cyclopentyl-NH-S(O)-, -O- cyclopentyl-NH-S(O2)-, -S-cyclohexyl-NH-C(O)-, -S-cyclohexyl-NH-S(O)-, -S-cyclohexyl-NH-S(O2)-, -
S-cyclopentyl-NH-C(O)-, -S-cyclopentyl-NH-S(O)-, -S-cyclopentyl-NH-S(O2)-, -NH-cyclohexyl-NH-
C(O)-, -NH-cyclohexyl-NH-S(O)-, -NH-cyclohexyl-NH-S(O2)-, -NH-cyclopentyl-NH-C(O)-, -NH- cyclopentyl-NH-S(O)-, -NH-cyclopentyl-NH-S(O2)-, -O-piperidinyl-C(O)-, -S-piperidinyl-C(O)-, -NH- piperidinyl-C(O)-, -O-piperidinyl-S(O)-, -S-piperidinyl-S(O)-, -NH-piperidinyl-S(O)-, -O-piperidinyl-
S(02)-, -S-piperidinyl-S(O2)-, -NH-piperidinyl-S(O2)-, -piperidinyl-NH-C(O)-, -piperidinyl-NH-S(O)-, - piperidinyl-NH-S(O2)-, -O-pyrrolidinyl-C(O)-NH-, -S-pyrrolidinyl-C(O)-NH-, -NH-pyrrolidinyl-C(O)-
NH-, -O-pyrrolidinyl-S(O)-NH-, -S-pyrrolidinyl-S(O)-NH-, -NH-pyrrolidinyl-S(O)-NH-, -O- pyrrolidinyl-S(O2)-NH-, -S-pyrrolidinyl-S(O2)-NH-, -NH-pyrrolidinyl-S(O2)-NH-, -O-pyrrolidinyl-CH2-
NH-C(O)-, -S-pyrrolidinyl-CH2-NH-C(O)-, -NH-pyrrolidinyl-CH2-NH-C(O)-, -O-pyrrolidinyl-CH2-NH-
S(O)-, -S-pyrrolidinyl-CH2-NH-S(O)-, -NH-pyrrolidinyl-CH2-NH-S(O)-, -O-pyrrolidinyl-CH2-NH-S(O2)-,
-S-pyrrolidinyl-CH2-NH-S(O2)-, -NH-pyrrolidinyl-CH2-NH-S(O2)-, -O-tetrahydropyrimidyl-NH-C(O)-
(e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-C(O)- (e.g., -O- l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -S-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -NH-tetrahydropyrimidyl-NH-S(O2)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -S-tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -NH- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -O-CH2-; -S-CH2-; and -NH-CH2-; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-
NH-C(O)-, -NH-C(O)-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2-OCH3)-NH-C(O)-, -O-CH2-
CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -
O-CH2-CH2-NH-S(O2)-, piperidinyl-NH-C(O)-, -O-tetrahydropyrimidyl-NH-C(O)- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-NH-C(O)-), -O-tetrahydropyrimidyl- (e.g., -0-1, 4,5,6-
Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, -S-CH2-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O- cyclohexyl-NH-C(O)-, and -piperidinyl-NH-C(O)-; and
A is a ring selected from phenyl, pyridinyl, benzoxazolyl, benzothiazolyl, thiophenyl, thienopyridinyl, indolyl, isoindolinonyl, phthalimidyl and benzothiophenyl, said ring being
optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a pyrrolidonyl, a Ci-Cg alkyl optionally substituted by at least one halogen, a Ci-Cg alkyloxy optionally substituted by at least one halogen, said ring and Ci-Cg alkyl, preferably said Ci-Cg alkyl, being optionally substituted by a halogen, a cyano, a hydroxy, an ethynyl (-CECH), an amino group, a nitro, an amido, a guanidinyl, a Ci-Cg alkyloxy optionally substituted by at least one halogen, Co-C3alkyl-NH-C(0)-R, Co-C3alkyl-NH- C(O)-OR, Co-C3alkyl-NH- C(O)-NRR, C0-C3alkyl-C(O)-R, C0-C3alkyl-C(O)-OR, or C0-C3alkyl-NRR, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, by a guanidinyl, or by a group -NR'R', -OR', -C(O)- NR'R', -C(O)-OR', -SR' or combination thereof, with R' being independently H or a Ci-C3 alkyl optionally substituted by at least one halogen, and wherein, when A is a ring substituted by a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, this substitution is not in a vicinal position of the ring with respect to the connecting bound of A to the rest of the compound. - The compound for use according to claim 2 or 5-6, wherein
Ri is selected from the group consisting of a phenyl optionally substituted by at least one halogen, in ortho or para, preferably para, in particular at least one fluorine or chlorine, more preferably at least one fluorine; by a Ci-C3 alkyloxy, in, ortho, meta or para, preferably meta or ortho, optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyridinyl, preferably 2-pyridinyl, in ortho or para, preferably ortho, optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a pyrimidyl, preferably a 2-pyrimidyl, in para optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; or by a cyano; a morpholinyl optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a cyclohexyl, said cyclohexyl being optionally bridged and/or optionally substituted by a halogen, in particular a fluorine or chorine, more preferably a fluorine; by a Ci-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a Ci-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; preferably a bridged cyclohexyl;
a piperidinyl optionally substituted by at least one halogen, in particular a fluorine or chorine, more preferably a fluorine; by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; or by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably methoxy or isopropyloxy; a piperazinyl optionally substituted by a C1-C3 alkyl optionally substituted by at least one halogen, preferably a methyl or an isopropyl; and an ethynyl (-CECH),
XI is CH and X2 and X3 are N;
Y-L-B- is selected in the group consisting of -S-CH2-C(O)-NH-, -O-CH2-C(O)-NH-, -O-CH2-CH2-NH- C(O)-, -NH-CH2-CH2-NH-C(O)-, -NH-C(O)-NH-, -O-CH2-CH(CH2-OH)-NH-C(O)-, -O-CH2-CH(CH2- OCH3)-NH-C(O)-, - -O-CH2-CH(CH3)-NH-C(O)-, -O-CH(CH3)-CH2-NH-C(O)-, -O-cyclohexyl-NH-C(O)-, - O-cyclopentyl-NH-C(O)-, -NH-cyclohexyl-NH-C(O)-, -O-CH2-CH2-NH-S(O2)-, -O-piperidinyl-C(O)-, - piperidinyl-NH-C(O)-, -O-pyrrolidinyl-C(O)-NH-, -O-pyrrolidinyl-CH2-NH-C(O)-, -O- tetrahydropyrimidyl-NH-C(O)- (e.g., -O-l,4,5,6-Tetrahydropyrimidinyl-NH-C(O)-), -O- tetrahydropyrimidyl- (e.g., -O-1,4,5,6-Tetrahydropyrimidinyl-), -O-CH2-CH2-NH-, and -S-CH2-; and A is a ring selected from the group consisting of phenyl, benzoxazolyl, 2-pyridinyl, 3- pyridinyl and thiophenyl, said ring being optionally substituted by a halogen, preferably a chlorine and/or a fluorine, by a hydroxy, by a nitro, by a C1-C3 alkyloxy optionally substituted by at least one halogen, preferably a methoxy, by a pyridinyl, preferably a 2-pyridinyl, by a morpholinyl, by a pyrrolidonyl, by Co-C3alkyl-C(0)-OR, by a C1-C3 alkyl optionally substituted by at least one halogen, a guanidinyl, a C0-C3alkyl-NRR, a C0-C3alkyl-NH- C(O)-OR, a C0-C3alkyl-NH-C(O)-R, a C0-C3alkyl-NH-C(O)-NRR, with R being H or a Ci-C4 alkyl optionally substituted by a group -NR'R' or -OR', with R' being independently H or a C1-C3 alkyl optionally substituted by at least one halogen, preferably Ci- C2alkyl-NH2, Ci-C2alkyl-NH-C(O)-O-Ci-C4 alkyl, Ci-C2alkyl-NH-C(O)-Ci-C4 alkyl, Ci-C2alkyl-NH-C(O)- NH2, Ci-C2alkyl-NH-C(O)-Ci-C4alkyl-NH2, and Ci-C2alkyl-NH-C(O)-Ci-C2alkyl- N(CH3)2.
9- The compound according to any one of claims 4, 5 and 7 or the compound for use according to any one of claims 2, 5, 6 and 8, wherein the compound of formula (B) has one of the following formulae:
with Ri, Y and A as defined in any one of claims 2 and 4-8, Z being O, N or S, and n being an integer from
0 to 4, preferably being 1.
10- The compound according to claim 4 or the compound for use according to claim 1 or 2, wherein the compound is selected in any of the Tables 1, 2 and 3.
11- The compound for use according to claim 1 or 3, wherein the compound of formula (C) has a formula
(C-l)
with X4, X5 and Xg being N or CH; R2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 being H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of - S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-, C(O)-NH-, -S-(CH2)3- C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S- (CH2)2-NH- C(O)-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -S-CH2-, -O-(CH2)2-NH- C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S-cyclohexyl-C(O)-NH-, -N(CH3)-CH2-C(O)-NH-, -C(O)-NH-, -CH2- NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -S-(CH2)2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and -O-(CH2)- C(O)-N(CH3)-; preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, - S(O2)-CH2-C(O)-NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-C(O)-, -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH- , -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, -S-(CH2)-C(O)-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -S- cyclohexyl-C(O)-NH-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and -O-piperidinyl-C(O)-; more preferably selected from the group consisting of -S-CH2-C(O)-NH-, -S(O)-CH2-C(O)-NH-, -S(O2)-CH2-C(O)- NH-, -S-(CH2)3-C(O)-NH-, -S-(CH2)4-C(O)-NH-, -S-(CH2)2-NH-CO-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, - S-piperidinyl-C(O)-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, and -O-piperidinyl- C(O)- , and
A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A being benzoxazolyl, benzothiazolyl, thienopyridinyl, benzothiophenyl, or indolyl, preferably benzoxazolyl or benzothiazolyl, preferably substituted by a halogen, in particular a chlorine, preferably in position 6.
12- The compound, wherein the compound has a formula (C-l) or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof
with X4, X5 and Xg being N or CH; R2 being selected from the group consisting of a methyl, an ethyl, a n- propyl, an isopropyl, a n-butyl, an isobutyl, a tertbutyl, optionally substituted by at least one halogen, preferably a fluorine, or a methoxy; R3 being H or a methyl optionally substituted by a halogen, preferably a fluorine; R4 being H or a fluorine, R5 and Rg being H; and with -Y-L-B- being absent or selected from the group consisting of selected from the group consisting of - C(O)-NH-, -C(O)-piperazinyl-, -pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-CO-, -NH-CH2- C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3-C(O)-NH-, - piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -N(CH3)-CH2- C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)-, -(CH2)2-C(O)-NH-, -C(O)-NH-CH2-C(O)-NH-, -O-(CH2)3-C(O)-NH-, and - O-(CH2)-C(O)-N(CH3)-; preferably selected from the group consisting of -C(O)-piperazinyl-, -pyrrolidinyl- C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, -O-(CH2)-C(O)-NH-, -O-(CH2)3- C(O)-NH-, -piperazinyl-C(O)-, -O-2-oxo-pyrrolidinyl-, -NMe-CH2-C(O)-NH-, -C(O)-NH-, -CH2-NH-C(O)- and - O-piperidinyl-C(O)-; more preferably selected from the group consisting of -C(O)-piperazinyl-, - pyrrolidinyl-C(O)-NH-, -O-(CH2)2-NH-C(O)-, -O-(CH2)2-N(CH3)-C(O)-, -NH-CH2-C(O)-NH-, and -O-piperidinyl- C(O)- , and
A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted in para by an aminomethyl (-CH2-NH2), a phenyl substituted in para by a Co- C3alkyl-NH-C(O)-R, with R being H or a C1-C4 alkyl optionally substituted by at least one halogen, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, and a cyclohexyl; or with -Y-L-B- being absent or selected from the group consisting of -O-CH2-, -S-CH2-, and -S-(CH2)3- and A being a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6.
13- The compound for use according to claim 1 or 3, wherein the compound of formula (C) has a formula
(C-2)
with one of X7 and Xs being N and the other is CH, Xg being CH or N and X10 being CRb, with Rb being H or a C1-C3 alkyl optionally substituted by a halogen, a hydroxy, a C1-C3 alkyloxy, or a NR'R' with R' being independently H or a C1-C3 alkyl; R7 being H; with -Y-L-B- being selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, -S-(CH2)2-NH-CO-, - O-(CH2)2-N(CH3)-C(O)-, -O-CH2-C(O)-NH-, and -S-CH2-C(O)-NH-, preferably selected from the group consisting of -O-CH2-, -O-(CH2)2-NH-C(O)-, and -S-(CH2)2-NH-C(O)-; and with A being a ring selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, a morpholinyl, a piperazinyl or a piperidinyl optionally substituted by a methyl, a cyclohexyl and a benzoxazolyl or a benzothiazolyl substituted by a chlorine, preferably in position 6, preferably selected from the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para optionally substituted by an a C2-C3 acyl.
14- The compound for use according to claim 1 or 3, wherein the compound of formula (C) has a formula (C-3)
with Xu being S, O or NH, Xi2 and X13 being N or CH; Rs being H, a phenyl or a pyridinyl, in particular a 2- pyridinyl; with -Y-L-B- being absent or selected from the group consisting of -C(O)-NH-, and -CH2-NH-C(O)-; and with A being selected in the group consisting of a phenyl optionally substituted by a chlorine in para and optionally further substituted in ortho by a group selected from a iodine, an ethynyl (-CECH), and a cyano, a phenyl substituted by an aminomethyl in para which is optionally substituted by an a C2-C3 acyl, and a benzoxazolyl substituted by a chlorine, preferably in position 6.
15- The compound for use according to claim 1 or 3, wherein the compound is selected in any of the Tables 4, 5 and 6.
16- A compound selected in Table 7, 8 or 9.
17- A pharmaceutical composition comprising a compound according to any one of claims 4, 5, 7, 9-10,
12 and 16.
18- A compound according to any one of claims 4, 5, 7, 9-10, 12 and 16 for use as a medicament.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20195566 | 2020-09-10 | ||
EP20195566.3 | 2020-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022053541A1 true WO2022053541A1 (en) | 2022-03-17 |
Family
ID=72473377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/074763 WO2022053541A1 (en) | 2020-09-10 | 2021-09-09 | Compounds for use as appetite suppressant |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022053541A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024026061A1 (en) * | 2022-07-29 | 2024-02-01 | Biogen Ma Inc. | Compounds for treating huntington's disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003604A2 (en) * | 2005-07-04 | 2007-01-11 | Novo Nordisk A/S | Hists1mine h3 receptor antagonists |
WO2007137968A1 (en) * | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
WO2012126922A1 (en) * | 2011-03-24 | 2012-09-27 | F. Hoffmann-La Roche Ag | Heterocyclic amine derivatives |
JP2014015456A (en) * | 2012-06-15 | 2014-01-30 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
WO2014130608A1 (en) * | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
CN105461699A (en) * | 2014-09-25 | 2016-04-06 | 广东东阳光药业有限公司 | Substituted heterocyclic compound, and use method and use thereof |
-
2021
- 2021-09-09 WO PCT/EP2021/074763 patent/WO2022053541A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003604A2 (en) * | 2005-07-04 | 2007-01-11 | Novo Nordisk A/S | Hists1mine h3 receptor antagonists |
WO2007137968A1 (en) * | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
WO2012126922A1 (en) * | 2011-03-24 | 2012-09-27 | F. Hoffmann-La Roche Ag | Heterocyclic amine derivatives |
JP2014015456A (en) * | 2012-06-15 | 2014-01-30 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
WO2014130608A1 (en) * | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
CN105461699A (en) * | 2014-09-25 | 2016-04-06 | 广东东阳光药业有限公司 | Substituted heterocyclic compound, and use method and use thereof |
Non-Patent Citations (6)
Title |
---|
"Handbook of Pharmaceutical Salts: Properties, Selection", 2002, WERMUTH |
ACS INFECT. DIS, vol. 4, 2018, pages 1030 |
CHANDRAMOHAN & S SESHADRI M R: "Studies on the Vilsmeier-Haack Reaction: Part IV*-Reaction of 2-Methylbenzoxazole", INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 10, 1 June 1972 (1972-06-01), pages 573 - 576, XP008072935 * |
J. PHARM. SCI., vol. 66, no. 2, 1977 |
KLEINERT ET AL., NAT REV ENDOCRINOL, vol. 14, no. 3, March 2018 (2018-03-01), pages 140 - 162 |
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 11, 2007, pages 237 - 240 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024026061A1 (en) * | 2022-07-29 | 2024-02-01 | Biogen Ma Inc. | Compounds for treating huntington's disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102585860B1 (en) | Rg-related protein kinase inhibitors, pharmaceutical compositions containing the same, and methods and uses thereof | |
AU2016372048B2 (en) | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | |
US7407961B2 (en) | Pyrazine derivatives and pharmaceutical use thereof | |
ES2230316T3 (en) | PIRROLOPIRIDINONE DERIVATIVES SUBSTITUTED USEFUL AS INHIBITORS OF PHOSPHODIESTERASE. | |
ES2902676T3 (en) | Aminotriazolopyridines as kinase inhibitors | |
ES2459496T3 (en) | Diaza-spiro [5.5] undecans as orexin receptor antagonists | |
ES2460915T3 (en) | Pyridines fused with disubstituted heteroaryl | |
NZ760657A (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
KR101171433B1 (en) | Imidazolidinone derivatives | |
EP2152079A1 (en) | Heterocyclic compounds and uses thereof | |
KR20170044204A (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
JP2002507610A (en) | Imidazolone appetite suppressants: III. Heteroaryl derivative | |
WO2018109643A1 (en) | Bisaryl heterocycles as nrf2 acti | |
JP2008545756A (en) | 1-methyl-1H-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents | |
TW200914438A (en) | 3-disubstituted indol-2-one derivatives, preparation thereof and therapeutic application thereof | |
JP2016516691A (en) | Isoquinolines as potassium ion channel inhibitors | |
WO2022053541A1 (en) | Compounds for use as appetite suppressant | |
JP2019514951A (en) | Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
CA3195859A1 (en) | Inhaled formulations of pgdh inhibitors and methods of use thereof | |
AU2004236014A1 (en) | Substituted-1-phthalazinamines as VR-1 antagonists | |
US20040067955A1 (en) | Pyridazinone compound and pharmaceutical use thereof | |
EP3551620A1 (en) | 3-carboxylic acid pyrroles as nrf2 regulators | |
ES2616025T3 (en) | Pyrrolotriazines as potassium ion channel inhibitors | |
WO2023081367A2 (en) | 2-amino imidazole derivatives | |
JP2016512504A (en) | Pyrrolopyridazine as a potassium ion channel inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21790377 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21790377 Country of ref document: EP Kind code of ref document: A1 |